Patient_ID,CT(Empty = Unavailable),Patient-ID,Empty=0,cohort,hobbit_id,path_image_id,he_image_id,correlatives___1,correlatives___2,correlatives___3,sex,age,smoking_status,pack_years,ecog,albumin,dnlr,vital_status,os_int,disease,histo,io_line,tx_setting,mono_combo,io_drug,tx_discont___1,tx_discont___2,tx_discont___3,tx_discont___4,pfs,pfs_censor,bor,label,dcr,ct_scan_type,impact_pdl1_same,msk_mind_clinical_data_complete,n_lesions,pdl1_tiss_site,EGFR,ALK,ERBB2,ROS1,RET,BRAF,MET,STK11,ARID1A,EGFR_AMP,EGFR_HOMDEL,EGFR_MUT,EGFR_FUSION,ALK_AMP,ALK_HOMDEL,ALK_MUT,ALK_FUSION,ERBB2_AMP,ERBB2_HOMDEL,ERBB2_MUT,ERBB2_FUSION,ROS1_AMP,ROS1_HOMDEL,ROS1_MUT,ROS1_FUSION,RET_AMP,RET_HOMDEL,RET_MUT,RET_FUSION,BRAF_AMP,BRAF_HOMDEL,BRAF_MUT,BRAF_FUSION,MET_AMP,MET_HOMDEL,MET_MUT,MET_FUSION,STK11_AMP,STK11_HOMDEL,STK11_MUT,STK11_FUSION,ARID1A_AMP,ARID1A_HOMDEL,ARID1A_MUT,ARID1A_FUSION,Sample ID,Age,Age at Which Sequencing was Reported (Years),Albumin,ALK driver,ALK protein change,Archer Panel,ARID1A driver,ARID1A protein change,BOR,BRAF driver,BRAF protein change,Cancer Type,Cancer Type Detailed,Clinically reported PD-L1 score,CRDB_SURVEY_COMMENTS,CT scan type,Impact TMB Percentile (Across All Tumor Types),Impact TMB Score,Impact TMB Percentile (Within Tumor Type),Cytology fixation type,Date added to cBioPortal,Durable clinical response,Date of death,Disease,dNLR,Date of last drug administration,Drug start date,ECOG,EGFR driver,EGFR protein change,ERBB2 driver,ERBB2 protein change,Date of Last Contact,Fraction Genome Altered,Gene Panel,Halo tumor quality score,Histology,Was IMPACT done on the same tissue that PD-L1 IHC was done on?,Institute Source,IO drug name,Line of therapy,JS PD-L1 score,Manual tumor annotation,Metastatic Site,MET driver,MET protein change,MGMT Status,Monotherapy vs. Combination,Month added to cBioPortal,MSI Comment,MSI Score,MSI Type,MSK Slide ID,Mutation Count,Oncotree Code,Overall survival,Other Patient ID,Pack-year history,MSK Pathology Slide Available,PD-L1 tissue site,PFS date,PFS Months,PFS Status,Primary Tumor Site,Clinical trial IRB,RET driver,RET protein change,ROS1 driver,ROS1 protein change,Sample Class,Number of Samples Per Patient,Sample coverage,Sample Type,Sex,What is the patient's smoking status?,Somatic Status,SO comments,Status,STK11 driver,STK11 protein change,TMB,Tumor Purity,Treatment Setting,Is the patient deceased?,Week added to cBioPortal,WHO Grade,Birth Year
P-0001987_988730_347891,Empty,P-0001987,0,discovery,HobS14-814899684367,988730,2971775,1,1,1,1,57,2,33,1,4.3,2,0,,1,Adenocarcinoma,1,1,1,Atezolizumab,0,0,0,1,16.4,0,2,0,,2,1,2,,brain,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0001987-T01-IM3,57,55,4.3,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,80,NA,CT chest/abdomen,95.8,26.8,96.7,NA,2004/7/15,NA,NA,NSCLC,2,21532,20824,1,FALSE,NA,FALSE,NA,21532,0.429,IMPACT341,80,Adenocarcinoma,Yes,MSKCC,Atezolizumab,1,80,Yes,Brain,FALSE,NA,NA,PD1 alone,15-Apr,NA,0.73,Stable,NA,24,LUAD,NA,DMP1921,33,NO,brain,21322,16.4,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,465,Metastasis,Male,Current smoker (within 6 months of diagnosis),Matched,NA,Included,FALSE,NA,26.8,30,SOC,No,"2015, Wk. 15",NA,1960
P-0002485_3369204_190464,,P-0002485,1,discovery,HobS14-199821408350,3369204,2408358,1,1,1,1,43,1,10,1,4.7,2.4,1,24.2,1,Squamous,1,2,1,Durvalumab,1,0,0,0,7.4,1,3,1,1,3,2,2,1,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0002485-T01-IM3,43,45,4.7,FALSE,NA,NO,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Squamous Cell Carcinoma,0,NA,CT chest/abdomen/pelvis,43,3.3,29.4,NA,2004/7/15,Durable clinical benefit,16663,NSCLC,2.4,16135,15925,1,FALSE,NA,FALSE,NA,16663,0.0331,IMPACT341,95,Squamous,No,MSKCC,Durvalumab,1,5,No,NA,FALSE,NA,NA,PD1 alone,15-Apr,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,NA,3,LUSC,24.2,NA,10,NO,lung,16150,7.4,1:PROGRESS,Lung,12-179,FALSE,NA,FALSE,NA,Tumor,1,608,Primary,Male,Former smoker,Matched,NA,Included,FALSE,NA,3.3,NA,Clinical trial,Yes,"2015, Wk. 15",NA,1970
P-0002794_3687335_347919,,P-0002794,1,discovery,HobS14-116513114658,3687335,,1,1,1,2,61,2,5,2,4.2,3.3,0,,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,14.8,1,2,0,,3,2,2,1,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0002794-T01-IM3,61,61,4.2,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Lung Adenocarcinoma,Lung Adenocarcinoma,70,NA,CT chest/abdomen/pelvis,17.1,1.1,11.2,NA,2004/7/15,NA,NA,NSCLC,3.3,23830,22504,2,FALSE,NA,FALSE,NA,23842,0.0001,IMPACT341,70,Adenocarcinoma,No,MSKCC,Nivolumab,2,70,No,Bone,FALSE,NA,NA,PD1 alone,15-Apr,NA,-1,Do not report,NA,1,LUAD,NA,NA,5,NO,lung,22955,14.8,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,213,Metastasis,Female,Current smoker (within 6 months of diagnosis),Unmatched,NA,Included,FALSE,NA,1.1,20,SOC,No,"2015, Wk. 15",NA,1954
P-0003247_489645_347881,Empty,P-0003247,0,discovery,HobS15-209701813672,489645,3259474,1,1,1,2,76,1,24,0,2.8,3.6,0,,1,Adenocarcinoma,2,1,1,Pembrolizumab,0,1,1,0,12.5,0,1,0,,1,1,2,,pelvis,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0003247-T01-IM5,76,73,2.8,FALSE,NA,NO,FALSE,NA,CR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,20,NA,CT chest,79.1,7.9,63.8,NA,2004/7/15,NA,NA,NSCLC,3.6,28327,27894,0,FALSE,NA,FALSE,NA,28350,0.049,IMPACT410,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,2,70,No,RUQ,FALSE,NA,NA,PD1 alone,15-Apr,NA,0.09,Stable,NA,8,LUAD,NA,NA,24,NO,pelvis,28276,12.5,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,597,Metastasis,Female,Former smoker,Matched,NA,Included,FALSE,NA,7.9,20,SOC,No,"2015, Wk. 15",NA,1942
P-0003275_3687793_347885,Empty,P-0003275,0,discovery,HobS14-924960484726,3687793,3687503,1,1,1,1,69,1,20,1,4.1,3,1,16.6,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,5.5,1,3,1,2,1,1,2,,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0003275-T01-IM5,69,69,4.1,FALSE,NA,NO,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest,37.9,3,25.7,NA,2004/7/15,No durable clinical benefit,25908,NSCLC,3,25571,25402,1,FALSE,NA,FALSE,NA,25908,0.0021,IMPACT410,95,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,0,No,NA,FALSE,NA,NA,PD1 alone,15-Apr,NA,0,Stable,NA,3,LUAD,16.6,NA,20,NO,lung,25568,5.5,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,689,Primary,Male,Former smoker,Matched,NA,Included,FALSE,NA,3,20,SOC,Yes,"2015, Wk. 15",NA,1946
P-0003551_3756130_347921,,P-0003551,1,discovery,HobS17-352878424559,3756130,695150,1,1,1,2,50,0,0,1,4,1.7,0,,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,1.3,1,4,1,,3,1,2,2,lung,0,0,0,0,0,0,0,0,AMP (driver),AMP (driver),L858R (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0003551-T02-IM6,50,51,4,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,89.2,11.4,81.4,NA,9/28/17,NA,NA,NSCLC,1.7,18531,18503,1,TRUE,"AMP (driver), L858R (driver)",FALSE,NA,19146,0.5334,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,10,No,NA,FALSE,NA,NA,PD1 alone,17-Sep,MICROSATELLITE INSTABILITY-INDETERMINATE. See MSI note below.,4.17,Indeterminate,694578,13,LUAD,NA,NA,0,YES,lung,18542,1.3,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,801,Primary,Female,Never smoker,Matched,NA,Included,FALSE,NA,11.4,30,SOC,No,"2017, Wk. 39",NA,1967
P-0003735_3756170_347922,Empty,P-0003735,0,discovery,HobS15-641522093251,3756170,3756180,1,1,1,2,68,1,0,1,3.4,2.8,1,3.3,1,Adenocarcinoma,4,1,1,Nivolumab,1,0,0,0,0.9,1,4,1,,3,1,2,,pleura,0,0,0,0,0,X963_splice (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,X963_splice (driver),0,0,0,0,0,0,0,0,0,#REF!,P-0003635-T01-IM5,58,57,4.2,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,74.4,6.9,57.5,NA,2004/7/15,NA,21513,NSCLC,3.1,21481,21439,2,TRUE,E746_A750del (driver),FALSE,NA,21513,0.6668,IMPACT410,NA,Adenocarcinoma,No,MSKCC,Ipilimumab+Nivolumab,3,NA,NA,Brain,FALSE,NA,NA,PD1+CTLA4,15-Apr,MICROSATELLITE INSTABILITY-INDETERMINATE. See MSI note below.,3.8,Indeterminate,NA,7,LUAD,2.4,NA,0,NO,lung,21486,1.5,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,667,Metastasis,Female,Never smoker,Matched,"Note: Copy number profile is suggestive of broad copy number loss on Chromosome arm 20q        Note: Copy number profile is suggestive of a fragmented genome..        Note: The SRC, TOP1, PTPRT, and NCOA3 copy number gain falls slightly below the cut off ",Excluded,FALSE,NA,6.9,50,SOC,Yes,"2015, Wk. 15",NA,1958
P-0004271_3687859_347923,,P-0004271,1,discovery,HobS17-133316532778,3687859,565577,1,1,1,2,38,0,0,0,4.1,1,0,,1,Adenocarcinoma,1,1,1,Atezolizumab,0,0,1,0,7.1,0,3,1,1,3,2,2,2,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0004271-T01-IM5,38,36,4.1,FALSE,NA,NO,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,10,NA,CT chest/abdomen/pelvis,37.9,3,25.7,NA,2005/6/15,Durable clinical benefit,NA,NSCLC,1,14386,14176,0,FALSE,NA,FALSE,NA,14557,0.0496,IMPACT410,95,Adenocarcinoma,No,MSKCC,Atezolizumab,1,10,No,NA,FALSE,NA,NA,PD1 alone,15-May,NA,0.16,Stable,NA,3,LUAD,NA,NA,0,NO,lung,14393,7.1,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,422,Primary,Female,Never smoker,Matched,NA,Included,FALSE,NA,3,60,SOC,No,"2015, Wk. 19",NA,1979
P-0004588_3578868_190747,,P-0004588,1,discovery,HobS15-865190220306,3578868,3554752,1,1,1,1,73,1,0,1,4.1,1.7,0,,1,Adenocarcinoma,3,1,1,Nivolumab,0,0,1,0,49.1,0,2,0,,2,2,2,2,liver,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0004588-T01-IM5,73,74,4.1,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,80,NA,CT chest/abdomen,49.7,3.9,34.6,NA,2006/3/15,NA,NA,NSCLC,1.7,28267,26769,1,FALSE,NA,FALSE,NA,28267,0.0035,IMPACT410,95,Adenocarcinoma,No,MSKCC,Nivolumab,3,95,No,NA,FALSE,NA,NA,PD1 alone,15-Jun,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,1142804,4,LUAD,NA,NA,33.75,YES,liver,28263,49.1,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,756,Primary,Male,Former smoker,Matched,NA,Included,FALSE,NA,3.9,10,SOC,No,"2015, Wk. 23",NA,1942
P-0005783_3687878_347928,Empty,P-0005783,0,discovery,HobS17-580355034557,3687878,752519,1,1,1,2,53,1,10,0,4.1,2.3,0,,1,Adenocarcinoma,3,1,1,Nivolumab,0,1,0,0,22.8,0,1,0,,1,1,2,,brain,L63I,0,K1422N,"AMP, S829I",0,0,0,Q1552H,0,0,0,0,0,0,L63I,0,0,0,0,0,0,0,K1422N,0,AMP,AMP,S829I,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Q1552H,0,#REF!,P-0005783-T02-IM6,53,55,4.1,FALSE,L63I,YES,FALSE,Q1552H,CR,FALSE,NA,Lung Adenocarcinoma,Lung Adenocarcinoma,0,NA,CT chest,99.4,90.4,100,NA,2010/7/17,NA,NA,NSCLC,2.3,19949,19585,0,FALSE,NA,FALSE,NA,20375,0.6344,IMPACT468,80,Adenocarcinoma,Yes,MSKCC,Nivolumab,3,0,No,Brain,FALSE,NA,NA,PD1 alone,17-Oct,MICROSATELLITE INSTABILITY-INDETERMINATE. See MSI note below.,3.09,Indeterminate,721812,102,LUAD,NA,NA,10,YES,brain,20280,22.8,0:CENSORED,Lung,NA,FALSE,"AMP, S829I",FALSE,K1422N,Tumor,1,603,Metastasis,Female,Former smoker,Matched,NA,Included,FALSE,NA,90.4,30,SOC,No,"2017, Wk. 40",NA,1963
P-0006046_3687400_347918,Empty,P-0006046,0,discovery,HobS16-126753243820,3687400,,1,1,1,1,60,1,40,1,4.1,3.1,0,,1,Adenocarcinoma,3,1,1,Nivolumab,0,0,1,0,30.7,0,2,0,,2,2,2,,lymph node,0,0,0,0,I572F,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,I572F,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0006046-T01-IM5,60,60,4.1,FALSE,NA,NO,FALSE,NA,PR,FALSE,I572F,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen,94.4,20.7,94.1,Cytolyt,8/18/15,NA,NA,NSCLC,3.1,22753,22011,1,FALSE,NA,FALSE,NA,23040,0.2782,IMPACT410,95,Adenocarcinoma,No,MSKCC,Nivolumab,3,0,No,NA,FALSE,NA,NA,PD1 alone,15-Aug,NA,0.31,Stable,NA,21,LUAD,NA,NA,40,NO,lymph node,22946,30.7,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,716,Primary,Male,Former smoker,Matched,The FGFR2 p.M1 mutation disrupts translation start. It is uncertain if this mutation is inactivating.,Included,FALSE,NA,20.7,70,SOC,No,"2015, Wk. 34",NA,1956
P-0006071_3756192_190371,,P-0006071,1,discovery,HobS15-111574919524,3756192,3756208,1,1,1,2,53,2,40,1,4.3,1.1,1,21.8,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,4.7,1,3,1,2,3,1,2,3,pleura,0,0,0,0,0,0,Q220* (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Q220* (driver),0,0,0,0,0,#REF!,P-0006071-T01-IM5,53,53,4.3,FALSE,NA,NO,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,93.4,17.7,91.7,NA,8/20/15,No durable clinical benefit,20032,NSCLC,1.1,19503,19368,1,FALSE,NA,FALSE,NA,20032,0.4911,IMPACT410,95,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,0,No,NA,FALSE,NA,NA,PD1 alone,15-Aug,NA,3.99,Indeterminate,NA,18,LUAD,21.8,NA,40,NO,pleura,19510,4.7,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,752,Primary,Female,Current smoker (within 6 months of diagnosis),Matched,Note: The SMAD4 exon9 mutations all occur in cis (same allele).      Note: Copy number profile is suggestive of an intrangenic gain of NCOA3 exons 2-17.,Included,TRUE,Q220* (driver),17.7,70,SOC,Yes,"2015, Wk. 34",NA,1963
P-0006516_3687824_347931,Empty,P-0006516,0,discovery,HobS15-975682681846,3687824,3687681,1,1,1,1,73,1,0,1,2.4,5.5,1,0.9,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,0.9,1,8,1,,3,1,2,,pleura,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0006516-T01-IM5,73,74,2.4,FALSE,NA,NO,FALSE,NA,POD/death,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,25.2,2,16.2,NA,9/16/15,NA,26775,NSCLC,5.5,26761,26747,1,FALSE,NA,FALSE,NA,26775,0.0054,IMPACT410,50,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,0,No,NA,FALSE,NA,NA,PD1 alone,15-Sep,NA,0,Stable,1142945,2,LUAD,0.9,NA,55.2,YES,pleura,26775,0.9,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,888,Primary,Male,Former smoker,Matched,"Note: Low tumor content (approximately 20% or less). Negative mutation, copy number and structural variant results should be interpreted with caution.",Included,FALSE,NA,2,10,SOC,Yes,"2015, Wk. 38",NA,1942
P-0006607_3369379_191138,,P-0006607,1,discovery,HobS16-017281723491,3369379,2337955,1,1,1,1,61,0,0,1,4.3,2.3,0,,1,Adenocarcinoma,1,2,2,Ipilimumab+Nivolumab,1,0,0,0,9.4,1,3,1,1,3,2,2,1,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0006607-T01-IM5,61,62,4.3,FALSE,NA,NO,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,25.2,2,16.2,NA,9/29/15,Durable clinical benefit,NA,NSCLC,2.3,22993,22463,1,FALSE,NA,FALSE,NA,23694,0.0039,IMPACT410,NA,Adenocarcinoma,No,MSKCC,Ipilimumab+Nivolumab,1,0,No,NA,FALSE,NA,NA,PD1+CTLA4,15-Sep,MICROSATELLITE STABLE (MSS). See MSI note below.,0.14,Stable,NA,2,LUAD,NA,NA,0,NO,lung,22750,9.4,1:PROGRESS,Lung,15-251,FALSE,NA,FALSE,NA,Tumor,1,699,Primary,Male,Never smoker,Matched,"Note: Low tumor content (approximately 20% or less). Negative mutation, copy number and structural variant results should be interpreted with caution.",Included,FALSE,NA,2,20,Clinical trial,No,"2015, Wk. 40",NA,1954
P-0006663_3393878_190922,,P-0006663,1,discovery,HobS15-955308987465,3393878,,1,1,1,2,64,1,30,0,4.2,2.9,0,,1,Adenocarcinoma,2,1,1,Nivolumab,0,0,1,0,30.8,0,2,0,,3,1,2,1,lymph node,0,0,Y802C,0,0,0,D194Y (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Y802C,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,D194Y (driver),0,0,0,0,0,#REF!,P-0006663-T01-IM5,64,64,4.2,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,93.8,18.7,92.4,NA,2010/2/15,NA,NA,NSCLC,2.9,24421,23441,0,FALSE,NA,FALSE,NA,24421,0.0603,IMPACT410,90,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,0,No,Lymph Node,FALSE,NA,NA,PD1 alone,15-Oct,NA,0,Stable,NA,20,LUAD,NA,NA,30,NO,lymph node,24378,30.8,0:CENSORED,Lung,NA,FALSE,NA,FALSE,Y802C,Tumor,1,830,Metastasis,Female,Former smoker,Matched,NA,Included,TRUE,D194Y (driver),18.7,10,SOC,No,"2015, Wk. 40",NA,1952
P-0006768_4289946_347905,,P-0006768,1,discovery,HobS16-039265172823,4289946,2893400,1,1,1,1,66,2,30,0,4.2,3.8,1,28.4,1,Adenocarcinoma,1,1,1,Nivolumab,1,0,0,0,4.2,1,3,1,2,1,2,2,1,liver,0,0,0,0,0,0,S428L,0,AMP (driver),AMP (driver),0,EGFR-intragenic,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,S428L,0,0,0,0,0,#REF!,P-0006768-T01-IM5,66,67,4.2,FALSE,NA,NO,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest,79.1,7.9,63.8,NA,2010/9/15,No durable clinical benefit,25287,NSCLC,3.8,24550,24423,0,TRUE,"AMP (driver), EGFR-intragenic",FALSE,NA,25287,0.2796,IMPACT410,NA,Adenocarcinoma,No,MSKCC,Nivolumab,1,0,No,NA,FALSE,NA,NA,PD1 alone,15-Oct,MICROSATELLITE STABLE (MSS). See MSI note below.,0.57,Stable,1142908,8,LUAD,28.4,NA,30,YES,liver,24551,4.2,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,1424,Primary,Male,Current smoker (within 6 months of diagnosis),Matched,NA,Included,FALSE,S428L,7.9,50,SOC,Yes,"2015, Wk. 41",NA,1949
P-0007493_3369397_190323,,P-0007493,1,discovery,HobS16-731433646489,3369397,2069579,1,1,1,1,76,2,116,1,4,1.8,0,,1,Adenocarcinoma,2,1,1,Pembrolizumab,1,0,0,0,5.6,1,2,0,,3,1,2,1,bone,0,0,0,0,0,0,0,H173R,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,H173R,0,#REF!,P-0007493-T02-IM5,76,75,4,FALSE,NA,NO,FALSE,H173R,PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,95,NA,CT chest/abdomen/pelvis,93.8,18.7,92.4,NA,4/16/16,NA,NA,NSCLC,1.8,28241,27751,1,FALSE,NA,FALSE,NA,28753,0.4615,IMPACT410,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,2,90,No,Bone,FALSE,NA,NA,PD1 alone,16-Apr,NA,0.96,Stable,416500,19,LUAD,NA,NA,116,YES,bone,27922,5.6,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,902,Metastasis,Male,Current smoker (within 6 months of diagnosis),Matched,NA,Included,FALSE,NA,18.7,40,SOC,No,"2016, Wk. 15",NA,1941
P-0008422_987842_190516,,P-0008422,1,discovery,HobS17-065091129355,987842,731110,1,1,1,1,69,1,30,0,3.9,3.3,0,,1,Squamous,1,1,1,Pembrolizumab,0,0,1,0,21.9,0,2,0,,1,1,2,3,lung,E275*,0,0,0,0,0,0,0,0,0,0,0,0,0,E275*,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0008422-T03-IM6,69,70,3.9,FALSE,E275*,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Squamous Cell Carcinoma,40,NA,CT chest,63.5,5.3,46.4,NA,8/27/17,NA,NA,NSCLC,3.3,26131,25375,0,FALSE,NA,FALSE,NA,26145,0.5332,IMPACT468,95,Squamous,Yes,MSKCC,Pembrolizumab,1,30,No,NA,FALSE,NA,NA,PD1 alone,17-Aug,MICROSATELLITE STABLE (MSS). See MSI note below.,2.32,Stable,678801,6,LUSC,NA,NA,30,YES,lung,26043,21.9,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,690,Primary,Male,Former smoker,Matched,NA,Included,FALSE,NA,5.3,40,SOC,No,"2017, Wk. 34",NA,1948
P-0009017_3687836_347912,,P-0009017,1,discovery,HobS16-561481393336,3687836,1596695,1,1,1,1,77,1,30,1,3.6,3.5,0,,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,8.5,0,3,1,1,3,1,2,1,lymph node,0,AMP (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,AMP (driver),AMP (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0009017-T01-IM5,77,77,3.6,FALSE,NA,NO,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,96.7,33.4,98,NA,1/25/16,Durable clinical benefit,NA,NSCLC,3.5,28589,28345,1,FALSE,NA,TRUE,AMP (driver),28659,0.1702,IMPACT410,95,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,0,No,Lymph Node,FALSE,NA,NA,PD1 alone,16-Jan,NA,2.34,Stable,NA,34,LUAD,NA,NA,30,NO,lymph node,28603,8.5,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,1097,Metastasis,Male,Former smoker,Matched,NA,Included,FALSE,NA,33.4,40,SOC,No,"2016, Wk. 04",NA,1939
P-0009068_3578873_191095,Empty,P-0009068,0,discovery,HobS14-888560561614,3578873,3030588,1,1,1,2,73,1,0,1,3.8,4.1,0,,1,NOS,2,1,1,Nivolumab,0,0,1,0,40.3,0,2,0,,3,1,2,,adrenal,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0009068-T01-IM5,73,74,3.8,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Poorly Differentiated Non-Small Cell Lung Cancer,70,NA,CT chest/abdomen/pelvis,94.1,19.7,93.3,NA,2002/5/16,NA,NA,NSCLC,4.1,28264,26995,1,FALSE,NA,FALSE,NA,28264,0.1331,IMPACT410,95,NOS,Yes,MSKCC,Nivolumab,2,90,No,Adrenal Gland,FALSE,NA,NA,PD1 alone,16-Feb,MICROSATELLITE INSTABILITY-HIGH (MSI-H). See MSI note below.,14.2,Instable,NA,20,NSCLCPD,NA,NA,28.5,NO,adrenal,28221,40.3,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,1030,Metastasis,Female,Former smoker,Matched,NA,Included,FALSE,NA,19.7,50,SOC,No,"2016, Wk. 05",NA,1942
P-0009110_3687829_190830,,P-0009110,1,discovery,HobS16-168664786132,3687829,3687679,1,1,1,2,54,1,28,0,3.7,3.3,0,,1,Adenocarcinoma,3,1,1,Nivolumab,1,0,0,0,14.7,1,2,0,,3,1,2,1,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0009110-T01-IM5,54,54,3.7,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,92.8,16.7,90.4,NA,1/30/16,NA,NA,NSCLC,3.3,20527,19988,0,FALSE,NA,FALSE,NA,20793,0,IMPACT410,95,Adenocarcinoma,Yes,MSKCC,Nivolumab,3,0,No,NA,FALSE,NA,NA,PD1 alone,16-Jan,MICROSATELLITE STABLE (MSS). See MSI note below.,0.31,Stable,399008,17,LUAD,NA,NA,28,YES,lung,20434,14.7,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,1102,Primary,Female,Former smoker,Matched,"Note: Low tumor content (approximately 20% or less). Negative mutation, copy number and structural variant results should be interpreted with caution.",Included,FALSE,NA,16.7,10,SOC,No,"2016, Wk. 04",NA,1962
P-0009168_4343310_347944,Empty,P-0009168,0,discovery,HobS16-810952739099,4343310,,1,1,1,1,75,1,60,1,3.9,1.1,1,16.4,1,Adenocarcinoma,1,1,1,Nivolumab,1,0,0,0,16.4,1,3,1,1,1,2,2,,lung,0,0,L1945Sfs*17,"E61K, Q371K",0,0,0,Q520* (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,L1945Sfs*17,0,0,0,"E61K, Q371K",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Q520* (driver),0,#REF!,P-0009168-T01-IM5,75,75,3.9,FALSE,NA,NO,TRUE,Q520* (driver),SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest,96.2,29.5,97.3,NA,2002/5/16,Durable clinical benefit,28147,NSCLC,1.1,27743,27647,1,FALSE,NA,FALSE,NA,28147,0.0039,IMPACT410,NA,Adenocarcinoma,No,MSKCC,Nivolumab,1,0,No,NA,FALSE,NA,NA,PD1 alone,16-Feb,NA,0.08,Stable,NA,29,LUAD,16.4,NA,60,NO,lung,28147,16.4,1:PROGRESS,Lung,NA,FALSE,"E61K, Q371K",FALSE,L1945Sfs*17,Tumor,1,1044,Primary,Male,Former smoker,Matched,NA,Included,FALSE,NA,29.5,20,SOC,Yes,"2016, Wk. 05",NA,1941
P-0009473_3578891_190972,Empty,P-0009473,0,discovery,HobS15-536807624430,3578891,383034,1,1,1,1,79,1,9,0,4,1.5,0,,1,Adenocarcinoma,2,1,1,Nivolumab,0,1,0,0,40.3,0,2,0,,3,1,2,,unknown,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0009473-T01-IM5,79,80,4,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenosquamous Carcinoma,80,NA,CT chest/abdomen/pelvis,84.8,8.9,72.7,NA,2/19/16,NA,NA,NSCLC,1.5,29554,29082,0,FALSE,NA,FALSE,NA,30389,0.0794,IMPACT410,70,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,80,Yes,NA,FALSE,NA,NA,PD1 alone,16-Feb,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,398027,9,LUAS,NA,NA,9,YES,unknown,30309,40.3,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,709,Primary,Male,Former smoker,Matched,NA,Included,FALSE,NA,8.9,20,SOC,No,"2016, Wk. 07",NA,1936
P-0009476_3756012_347943,,P-0009476,1,discovery,HobS16-005067133953,3756012,1760154,1,1,1,2,58,1,20,1,3.3,6.5,1,0.7,1,NOS,4,1,1,Pembrolizumab,1,0,0,0,0.7,1,8,1,,3,1,2,2,"skin, muscle, fat",G718A,0,0,0,0,0,0,0,0,0,0,0,0,0,G718A,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0009476-T01-IM5,58,58,3.3,FALSE,G718A,NO,FALSE,NA,POD/death,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,60,NA,CT chest/abdomen/pelvis,78.9,7.9,63.7,NA,2/19/16,NA,21258,NSCLC,6.5,21238,21238,1,FALSE,NA,FALSE,NA,21258,0.1335,IMPACT410,95,NOS,Yes,MSKCC,Pembrolizumab,4,80,No,Spine,FALSE,NA,NA,PD1 alone,16-Feb,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,398112,7,LUAD,0.7,NA,20,YES,"skin, muscle, fat",21258,0.7,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,717,Metastasis,Female,Former smoker,Matched,NA,Included,FALSE,NA,7.9,60,SOC,Yes,"2016, Wk. 07",NA,1958
P-0009483_3756049_347945,Empty,P-0009483,0,discovery,HobS16-252074398449,3756049,2671565,1,1,1,2,82,1,45,0,3.9,3,1,8.9,1,Adenocarcinoma,1,1,2,Nivolumab (+added ipilimumab),1,0,0,0,1.4,1,4,1,,3,2,2,,lung,0,0,0,0,G464R (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,G464R (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0009483-T01-IM5,82,82,3.9,FALSE,NA,NO,FALSE,NA,POD,TRUE,G464R (driver),Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,85.9,9.8,74.8,NA,2/21/16,NA,30234,NSCLC,3,30081,29962,0,FALSE,NA,FALSE,NA,30234,0,IMPACT410,80,Adenocarcinoma,No,MSKCC,Nivolumab (+added ipilimumab),1,0,No,NA,FALSE,NA,NA,PD1+CTLA4,16-Feb,NA,0,Stable,398136,10,LUAD,8.9,NA,45,YES,lung,30006,1.4,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,802,Primary,Female,Former smoker,Matched,Note: Low tumor content (approximately 20% or less). Negative copy number and structural variant results should be interpreted with caution.,Included,FALSE,NA,9.8,NA,SOC,Yes,"2016, Wk. 07",NA,1934
P-0009952_3756320_347947,Empty,P-0009952,0,discovery,HobS16-073883024449,3756320,,1,1,1,1,63,1,23,0,3.7,2.8,1,12.9,1,Squamous,2,1,1,Nivolumab,1,0,0,0,2.1,1,4,1,,1,1,2,,lymph node,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0009952-T01-IM5,63,63,3.7,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Squamous Cell Carcinoma,0,NA,CT chest,13.1,1,7.8,Cytolyt,3/13/16,NA,23736,NSCLC,2.8,23399,23343,0,FALSE,NA,FALSE,NA,23736,0.0079,IMPACT410,50,Squamous,Yes,MSKCC,Nivolumab,2,50,Yes,Lymph Node,FALSE,NA,NA,PD1 alone,16-Mar,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,405370,1,LUSC,12.9,NA,23,YES,lymph node,23407,2.1,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,1101,Metastasis,Male,Former smoker,Matched,"Note: Low tumor content (approximately 20% or less). Negative mutation, copy number and structural variant results should be interpreted with caution.",Included,FALSE,NA,1,10,SOC,Yes,"2016, Wk. 10",NA,1953
P-0010063_3369815_191036,,P-0010063,1,discovery,HobS16-741060224199,3369815,3576203,1,1,1,1,73,1,6,0,4.1,1.7,1,19.4,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,2.6,1,4,1,,1,2,2,2,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0010063-T01-IM5,73,73,4.1,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest,59.8,4.9,43,NA,3/19/16,NA,27597,NSCLC,1.7,27078,27007,0,FALSE,NA,FALSE,NA,27597,0.0926,IMPACT410,80,Adenocarcinoma,No,MSKCC,Nivolumab,2,0,No,NA,FALSE,NA,NA,PD1 alone,16-Mar,NA,0.31,Stable,404041,4,LUAD,19.4,NA,6,YES,lung,27087,2.6,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,1157,Primary,Male,Former smoker,Matched,NA,Included,FALSE,NA,4.9,40,SOC,Yes,"2016, Wk. 11",NA,1943
P-0010507_3756254_347882,,P-0010507,1,discovery,HobS17-323002585318,3756254,588080,1,1,1,1,83,0,0,1,4.3,1.2,0,,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,4.1,1,4,1,,3,1,2,1,lung,0,0,0,0,0,0,STK11-intragenic,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,STK11-intragenic,0,0,0,0,#REF!,P-0010507-T03-IM6,83,82,4.3,FALSE,NA,YES,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,25.2,1.8,16.1,NA,2004/5/17,NA,NA,NSCLC,1.2,30633,30549,1,FALSE,NA,FALSE,NA,30868,0.0905,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,0,No,NA,FALSE,NA,NA,PD1 alone,17-Apr,MICROSATELLITE STABLE (MSS). This result is for investigational use only. See MSI note below.,0.06,Stable,589024,2,LUAD,NA,NA,0,YES,lung,30673,4.1,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,802,Primary,Male,Never smoker,Matched,NA,Included,FALSE,STK11-intragenic,1.8,30,SOC,No,"2017, Wk. 14",NA,1935
P-0010514_3369510_190734,,P-0010514,1,discovery,HobS17-706271549950,3369510,633177,1,1,1,2,63,1,54,1,3.4,0.9,0,,1,Adenocarcinoma,4,1,1,Pembrolizumab,1,0,0,0,6.9,1,2,0,,1,2,2,1,mediastinum,F255L,0,0,0,0,0,0,0,0,0,0,0,0,0,F255L,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0010514-T01-IM5,63,62,3.4,FALSE,F255L,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,90,NA,CT chest,59.8,4.9,43,NA,2004/9/16,NA,NA,NSCLC,0.9,23525,23098,1,FALSE,NA,FALSE,NA,23910,0.535,IMPACT410,50,Adenocarcinoma,No,MSKCC,Pembrolizumab,4,90,Yes,Lymph Node,FALSE,NA,NA,PD1 alone,16-Apr,NA,3.85,Indeterminate,413900,5,NSCLC,NA,NA,54,YES,mediastinum,23308,6.9,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,80,Metastasis,Female,Former smoker,Matched,"Note: Low sequencing depth of coverage of 80X, negative results should be interpreted with caution.",Included,FALSE,NA,4.9,50,SOC,No,"2016, Wk. 14",NA,1954
P-0010927_704652_190939,,P-0010927,1,discovery,HobS17-193838034559,704652,704655,1,1,1,2,67,1,8,0,4.1,2.2,0,,1,Adenocarcinoma,4,1,1,Atezolizumab,0,0,1,0,24,0,2,0,,3,1,2,2,soft tissue (L3),0,L755P (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,L755P (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0010927-T03-IM6,67,68,4.1,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,60,NA,CT chest/abdomen/pelvis,54.1,4.4,38.5,NA,9/20/17,NA,NA,NSCLC,2.2,25228,24493,0,FALSE,NA,TRUE,L755P (driver),25228,0.0624,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Atezolizumab,4,50,No,Lumbar spine,FALSE,NA,NA,PD1 alone,17-Sep,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,725884,5,LUAD,NA,NA,8,YES,soft tissue (L3),25224,24,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,762,Metastasis,Female,Former smoker,Matched,NA,Included,FALSE,NA,4.4,30,SOC,No,"2017, Wk. 38",NA,1950
P-0010980_3687687_347951,,P-0010980,1,discovery,HobS18-187679923882,3687687,3687420,1,1,1,2,75,1,11,1,4.3,4.5,1,12.2,1,Adenocarcinoma,1,1,1,Atezolizumab,1,0,0,0,1.3,1,4,1,,3,1,2,2,lung,0,0,0,0,0,0,W308C (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,W308C (driver),0,0,0,0,0,#REF!,P-0010980-T02-IM6,75,75,4.3,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,82.2,8.8,68.4,NA,2/17/18,NA,27941,NSCLC,4.5,27591,27570,1,FALSE,NA,FALSE,NA,27941,0.2698,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Atezolizumab,1,1,No,NA,FALSE,NA,NA,PD1 alone,18-Feb,MICROSATELLITE STABLE (MSS). See MSI note below.,0.78,Stable,945580,9,LUAD,12.2,NA,11,YES,lung,27609,1.3,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,796,Primary,Female,Former smoker,Matched,NA,Included,TRUE,W308C (driver),8.8,40,SOC,Yes,"2018, Wk. 07",NA,1943
P-0011260_3687711_347942,,P-0011260,1,discovery,HobS16-305466246210,3687711,3687633,1,1,1,2,47,1,9,1,3.4,2.5,1,1.5,1,Adenocarcinoma,2,2,2,Durvalumab+Tremelimumab,1,0,0,0,0.6,1,4,1,,3,2,2,1,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0011260-T01-IM5,47,48,3.4,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,50,NA,CT chest/abdomen/pelvis,89.2,11.8,81.4,NA,5/18/16,NA,17196,NSCLC,2.5,17151,17151,1,FALSE,NA,FALSE,NA,17196,0.1724,IMPACT410,95,Adenocarcinoma,No,MSKCC,Durvalumab+Tremelimumab,2,50,No,Pleural Fluid,FALSE,NA,NA,PD1+CTLA4,16-May,MICROSATELLITE STABLE (MSS). See MSI note below.,0.54,Stable,1142966,12,LUAD,1.5,NA,9,YES,lung,17169,0.6,1:PROGRESS,Lung,13-197,FALSE,NA,FALSE,NA,Tumor,1,1035,Metastasis,Female,Former smoker,Matched,NA,Included,FALSE,NA,11.8,80,Clinical trial,Yes,"2016, Wk. 20",NA,1969
P-0011537_3756249_347952,,P-0011537,1,discovery,HobS17-922804878949,3756249,767336,1,1,1,1,70,2,0,1,3.9,2,0,,1,Squamous,1,1,1,Pembrolizumab,1,0,0,0,15.6,1,3,1,1,1,2,2,1,chest wall,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0011537-T02-IM6,70,70,3.9,FALSE,NA,NO,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Squamous Cell Carcinoma,30,NA,CT chest,44.1,3.5,30.4,NA,3/27/17,Durable clinical benefit,NA,NSCLC,2,25905,25688,1,FALSE,NA,FALSE,NA,26374,0.7981,IMPACT468,95,Squamous,No,MSKCC,Pembrolizumab,1,30,No,NA,FALSE,NA,NA,PD1 alone,17-Mar,MICROSATELLITE STABLE (MSS). This result is for investigational use only. See MSI note below.,2.24,Stable,583617,4,LUSC,NA,NA,6.25,YES,chest wall,26163,15.6,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,909,Primary,Male,Current smoker (within 6 months of diagnosis),Matched,Note: Copy number profile is suggestive of a fragmented genome.,Included,FALSE,NA,3.5,50,SOC,No,"2017, Wk. 13",NA,1947
P-0012056_3369570_190787,Empty,P-0012056,0,discovery,HobS17-053626062411,3369570,673939,1,1,1,1,63,1,70,1,3.8,2.9,1,3.6,1,Adenocarcinoma,2,1,1,Atezolizumab,1,0,0,0,1.3,1,4,1,,3,1,2,,liver,0,AMP (driver),0,0,0,0,0,0,0,0,G1185S,0,0,0,0,0,AMP (driver),AMP (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0012056-T02-IM6,63,65,3.8,FALSE,NA,YES,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,87.1,10.5,77,NA,8/18/17,NA,23466,NSCLC,2.9,23377,23356,1,FALSE,G1185S,TRUE,AMP (driver),23466,0.3752,IMPACT468,NA,Adenocarcinoma,Yes,MSKCC,Atezolizumab,2,NA,NA,Liver,FALSE,NA,NA,PD1 alone,17-Aug,MICROSATELLITE STABLE (MSS). See MSI note below.,0.27,Stable,708108,12,LUAD,3.6,NA,70,YES,liver,23397,1.3,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,721,Metastasis,Male,Former smoker,Matched,NA,Excluded,FALSE,NA,10.5,20,SOC,Yes,"2017, Wk. 33",NA,1953
P-0012090_4343300_347937,,P-0012090,1,discovery,HobS16-891963640062,4343300,,1,1,1,1,79,1,15,1,3.8,4.2,1,0.8,1,Adenocarcinoma,3,1,1,Atezolizumab,1,0,0,0,0.8,1,8,1,,3,1,2,2,lung,0,Y772_A775dup (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Y772_A775dup (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0012090-T01-IM5,79,79,3.8,FALSE,NA,NO,FALSE,NA,POD/death,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,68,5.9,50.9,NA,2006/10/16,NA,29064,NSCLC,4.2,29041,29041,1,FALSE,NA,TRUE,Y772_A775dup (driver),29064,0.009,IMPACT410,NA,Adenocarcinoma,Yes,MSKCC,Atezolizumab,3,0,No,NA,FALSE,NA,NA,PD1 alone,16-Jun,NA,0.15,Stable,405452,6,LUAD,0.8,NA,15,YES,lung,29064,0.8,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,988,Primary,Male,Former smoker,Matched,"Note: Low tumor content (approximately 20% or less). Negative mutation, copy number and structural variant results should be interpreted with caution.",Included,FALSE,NA,5.9,40,SOC,Yes,"2016, Wk. 23",NA,1938
P-0012476_3687747_347901,Empty,P-0012476,0,discovery,HobS16-849168734052,3687747,541139,1,1,1,2,84,1,50,1,4,2,1,6.7,1,Adenocarcinoma,2,1,1,Atezolizumab,1,0,0,0,3.1,1,3,1,2,3,2,2,,bone,0,0,0,C528S,0,0,P281Rfs*6 (driver),A1029S,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,C528S,0,0,0,0,0,0,0,0,0,0,0,P281Rfs*6 (driver),0,0,0,A1029S,0,#REF!,P-0012476-T02-IM6,84,84,4,FALSE,NA,NO,FALSE,A1029S,SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,87.1,10.5,77,NA,2003/2/17,No durable clinical benefit,31076,NSCLC,2,30871,30871,1,FALSE,NA,FALSE,NA,31076,0.0066,IMPACT468,NA,Adenocarcinoma,No,MSKCC,Atezolizumab,2,0,No,NA,FALSE,NA,NA,PD1 alone,17-Mar,NA,0,Do not report,NA,12,LUAD,6.7,NA,50,NO,bone,30966,3.1,1:PROGRESS,Lung,NA,FALSE,C528S,FALSE,NA,Tumor,1,726,Primary,Female,Former smoker,Matched,NA,Included,TRUE,P281Rfs*6 (driver),10.5,20,SOC,Yes,"2017, Wk. 09",NA,1933
P-0012679_3687700_347900,Empty,P-0012679,0,discovery,HobS16-577951070811,3687700,3687661,1,1,1,2,57,0,0,1,3.7,3.6,1,1.1,1,Adenocarcinoma,7,1,1,Pembrolizumab,1,0,0,0,1.1,1,8,1,,3,1,2,,liver,EML4-ALK fusion,0,0,0,0,0,0,0,0,0,0,0,0,0,0,EML4-ALK fusion,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0012679-T01-IM5,57,58,3.7,FALSE,EML4-ALK fusion,NO,FALSE,NA,POD/death,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,5,NA,CT chest/abdomen/pelvis,49.7,3.9,34.6,NA,6/29/16,NA,21027,NSCLC,3.6,20993,20993,1,FALSE,NA,FALSE,NA,21027,0.2179,IMPACT410,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,7,60,No,Liver,FALSE,NA,NA,PD1 alone,16-Jun,NA,0.16,Stable,448837,4,LUAD,1.1,NA,0,YES,liver,21027,1.1,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,1071,Metastasis,Female,Never smoker,Matched,NA,Included,FALSE,NA,3.9,40,SOC,Yes,"2016, Wk. 26",NA,1959
P-0012894_3369264_191166,,P-0012894,1,discovery,HobS17-945375710139,3369264,,1,1,1,2,58,2,0,1,4.1,4,1,5.2,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,1.6,1,4,1,,3,2,2,2,lymph node,0,0,0,0,N581I (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,N581I (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0012894-T01-IM5,58,58,4.1,FALSE,NA,NO,FALSE,NA,POD,TRUE,N581I (driver),Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,25.2,2,16.2,Cytolyt,2007/12/16,NA,21343,NSCLC,4,21224,21184,1,FALSE,NA,FALSE,NA,21343,0.0116,IMPACT410,90,Adenocarcinoma,No,MSKCC,Nivolumab,2,0,No,NA,FALSE,NA,NA,PD1 alone,16-Jul,NA,0,Stable,NA,2,LUAD,5.2,NA,12.75,NO,lymph node,21234,1.6,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,842,Primary,Female,Current smoker (within 6 months of diagnosis),Matched,NA,Included,FALSE,NA,2,40,SOC,Yes,"2016, Wk. 28",NA,1959
P-0013406_459288_347960,,P-0013406,1,discovery,HobS16-710553668962,459288,459279,1,1,1,1,69,0,0,1,2.5,6.5,1,0.6,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,0.6,1,8,1,,3,1,2,1,pleura,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0013406-T01-IM5,69,70,2.5,FALSE,NA,NO,FALSE,NA,POD/death,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,60,NA,CT chest/abdomen/pelvis,NA,NA,NA,NA,2008/4/16,NA,25370,NSCLC,6.5,25351,25351,1,FALSE,NA,FALSE,NA,25370,0.0029,IMPACT410,80,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,60,Yes,Pleura,FALSE,NA,NA,PD1 alone,16-Aug,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,458585,NA,LUAD,0.6,NA,0,YES,pleura,25370,0.6,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,1023,Metastasis,Male,Never smoker,Matched,"Note: Low tumor content (approximately 20% or less). Negative mutation, copy number and structural variant results should be interpreted with caution. Repeat testing is recommended on a separate tumor block.",Included,FALSE,NA,0,10,SOC,Yes,"2016, Wk. 31",NA,1947
P-0013653_453907_190430,,P-0013653,1,discovery,HobS16-040415040780,453907,453905,1,1,1,2,69,1,48,1,4,2.4,0,,1,Adenocarcinoma,2,2,2,Durvalumab+Tremelimumab,1,0,0,0,5.4,1,3,1,2,3,1,2,1,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0013653-T01-IM5,69,71,4,FALSE,NA,NO,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,84.8,8.9,72.7,NA,8/17/16,No durable clinical benefit,NA,NSCLC,2.4,25759,25500,1,FALSE,NA,FALSE,NA,26655,0.0024,IMPACT410,70,Adenocarcinoma,Yes,MSKCC,Durvalumab+Tremelimumab,2,20,Yes,NA,FALSE,NA,NA,PD1+CTLA4,16-Aug,MICROSATELLITE STABLE (MSS). See MSI note below.,0.14,Stable,458240,9,LUAD,NA,NA,48,YES,lung,25663,5.4,1:PROGRESS,Lung,13-197,FALSE,NA,FALSE,NA,Tumor,1,1071,Primary,Female,Former smoker,Matched,NA,Included,FALSE,NA,8.9,20,Clinical trial,No,"2016, Wk. 33",NA,1946
P-0013656_3369367_191007,,P-0013656,1,discovery,HobS16-115216236140,3369367,2538195,1,1,1,2,55,1,15,1,4.5,2.5,1,4.7,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,2.7,1,4,1,,3,1,2,1,lymph node,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0013656-T01-IM5,55,56,4.5,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,50,NA,CT chest/abdomen/pelvis,49.7,3.9,34.6,NA,8/17/16,NA,20508,NSCLC,2.5,20438,20364,1,FALSE,NA,FALSE,NA,20508,0.0495,IMPACT410,70,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,60,Yes,Lymph Node,FALSE,NA,NA,PD1 alone,16-Aug,NA,0,Stable,448839,4,LUAD,4.7,NA,15,YES,lymph node,20447,2.7,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,1049,Metastasis,Female,Former smoker,Matched,NA,Included,FALSE,NA,3.9,20,SOC,Yes,"2016, Wk. 33",NA,1961
P-0013719_3369521_190836,,P-0013719,1,discovery,HobS17-810483260313,3369521,626298,1,1,1,2,68,0,0,1,3.9,1.2,1,17.9,1,Adenocarcinoma,4,1,1,Atezolizumab,1,0,0,0,2.2,1,4,1,,3,2,2,1,bone,0,0,0,0,0,0,0,0,0,0,L858R (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0013719-T01-IM5,68,67,3.9,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,60,NA,CT chest/abdomen/pelvis,68,5.9,50.9,NA,8/18/16,NA,25371,NSCLC,1.2,24873,24827,1,TRUE,L858R (driver),FALSE,NA,25371,0.1299,IMPACT410,60,Adenocarcinoma,No,MSKCC,Atezolizumab,4,60,Yes,Bone,FALSE,NA,NA,PD1 alone,16-Aug,NA,0.14,Stable,460099,6,LUAD,17.9,NA,0,YES,bone,24893,2.2,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,964,Metastasis,Female,Never smoker,Matched,NA,Included,FALSE,NA,5.9,30,SOC,Yes,"2016, Wk. 33",NA,1950
P-0014061_3756089_347914,,P-0014061,1,discovery,HobS16-645889031351,3756089,3556607,1,1,1,2,74,1,46,1,4,1.9,0,,1,Adenocarcinoma,1,1,1,Pembrolizumab,0,0,1,0,9.6,0,3,1,1,1,2,2,1,lung,R121Q,0,0,0,0,0,R40L,E1774* (driver),0,0,0,0,0,0,R121Q,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R40L,0,0,0,E1774* (driver),0,#REF!,P-0014061-T02-IM6,74,74,4,FALSE,R121Q,NO,TRUE,E1774* (driver),SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,80,NA,CT chest,95.5,25.5,96.4,NA,4/25/18,Durable clinical benefit,NA,NSCLC,1.9,27558,27192,1,FALSE,NA,FALSE,NA,27577,0.2561,IMPACT468,60,Adenocarcinoma,No,MSKCC,Pembrolizumab,1,90,Yes,Brain,FALSE,NA,NA,PD1 alone,18-Apr,MICROSATELLITE STABLE (MSS). See MSI note below.,0.16,Stable,1016803,29,LUAD,NA,NA,46,YES,lung,27484,9.6,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,644,Metastasis,Female,Former smoker,Matched,Note: Copy number profile is suggestive of broad copy number gain on Chromosome arm 5p.,Included,FALSE,R40L,25.5,60,SOC,No,"2018, Wk. 17",NA,1944
P-0014065_3369610_191079,,P-0014065,1,discovery,HobS17-244782152342,3369610,909557,1,1,1,2,53,2,10,1,3.9,1,0,,1,Adenocarcinoma,1,1,1,Pembrolizumab,0,0,1,0,20,0,2,0,,1,2,2,3,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0014065-T01-IM5,53,53,3.9,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,90,NA,CT chest,25.2,2,16.2,NA,2009/3/16,NA,NA,NSCLC,1,20031,19396,1,FALSE,NA,FALSE,NA,20031,0.119,IMPACT410,95,Adenocarcinoma,No,MSKCC,Pembrolizumab,1,95,No,Lung,FALSE,NA,NA,PD1 alone,16-Sep,NA,0.23,Do not report,472754,2,LUAD,NA,NA,10,YES,lung,20006,20,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,674,Metastasis,Female,Current smoker (within 6 months of diagnosis),Matched,NA,Included,FALSE,NA,2,60,SOC,No,"2016, Wk. 35",NA,1964
P-0014207_3369752_190626,,P-0014207,1,discovery,HobS16-063003194586,3369752,2989479,1,1,1,1,78,1,35,1,3.2,3.9,1,3.6,1,NOS,1,1,1,Pembrolizumab,1,0,0,0,1.9,1,4,1,,3,2,2,4,bone,0,0,0,0,0,0,V110D,Q521* (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,V110D,0,0,0,Q521* (driver),0,#REF!,P-0014207-T01-IM6,78,80,3.2,FALSE,NA,NO,TRUE,Q521* (driver),POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,40,NA,CT chest/abdomen/pelvis,76.6,7,60.3,NA,9/15/16,NA,28907,NSCLC,3.9,28860,28797,1,FALSE,NA,FALSE,NA,28907,0.0123,IMPACT468,95,NOS,No,MSKCC,Pembrolizumab,1,80,No,Lymph Node,FALSE,NA,NA,PD1 alone,16-Sep,NA,0,Do not report,476967,8,LUAD,3.6,NA,35,YES,bone,28854,1.9,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,619,Metastasis,Male,Former smoker,Matched,Note: Low tumor content (approximately 20% or less). Negative copy number and structural variant results should be interpreted with caution.,Included,FALSE,V110D,7,10,SOC,Yes,"2016, Wk. 37",NA,1937
P-0014285_642622_190908,,P-0014285,1,discovery,HobS17-335448713243,642622,642635,1,1,1,2,62,1,15,0,4.1,2.4,0,,1,Adenocarcinoma,1,1,1,Pembrolizumab,1,0,0,0,12,1,2,0,,3,2,2,2,lymph node,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0014285-T02-IM6,62,62,4.1,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,90,NA,CT chest/abdomen/pelvis,44.1,3.5,30.4,NA,2010/4/16,NA,NA,NSCLC,2.4,23095,22761,0,FALSE,NA,FALSE,NA,23490,0.0623,IMPACT468,95,Adenocarcinoma,No,MSKCC,Pembrolizumab,1,95,No,NA,FALSE,NA,NA,PD1 alone,16-Oct,NA,0.06,Do not report,NA,4,LUAD,NA,NA,15,NO,lymph node,23125,12,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,834,Primary,Female,Former smoker,Matched,NA,Included,FALSE,NA,3.5,10,SOC,No,"2016, Wk. 40",NA,1955
P-0014293_3756102_347964,,P-0014293,1,discovery,HobS16-410168767485,3756102,2869344,1,1,1,1,88,1,30,1,3.7,2.4,0,,1,NOS,2,1,1,Pembrolizumab,0,0,1,0,10.5,0,2,0,,3,1,2,3,brain,E273*,0,0,0,0,0,0,0,0,0,0,0,0,0,E273*,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0014293-T01-IM6,88,87,3.7,FALSE,E273*,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,70,NA,CT chest/abdomen/pelvis,89.7,12.3,82.3,NA,9/17/16,NA,NA,NSCLC,2.4,32657,32293,1,FALSE,NA,FALSE,NA,32678,0.3482,IMPACT468,95,NOS,Yes,MSKCC,Pembrolizumab,2,90,No,Brain,FALSE,NA,NA,PD1 alone,16-Sep,NA,0.91,Do not report,470296,14,LUAD,NA,NA,30,YES,brain,32613,10.5,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,586,Metastasis,Male,Former smoker,Matched,Note: Copy number profile is suggestive of broad copy number gains on Chromosome arms 5p including TERT and 7p including EGFR.,Included,FALSE,NA,12.3,50,SOC,No,"2016, Wk. 37",NA,1930
P-0014319_3687322_347969,,P-0014319,1,discovery,HobS16-523629998606,3687322,3687436,1,1,1,2,73,1,0,1,3.5,5.7,1,4.3,1,Adenocarcinoma,2,1,1,Atezolizumab,1,0,0,0,0.7,1,4,1,,3,2,2,2,lung,0,0,0,0,0,0,HOMDEL (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,HOMDEL (driver),HOMDEL (driver),0,0,0,0,0,0,#REF!,P-0014319-T01-IM6,73,74,3.5,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,37.9,2.6,25.7,Cytolyt,9/22/16,NA,27069,NSCLC,5.7,26959,26937,1,FALSE,NA,FALSE,NA,27069,0.3658,IMPACT468,95,Adenocarcinoma,No,MSKCC,Atezolizumab,2,0,No,NA,FALSE,NA,NA,PD1 alone,16-Sep,NA,0.99,Do not report,479993,3,LUAD,4.3,NA,12.5,YES,lung,26959,0.7,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,684,Primary,Female,Former smoker,Matched,NA,Included,TRUE,HOMDEL (driver),2.6,40,SOC,Yes,"2016, Wk. 38",NA,1943
P-0014328_4289832_347970,,P-0014328,1,discovery,HobS16-226883464763,4289832,475138,1,1,1,2,61,2,20,0,3.1,2.3,1,0.8,1,Large cell,2,1,2,Ipilimumab+Nivolumab,1,0,0,0,0.8,1,8,1,,3,1,2,3,lymph node,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0014328-T01-IM6,61,62,3.1,FALSE,NA,NO,FALSE,NA,POD/death,FALSE,NA,Non-Small Cell Lung Cancer,Large Cell Neuroendocrine Carcinoma,0,NA,CT chest/abdomen/pelvis,63.5,5.3,46.4,NA,9/22/16,NA,22502,NSCLC,2.3,22478,22478,0,FALSE,NA,FALSE,NA,22502,0.5612,IMPACT468,NA,Large cell neuroendocrine,Yes,MSKCC,Ipilimumab+Nivolumab,2,0,No,Lymph Node,FALSE,NA,NA,PD1+CTLA4,16-Sep,NA,2.89,Do not report,479988,6,LUNE,0.8,NA,20,YES,lymph node,22502,0.8,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,1288,Metastasis,Female,Current smoker (within 6 months of diagnosis),Matched,NA,Included,FALSE,NA,5.3,80,SOC,Yes,"2016, Wk. 38",NA,1955
P-0014451_3756109_347953,,P-0014451,1,discovery,HobS16-158645355730,3756109,3042248,1,1,1,2,64,1,15,1,3.9,1.7,1,7.5,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,0.6,1,4,1,,3,1,2,3,lung,0,0,0,0,0,0,0,0,0,0,L858R (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0014451-T01-IM6,64,66,3.9,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,85.9,9.7,74.8,NA,9/27/16,NA,23913,NSCLC,1.7,23714,23684,1,TRUE,L858R (driver),FALSE,NA,23913,0.383,IMPACT468,70,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,0,No,NA,FALSE,NA,NA,PD1 alone,16-Sep,NA,0.69,Do not report,484466,11,LUAD,7.5,NA,15,YES,lung,23702,0.6,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,375,Primary,Female,Former smoker,Matched,NA,Included,FALSE,NA,9.7,20,SOC,Yes,"2016, Wk. 39",NA,1951
P-0014764_4289819_347968,,P-0014764,1,discovery,HobS16-597186453897,4289819,483949,1,1,1,2,67,0,0,1,3.6,6.6,1,1.5,1,NOS,2,1,1,Atezolizumab,1,0,0,0,1,1,7,1,,3,1,2,1,bone,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0014764-T01-IM6,67,68,3.6,FALSE,NA,NO,FALSE,NA,POD/clinical,FALSE,NA,Non-Small Cell Lung Cancer,Poorly Differentiated Non-Small Cell Lung Cancer,0,NA,CT chest/abdomen/pelvis,54.1,4.4,38.5,NA,2010/8/16,NA,24862,NSCLC,6.6,24817,24817,1,FALSE,NA,FALSE,NA,24862,0.0294,IMPACT468,NA,NOS,Yes,MSKCC,Atezolizumab,2,0,No,Rib,FALSE,NA,NA,PD1 alone,16-Oct,NA,0.07,Do not report,490604,5,NSCLCPD,1.5,NA,0,YES,bone,24846,1,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,738,Metastasis,Female,Never smoker,Matched,NA,Included,FALSE,NA,4.4,10,SOC,Yes,"2016, Wk. 40",NA,1949
P-0014885_489997_190689,,P-0014885,1,discovery,HobS16-416808126004,489997,,1,1,1,2,54,1,6,1,3.9,2.1,0,,1,Adenocarcinoma,2,1,1,Pembrolizumab,1,0,0,0,2.6,1,4,1,,3,1,2,2,lymph node,0,0,0,0,0,0,0,0,0,0,"G719S (driver), E709A (driver)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0014885-T01-IM6,54,55,3.9,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,90,NA,CT chest/abdomen/pelvis,25.2,1.8,16.1,NA,10/17/16,NA,NA,NSCLC,2.1,19910,19804,1,TRUE,"G719S (driver), E709A (driver)",FALSE,NA,20226,0,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,2,95,No,Lymph node,FALSE,NA,NA,PD1 alone,16-Oct,NA,0.06,Do not report,492913,2,LUAD,NA,NA,6,YES,lymph node,19883,2.6,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,695,Metastasis,Female,Former smoker,Matched,"Note: Low tumor content (approximately 20% or less). Negative mutation, copy number and structural variant results should be interpreted with caution.",Included,FALSE,NA,1.8,20,SOC,No,"2016, Wk. 42",NA,1962
P-0015075_3687726_347878,,P-0015075,1,discovery,HobS16-100543090509,3687726,3687643,1,1,1,1,59,1,10,1,3.1,6.2,1,11.3,1,Adenocarcinoma,4,1,1,Nivolumab,1,0,0,0,0.4,1,4,1,,3,1,2,1,lung,0,0,0,0,0,0,0,0,0,0,L858R (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0015075-T01-IM6,59,60,3.1,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,63.5,5.3,46.4,NA,10/25/16,NA,22030,NSCLC,6.2,21729,21687,1,TRUE,L858R (driver),FALSE,NA,22030,0.0026,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Nivolumab,4,0,No,NA,FALSE,NA,NA,PD1 alone,16-Oct,NA,0.07,Do not report,484513,6,LUAD,11.3,NA,10,YES,lung,21698,0.4,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,869,Primary,Male,Former smoker,Matched,NA,Included,FALSE,NA,5.3,20,SOC,Yes,"2016, Wk. 43",NA,1957
P-0015296_499921_190883,,P-0015296,1,discovery,HobS16-434734495727,499921,502395,1,1,1,1,67,1,35,0,3.8,1.9,0,,1,NOS,1,1,1,Pembrolizumab,0,1,0,0,14.9,0,2,0,,3,1,2,1,adrenal,0,0,0,0,0,AMP (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,AMP (driver),AMP (driver),0,0,0,0,0,0,0,0,0,0,#REF!,P-0015296-T01-IM6,67,69,3.8,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Poorly Differentiated Non-Small Cell Lung Cancer,100,NA,CT chest/abdomen/pelvis,94.3,20.2,93.7,NA,2011/3/16,NA,NA,NSCLC,1.9,25034,24770,0,FALSE,NA,FALSE,NA,25503,0.2041,IMPACT468,95,NOS,Yes,MSKCC,Pembrolizumab,1,95,No,Adrenal Gland,TRUE,AMP (driver),NA,PD1 alone,16-Nov,NA,1.69,Do not report,501592,23,NSCLCPD,NA,NA,35,YES,adrenal,25223,14.9,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,893,Metastasis,Male,Former smoker,Matched,NA,Included,FALSE,NA,20.2,70,SOC,No,"2016, Wk. 44",NA,1948
P-0015348_4290238_347966,,P-0015348,1,discovery,HobS16-884029605427,4290238,3687626,1,1,1,1,62,1,35,2,3.3,4.1,1,17.2,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,2.1,1,4,1,,3,2,2,1,chest wall,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0015348-T01-IM6,62,63,3.3,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,87.1,10.5,77,NA,2011/4/16,NA,23293,NSCLC,4.1,22821,22770,2,FALSE,NA,FALSE,NA,23293,0.2869,IMPACT468,NA,Adenocarcinoma,No,MSKCC,Nivolumab,2,0,No,Bone,FALSE,NA,NA,PD1 alone,16-Nov,NA,0.52,Do not report,503153,12,LUAD,17.2,NA,35,YES,chest wall,22834,2.1,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,788,Metastasis,Male,Former smoker,Matched,NA,Included,FALSE,NA,10.5,20,SOC,Yes,"2016, Wk. 44",NA,1954
P-0015529_3687736_347873,,P-0015529,1,discovery,HobS16-589464190100,3687736,3687646,1,1,1,2,76,1,98,1,3.3,2.1,1,1.9,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,1.8,1,4,1,,1,2,2,1,soft tissue (glenoid),0,0,0,0,0,0,X199_splice (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,X199_splice (driver),0,0,0,0,0,#REF!,P-0015529-T01-IM6,76,76,3.3,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest,73.7,6.1,56.8,NA,2012/1/16,NA,27875,NSCLC,2.1,27872,27816,1,FALSE,NA,FALSE,NA,27875,0.0048,IMPACT468,95,Adenocarcinoma,No,MSKCC,Nivolumab,2,0,No,Soft Tissue,FALSE,NA,NA,PD1 alone,16-Dec,NA,0,Do not report,506109,7,LUAD,1.9,NA,98,YES,soft tissue (glenoid),27872,1.8,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,723,Metastasis,Female,Former smoker,Matched,NA,Included,TRUE,X199_splice (driver),6.1,20,SOC,Yes,"2016, Wk. 48",NA,1941
P-0015693_512406_347974,Empty,P-0015693,0,discovery,HobS16-270506563309,512406,512530,1,1,1,1,79,0,0,1,4.1,2,0,,1,Adenocarcinoma,1,2,2,Ipilimumab+Nivolumab,1,0,0,0,1.1,1,8,1,,1,1,2,,pleura,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0015693-T01-IM6,79,80,4.1,FALSE,NA,YES,FALSE,NA,POD/death,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,1,NA,CT chest,37.9,2.6,25.7,NA,2012/1/16,NA,NA,NSCLC,2,29151,29132,1,FALSE,NA,FALSE,NA,29179,0,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Ipilimumab+Nivolumab,1,5,No,NA,FALSE,NA,NA,PD1+CTLA4,16-Dec,NA,0,Do not report,513235,3,LUAD,NA,NA,0,YES,pleura,29165,1.1,1:PROGRESS,Lung,16-183,FALSE,NA,FALSE,NA,Tumor,1,773,Primary,Male,Never smoker,Matched,NA,Included,FALSE,NA,2.6,20,Clinical trial,No,"2016, Wk. 48",NA,1937
P-0015749_3369650_190826,,P-0015749,1,discovery,HobS16-688235107843,3369650,534815,1,1,1,1,68,1,46,1,3.6,0.7,1,12.6,1,Squamous,2,1,1,Atezolizumab,1,0,0,0,2.9,1,4,1,,3,1,2,1,pleura,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0015749-T01-IM6,68,69,3.6,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Squamous Cell Carcinoma,0,NA,CT chest/abdomen/pelvis,82.2,8.8,68.4,NA,2012/1/16,NA,25439,NSCLC,0.7,25117,25054,1,FALSE,NA,FALSE,NA,25439,0.3106,IMPACT468,NA,Squamous,Yes,MSKCC,Atezolizumab,2,0,No,Pleura,FALSE,NA,NA,PD1 alone,16-Dec,MICROSATELLITE STABLE (MSS). This result is for investigational use only. See MSI note below.,0.26,Stable,NA,10,LUSC,12.6,NA,46,NO,pleura,25141,2.9,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,886,Metastasis,Male,Former smoker,Matched,NA,Included,FALSE,NA,8.8,30,SOC,Yes,"2016, Wk. 48",NA,1948
P-0015937_490063_190764,,P-0015937,1,discovery,HobS16-572729713516,490063,3116126,1,1,1,2,73,0,0,1,3.2,4.8,1,33.3,1,Adenocarcinoma,5,1,1,Pembrolizumab,1,0,0,0,2.6,1,4,1,,3,2,2,2,lung,0,0,0,A479P,0,0,0,0,AMP (driver),AMP (driver),L858R (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,A479P,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0015937-T01-IM6,73,74,3.2,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,75,NA,CT chest/abdomen/pelvis,87.1,10.5,77,NA,2012/6/16,NA,27796,NSCLC,4.8,26845,26782,1,TRUE,"AMP (driver), L858R (driver)",FALSE,NA,27796,0.5535,IMPACT468,NA,Adenocarcinoma,No,MSKCC,Pembrolizumab,5,NA,NA,Lymph Node,FALSE,NA,NA,PD1 alone,16-Dec,NA,2.58,Do not report,516473,12,LUAD,33.3,NA,0,YES,lung,26862,2.6,1:PROGRESS,Lung,NA,FALSE,A479P,FALSE,NA,Tumor,1,311,Metastasis,Female,Never smoker,Matched,NA,Excluded,FALSE,NA,10.5,30,SOC,Yes,"2016, Wk. 49",NA,1943
P-0015950_524041_190346,,P-0015950,1,discovery,HobS16-727854485981,524041,524036,1,1,1,1,60,1,6,1,4.4,1.6,0,,1,Squamous,1,2,2,Ipilimumab+Nivolumab,1,0,0,0,1.2,1,4,1,,3,1,2,2,lung,0,G778_P780dup (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,G778_P780dup (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0015950-T01-IM6,60,61,4.4,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,54.1,4.4,38.5,NA,2012/6/16,NA,NA,NSCLC,1.6,22218,22190,1,FALSE,NA,TRUE,G778_P780dup (driver),23243,0.4418,IMPACT468,95,Squamous,Yes,MSKCC,Ipilimumab+Nivolumab,1,0,No,NA,FALSE,NA,NA,PD1+CTLA4,16-Dec,NA,1.79,Do not report,517743,5,LUAD,NA,NA,6,YES,lung,22226,1.2,1:PROGRESS,Lung,16-183,FALSE,NA,FALSE,NA,Tumor,1,942,Primary,Male,Former smoker,Matched,NA,Included,FALSE,NA,4.4,40,Clinical trial,No,"2016, Wk. 49",NA,1956
P-0015987_3369660_190948,Empty,P-0015987,0,discovery,HobS16-096159084410,3369660,3241222,1,1,1,2,70,1,20,1,4.1,3.8,1,10.3,1,Adenocarcinoma,1,1,1,Nivolumab,1,0,0,0,3.2,1,5,1,,3,1,2,,liver,0,0,0,0,0,0,G163V (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,G163V (driver),0,0,0,0,0,#REF!,P-0015987-T01-IM6,70,71,4.1,FALSE,NA,NO,FALSE,NA,POD/brain,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,79.1,7.9,63.8,NA,2012/6/16,NA,25975,NSCLC,3.8,25946,25662,1,FALSE,NA,FALSE,NA,25975,0.3703,IMPACT468,60,Adenocarcinoma,Yes,MSKCC,Nivolumab,1,0,No,Liver,FALSE,NA,NA,PD1 alone,16-Dec,NA,1.67,Do not report,504637,9,LUAD,10.3,NA,20,YES,liver,25760,3.2,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,929,Metastasis,Female,Former smoker,Matched,NA,Included,TRUE,G163V (driver),7.9,60,SOC,Yes,"2016, Wk. 49",NA,1946
P-0016016_514599_190678,,P-0016016,1,discovery,HobS16-775222539274,514599,514596,1,1,1,2,82,1,6,1,4.1,2.6,1,6.2,1,Adenocarcinoma,2,1,1,Pembrolizumab,1,0,0,0,2,1,4,1,,3,1,2,3,lung,0,0,0,0,0,0,Q37* (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Q37* (driver),0,0,0,0,0,#REF!,P-0016016-T01-IM6,82,83,4.1,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,30,NA,CT chest/abdomen/pelvis,89.2,11.4,81.4,NA,2012/6/16,NA,30388,NSCLC,2.6,30286,30200,1,FALSE,NA,FALSE,NA,30388,0.0514,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,2,50,No,NA,FALSE,NA,NA,PD1 alone,16-Dec,NA,0.15,Do not report,523096,13,LUAD,6.2,NA,6,YES,lung,30261,2,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,744,Primary,Female,Former smoker,Matched,NA,Included,TRUE,Q37* (driver),11.4,20,SOC,Yes,"2016, Wk. 49",NA,1934
P-0016174_3756023_347883,,P-0016174,1,discovery,HobS16-382853031133,3756023,3289847,1,1,1,2,72,0,0,0,3.8,2.8,1,27.6,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,3.2,1,4,1,,3,1,2,2,lung,0,Y772_A775dup (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Y772_A775dup (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0016174-T01-IM6,72,73,3.8,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,91.3,14,86.9,NA,12/15/16,NA,27471,NSCLC,2.8,26842,26632,0,FALSE,NA,TRUE,Y772_A775dup (driver),27471,0.1631,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,0,No,NA,FALSE,NA,NA,PD1 alone,16-Dec,NA,0.06,Do not report,506050,16,LUAD,27.6,NA,0,YES,lung,26728,3.2,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,811,Primary,Female,Never smoker,Matched,Note: Low tumor content (approximately 20% or less). Negative copy number and structural variant results should be interpreted with caution.,Included,FALSE,NA,14,20,SOC,Yes,"2016, Wk. 50",NA,1944
P-0016175_3343292_347879,,P-0016175,1,discovery,HobS16-972241650038,3343292,464485,1,1,1,2,76,1,45,1,2.9,8.4,1,1.4,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,1.4,1,8,1,,3,2,2,3,lung,0,0,ROS1-EYS fusion,R820C,0,0,G251C (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,ROS1-EYS fusion,0,0,R820C,0,0,0,0,0,0,0,0,0,0,0,G251C (driver),0,0,0,0,0,#REF!,P-0016175-T01-IM6,76,77,2.9,FALSE,NA,YES,FALSE,NA,POD/death,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,25,NA,CT chest/abdomen/pelvis,92.3,14.9,89.1,NA,12/16/16,NA,27919,NSCLC,8.4,27877,27877,1,FALSE,NA,FALSE,NA,27919,0.3645,IMPACT468,95,Adenocarcinoma,No,MSKCC,Nivolumab,2,75,No,Bone,FALSE,NA,NA,PD1 alone,16-Dec,NA,0.36,Do not report,479340,17,LUAD,1.4,NA,45,YES,lung,27919,1.4,1:PROGRESS,Lung,NA,FALSE,R820C,FALSE,ROS1-EYS fusion,Tumor,1,806,Metastasis,Female,Former smoker,Matched,NA,Included,TRUE,G251C (driver),14.9,30,SOC,Yes,"2016, Wk. 50",NA,1940
P-0016185_3369766_191085,,P-0016185,1,discovery,HobS16-719232821598,3369766,481212,1,1,1,1,72,1,45,1,3.1,2,1,9.1,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,3.5,1,2,0,,3,1,2,2,lung,0,0,0,0,0,0,E57_G58del,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,E57_G58del,0,0,0,0,0,#REF!,P-0016185-T01-IM6,72,73,3.1,FALSE,NA,YES,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,73.7,6.1,56.8,NA,12/15/16,NA,26787,NSCLC,2,26612,26510,1,FALSE,NA,FALSE,NA,26787,0.4333,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,0,No,NA,FALSE,NA,NA,PD1 alone,16-Dec,NA,1.13,Do not report,479305,7,LUAD,9.1,NA,45,YES,lung,26616,3.5,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,594,Primary,Male,Former smoker,Matched,NA,Included,FALSE,E57_G58del,6.1,10,SOC,Yes,"2016, Wk. 50",NA,1944
P-0016224_3369684_191135,Empty,P-0016224,0,discovery,HobS16-183957539808,3369684,492553,1,1,1,2,69,2,40,1,4,3,1,7.8,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,7.8,1,3,1,1,1,1,2,,bone,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0016224-T01-IM6,69,70,4,FALSE,NA,NO,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest,93.7,18.4,92.4,NA,1/13/17,Durable clinical benefit,25676,NSCLC,3,25561,25438,1,FALSE,NA,FALSE,NA,25676,0.156,IMPACT468,50,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,0,No,Bone,FALSE,NA,NA,PD1 alone,17-Jan,NA,0.42,Do not report,525623,21,LUAD,7.8,NA,40,YES,bone,25676,7.8,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,792,Metastasis,Female,Current smoker (within 6 months of diagnosis),Matched,NA,Included,FALSE,NA,18.4,10,SOC,Yes,"2017, Wk. 02",NA,1947
P-0016692_3369302_191093,Empty,P-0016692,0,discovery,HobS16-247545100230,3369302,,1,1,1,1,71,2,30,1,2.6,3.4,1,7.1,1,NOS,2,1,1,Nivolumab,1,0,0,0,1.1,1,5,1,,3,1,2,,lung,0,0,W21C,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,W21C,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0016692-T01-IM6,71,72,2.6,FALSE,NA,NO,FALSE,NA,POD/brain,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,89.7,12.3,82.3,Cytolyt,2001/5/17,NA,26430,NSCLC,3.4,26374,26213,1,FALSE,NA,FALSE,NA,26430,0.5184,IMPACT468,90,NOS,Yes,MSKCC,Nivolumab,2,0,No,NA,FALSE,NA,NA,PD1 alone,17-Jan,NA,2.45,Do not report,533509,14,LUAD,7.1,NA,30,YES,lung,26248,1.1,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,W21C,Tumor,1,830,Primary,Male,Current smoker (within 6 months of diagnosis),Matched,Note: Relatively low tumor content (approximately 20%). Assessment of the copy number profile is limited by increased background noise. False negatives cannot be ruled out. Confirmation of copy number changes by alternate methods is suggested if clinicall,Included,FALSE,NA,12.3,20,SOC,Yes,"2017, Wk. 01",NA,1945
P-0017048_3687847_347981,,P-0017048,1,discovery,HobS16-572695550471,3687847,3687617,1,1,1,2,64,1,15,2,2.4,3.5,1,0.4,1,Adenocarcinoma,2,1,1,Atezolizumab,1,0,0,0,0.4,1,8,1,,3,1,2,1,"bone, soft tissue",0,"AMP (driver), G778_P780dup (driver)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,AMP (driver),AMP (driver),G778_P780dup (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0017048-T01-IM6,64,64,2.4,FALSE,NA,NO,FALSE,NA,POD/death,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,73.7,6.1,56.8,NA,1/26/17,NA,23408,NSCLC,3.5,23396,23396,2,FALSE,NA,TRUE,"AMP (driver), G778_P780dup (driver)",23408,0.1253,IMPACT468,50,Adenocarcinoma,Yes,MSKCC,Atezolizumab,2,0,No,Spine,FALSE,NA,NA,PD1 alone,17-Jan,NA,0,Do not report,544253,7,LUAD,0.4,NA,15,YES,"bone, soft tissue",23408,0.4,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,834,Metastasis,Female,Former smoker,Matched,NA,Included,FALSE,NA,6.1,20,SOC,Yes,"2017, Wk. 04",NA,1953
P-0017184_3687742_347917,,P-0017184,1,discovery,HobS16-716010493713,3687742,3687623,1,1,1,2,69,1,15,2,3.8,4.7,1,0.5,1,Adenocarcinoma,3,1,1,Nivolumab,1,0,0,0,0.5,1,8,1,,3,1,2,1,pleura,0,0,0,0,0,0,0,0,0,0,L747_T751del (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0017184-T01-IM6,69,69,3.8,FALSE,NA,NO,FALSE,NA,POD/death,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,37.9,2.6,25.7,NA,2002/2/17,NA,25293,NSCLC,4.7,25278,25278,2,TRUE,L747_T751del (driver),FALSE,NA,25293,0.002,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Nivolumab,3,0,No,Pleura,FALSE,NA,NA,PD1 alone,17-Feb,NA,0,Do not report,544194,3,LUAD,0.5,NA,15,YES,pleura,25293,0.5,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,950,Metastasis,Female,Former smoker,Matched,Note: Low tumor content (approximately 20% or less). Negative copy number and structural variant results should be interpreted with caution.,Included,FALSE,NA,2.6,10,SOC,Yes,"2017, Wk. 05",NA,1948
P-0017253_3369634_190533,,P-0017253,1,discovery,HobS16-559543369087,3369634,529663,1,1,1,1,66,2,0,1,3.3,4.4,0,,1,Adenocarcinoma,2,1,1,Atezolizumab,1,0,0,0,2.1,1,4,1,,1,1,2,2,bone,0,0,L806F,0,X380_splice,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,L806F,0,0,0,0,0,0,0,X380_splice,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0017253-T01-IM6,66,67,3.3,FALSE,NA,NO,FALSE,NA,POD,FALSE,X380_splice,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest,91.4,14,86.9,NA,1/31/17,NA,NA,NSCLC,4.4,24440,24398,1,FALSE,NA,FALSE,NA,24468,0.0393,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Atezolizumab,2,0,No,Rib,FALSE,NA,NA,PD1 alone,17-Jan,NA,0,Do not report,538583,16,LUAD,NA,NA,70.5,YES,bone,24463,2.1,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,L806F,Tumor,1,751,Metastasis,Male,Current smoker (within 6 months of diagnosis),Matched,NA,Included,FALSE,NA,14,20,SOC,No,"2017, Wk. 05",NA,1950
P-0017484_554968_347989,,P-0017484,1,discovery,HobS17-690586156513,554968,562762,1,1,1,1,80,1,60,1,3.5,3.1,0,,1,Squamous,2,1,1,Pembrolizumab,1,0,0,0,1.9,1,7,1,,1,1,2,3,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0017484-T01-IM6,80,80,3.5,FALSE,NA,NO,FALSE,NA,POD/clinical,FALSE,NA,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,50,NA,CT chest,89.2,11.4,81.4,NA,2002/9/17,NA,NA,NSCLC,3.1,29351,29300,1,FALSE,NA,FALSE,NA,29367,0.0927,IMPACT468,95,Squamous,Yes,MSKCC,Pembrolizumab,2,50,No,NA,FALSE,NA,NA,PD1 alone,17-Feb,NA,0.5,Do not report,560148,13,NSCLC,NA,NA,60,YES,lung,29358,1.9,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,904,Primary,Male,Former smoker,Matched,NA,Included,FALSE,NA,11.4,40,SOC,No,"2017, Wk. 06",NA,1937
P-0017613_3756078_347871,Empty,P-0017613,0,discovery,HobS16-813514154523,3756078,3646608,1,1,1,2,68,1,0,2,4.3,2.6,1,14,1,Adenocarcinoma,1,1,1,Pembrolizumab,1,0,0,0,7,1,3,1,1,3,1,2,,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0017613-T01-IM5,68,68,4.3,FALSE,NA,YES,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,5,NA,CT chest/abdomen/pelvis,25.2,2,16.2,NA,2/16/17,Durable clinical benefit,25478,NSCLC,2.6,25445,25053,2,FALSE,NA,FALSE,NA,25478,0,IMPACT410,70,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,1,5,Yes,NA,FALSE,NA,NA,PD1 alone,17-Feb,NA,0.15,Do not report,544119,2,LUAD,14,NA,3.75,YES,lung,25266,7,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,1047,Primary,Female,Former smoker,Matched,"Note: Low tumor content (approximately 20% or less). Negative mutation, copy number and structural variant results should be interpreted with caution.",Included,FALSE,NA,2,10,SOC,Yes,"2017, Wk. 07",NA,1949
P-0017735_3687871_347979,,P-0017735,1,discovery,HobS17-748902495699,3687871,565034,1,1,1,1,66,2,0,1,2.6,4.3,1,23.6,1,Squamous,2,1,1,Nivolumab,1,0,0,0,3.9,1,4,1,,3,1,2,0,lung,0,AMP (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,AMP (driver),AMP (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0017735-T01-IM6,66,67,2.6,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Squamous Cell Carcinoma,0,NA,CT chest/abdomen/pelvis,87.1,10.5,77,NA,2/22/17,NA,25076,NSCLC,4.3,24589,24358,1,FALSE,NA,TRUE,AMP (driver),25076,0.2589,IMPACT468,60,Squamous,Yes,MSKCC,Nivolumab,2,10,Yes,NA,FALSE,NA,NA,PD1 alone,17-Feb,NA,0.41,Do not report,557474,12,LUSC,23.6,NA,33.75,YES,lung,24476,3.9,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,994,Primary,Male,Current smoker (within 6 months of diagnosis),Matched,NA,Included,FALSE,NA,10.5,30,SOC,Yes,"2017, Wk. 08",NA,1950
P-0017781_3687358_347982,,P-0017781,1,discovery,HobS16-568599039289,3687358,543557,1,1,1,1,80,1,15,1,3.8,1.1,1,1.5,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,1.5,1,8,1,,3,1,2,3,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0017781-T01-IM6,80,81,3.8,FALSE,NA,NO,FALSE,NA,POD/death,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,54.1,4.4,38.5,SSL,2/25/17,NA,29472,NSCLC,1.1,29440,29426,1,FALSE,NA,FALSE,NA,29472,0.6335,IMPACT468,NA,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,0,No,NA,FALSE,NA,NA,PD1 alone,17-Feb,NA,3.31,Do not report,556756,5,LUAD,1.5,NA,15,YES,lung,29472,1.5,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,509,Primary,Male,Former smoker,Matched,NA,Included,FALSE,NA,4.4,60,SOC,Yes,"2017, Wk. 08",NA,1936
P-0017910_3756353_347903,Empty,P-0017910,0,discovery,HobS16-437445161212,3756353,3756337,1,1,1,2,52,1,30,1,4.3,2.7,0,,1,Adenocarcinoma,2,1,1,Nivolumab,0,0,0,1,23.5,0,3,1,1,3,2,2,,lymph node,0,0,0,0,0,0,E130* (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,E130* (driver),0,0,0,0,0,#REF!,P-0017910-T01-IM6,52,52,4.3,FALSE,NA,NO,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,89.2,11.4,81.4,Cytolyt,2/24/17,Durable clinical benefit,NA,NSCLC,2.7,19601,19188,1,FALSE,NA,FALSE,NA,19934,0.1401,IMPACT468,NA,Adenocarcinoma,No,MSKCC,Nivolumab,2,0,No,NA,FALSE,NA,NA,PD1 alone,17-Feb,NA,0.15,Do not report,558717,13,LUAD,NA,NA,30,YES,lymph node,19902,23.5,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,582,Primary,Female,Former smoker,Matched,NA,Included,TRUE,E130* (driver),11.4,30,SOC,No,"2017, Wk. 08",NA,1965
P-0018078_4289817_347991,,P-0018078,1,discovery,HobS17-002022371421,4289817,,1,1,1,2,68,2,40,1,3.4,1.6,1,6.4,1,Adenocarcinoma,2,1,1,Pembrolizumab,1,0,0,0,1.1,1,4,1,,3,2,2,0,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0018078-T01-IM6,68,68,3.4,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,5,NA,CT chest/abdomen/pelvis,73.7,6.1,56.8,NA,2003/9/17,NA,25281,NSCLC,1.6,25108,25087,1,FALSE,NA,FALSE,NA,25281,0.1624,IMPACT468,95,Adenocarcinoma,No,MSKCC,Pembrolizumab,2,10,No,Liver,FALSE,NA,NA,PD1 alone,17-Mar,NA,0.24,Do not report,569448,7,LUAD,6.4,NA,40,YES,lung,25121,1.1,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,649,Metastasis,Female,Current smoker (within 6 months of diagnosis),Matched,"Note: Copy number profile is suggestive of broad copy number gains on Chromosome arms 1q31-44, 8q11-21, and 14q13-21. Note: Copy number profile is suggestive of broad copy number losses on Chromosome arms 2q35-37, 6q15-26, 8p12-21, 10q21-23, and 12p12-13.",Included,FALSE,NA,6.1,30,SOC,Yes,"2017, Wk. 10",NA,1949
P-0018179_4289840_347956,,P-0018179,1,discovery,HobS16-288245457704,4289840,2693096,1,1,1,1,69,1,20,1,3,2.5,1,23.5,1,NOS,1,2,2,Resection + Ipilimumab+Nivolumab,1,0,0,0,1.1,1,4,1,,1,2,2,1,pleura,0,0,0,0,0,D1010H (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,D1010H (driver),0,0,0,0,0,0,0,0,0,#REF!,P-0018179-T01-IM6,69,71,3,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Poorly Differentiated Non-Small Cell Lung Cancer,70,NA,CT chest,37.9,2.6,25.7,NA,2003/11/17,NA,26132,NSCLC,2.5,25432,25418,1,FALSE,NA,FALSE,NA,26132,0.0764,IMPACT468,95,NOS,No,MSKCC,Resection + Ipilimumab+Nivolumab,1,80,No,Soft Tissue,TRUE,D1010H (driver),NA,PD1+CTLA4,17-Mar,NA,0.12,Do not report,573350,3,NSCLCPD,23.5,NA,20,YES,pleura,25450,1.1,1:PROGRESS,Lung,14-137,FALSE,NA,FALSE,NA,Tumor,1,893,Metastasis,Male,Former smoker,Matched,NA,Included,FALSE,NA,2.6,50,Clinical trial,Yes,"2017, Wk. 10",NA,1946
P-0018197_3369855_190794,,P-0018197,1,discovery,HobS17-985183327924,3369855,571796,1,1,1,1,66,2,0,1,3.8,2.9,0,,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,10.5,1,3,1,1,3,1,2,1,lung,L1044H,0,0,0,R260C,0,0,0,AMP (driver),AMP (driver),0,0,0,0,L1044H,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R260C,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0018197-T01-IM6,66,67,3.8,FALSE,L1044H,NO,FALSE,NA,SD,FALSE,R260C,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,98.2,48.3,99.4,NA,2003/9/17,Durable clinical benefit,NA,NSCLC,2.9,24352,24274,1,TRUE,AMP (driver),FALSE,NA,24907,0.127,IMPACT468,70,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,0,No,NA,FALSE,NA,NA,PD1 alone,17-Mar,NA,0,Do not report,569095,55,LUAD,NA,NA,17.5,YES,lung,24595,10.5,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,753,Primary,Male,Current smoker (within 6 months of diagnosis),Matched,NA,Included,FALSE,NA,48.3,30,SOC,No,"2017, Wk. 10",NA,1950
P-0018366_3687864_347955,,P-0018366,1,discovery,HobS17-046303618332,3687864,3687854,1,1,1,1,48,1,15,1,4.3,0.9,1,23.9,1,Adenocarcinoma,1,1,1,Pembrolizumab,0,1,0,0,5.8,0,2,0,,1,1,2,2,lymph node,0,0,0,0,0,0,0,Q766Sfs*67 (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Q766Sfs*67 (driver),0,#REF!,P-0018366-T01-IM6,48,48,4.3,FALSE,NA,NO,TRUE,Q766Sfs*67 (driver),PR,FALSE,NA,Non-Small Cell Lung Cancer,Poorly Differentiated Non-Small Cell Lung Cancer,20,NA,CT chest,89.7,12.3,82.3,NA,3/15/17,NA,18408,NSCLC,0.9,18403,17681,1,FALSE,NA,FALSE,NA,18408,0.1182,IMPACT468,60,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,1,30,Yes,Lymph Node,FALSE,NA,NA,PD1 alone,17-Mar,NA,0.3,Do not report,575986,14,NSCLCPD,23.9,NA,15,YES,lymph node,17858,5.8,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,396,Metastasis,Male,Former smoker,Matched,NA,Included,FALSE,NA,12.3,30,SOC,Yes,"2017, Wk. 11",NA,1969
P-0018511_4290937_347911,,P-0018511,1,discovery,HobS17-384946182187,4290937,,1,1,1,2,74,1,30,2,3.4,7.4,1,1.9,1,Adenocarcinoma,1,1,1,Pembrolizumab,1,0,0,0,1.2,1,4,1,,3,1,2,3,lymph node,0,0,0,0,0,D1228H (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,D1228H (driver),0,0,0,0,0,0,0,0,0,#REF!,P-0018511-T01-IM6,74,75,3.4,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,50,NA,CT chest/abdomen/pelvis,82.2,8.8,68.4,Cytolyt,3/21/17,NA,27189,NSCLC,7.4,27132,27132,2,FALSE,NA,FALSE,NA,27189,0.2762,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,1,80,No,Lymph Node,TRUE,D1228H (driver),NA,PD1 alone,17-Mar,NA,2.67,Do not report,578752,10,LUAD,1.9,NA,30,YES,lymph node,27170,1.2,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,777,Metastasis,Female,Former smoker,Matched,NA,Included,FALSE,NA,8.8,40,SOC,Yes,"2017, Wk. 12",NA,1942
P-0018517_3756226_347874,Empty,P-0018517,0,discovery,HobS17-813184157142,3756226,576412,1,1,1,1,80,1,80,1,4,3.6,1,2.3,1,Adenocarcinoma,1,1,1,Nivolumab,1,0,0,0,2.3,1,3,1,2,3,1,2,,lung,0,0,0,0,0,0,E256* (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,E256* (driver),0,0,0,0,0,#REF!,P-0018517-T01-IM6,80,80,4,FALSE,NA,NO,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,73.7,6.1,56.8,NA,3/21/17,No durable clinical benefit,29356,NSCLC,3.6,29314,29286,1,FALSE,NA,FALSE,NA,29356,0.1755,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Nivolumab,1,0,No,NA,FALSE,NA,NA,PD1 alone,17-Mar,NA,0.07,Do not report,581781,7,LUAD,2.3,NA,80,YES,lung,29356,2.3,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,788,Primary,Male,Former smoker,Matched,NA,Included,TRUE,E256* (driver),6.1,30,SOC,Yes,"2017, Wk. 12",NA,1937
P-0018557_3756275_347933,Empty,P-0018557,0,discovery,HobS17-359149363437,3756275,3920867,1,1,1,2,83,1,50,1,3.9,1.7,1,1.6,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,1.2,1,4,1,,3,1,2,,liver,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0018557-T01-IM6,83,83,3.9,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,1,NA,CT chest/abdomen/pelvis,82.2,8.8,68.4,NA,3/21/17,NA,30573,NSCLC,1.7,30538,30524,1,FALSE,NA,FALSE,NA,30573,0.2191,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,5,No,Liver,FALSE,NA,NA,PD1 alone,17-Mar,NA,0.34,Do not report,579607,10,LUAD,1.6,NA,50,YES,liver,30561,1.2,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,771,Metastasis,Female,Former smoker,Matched,NA,Included,FALSE,NA,8.8,30,SOC,Yes,"2017, Wk. 12",NA,1934
P-0018722_3369564_191129,,P-0018722,1,discovery,HobS17-294157172036,3369564,,1,1,1,2,44,1,0,1,3.6,6.8,0,,1,Adenocarcinoma,3,1,1,Pembrolizumab,0,0,1,0,18.8,0,2,0,,3,1,2,2,lymph node,0,0,0,0,V600E (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,V600E (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0018722-T01-IM6,44,44,3.6,FALSE,NA,NO,FALSE,NA,PR,TRUE,V600E (driver),Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,70,NA,CT chest/abdomen/pelvis,94.1,19.3,93.4,NA,3/25/17,NA,NA,NSCLC,6.8,16855,16196,1,FALSE,NA,FALSE,NA,16859,0.1774,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,3,60,No,Lymph Node,FALSE,NA,NA,PD1 alone,17-Mar,MICROSATELLITE STABLE (MSS). This result is for investigational use only. See MSI note below.,0.09,Stable,NA,20,NSCLC,NA,NA,31.5,NO,lymph node,16768,18.8,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,887,Metastasis,Female,Former smoker,Matched,NA,Included,FALSE,NA,19.3,30,SOC,No,"2017, Wk. 12",NA,1973
P-0018763_3690195_347992,,P-0018763,1,discovery,HobS17-261873586711,3690195,3687587,1,1,1,1,83,1,40,2,3.6,2.7,0,,1,Adenocarcinoma,1,1,1,Pembrolizumab,1,0,0,0,2,1,4,1,,1,1,2,2,lymph node,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0018763-T01-IM6,83,82,3.6,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Lung Adenocarcinoma,Lung Adenocarcinoma,50,NA,CT chest,0,0,0,NA,3/28/17,NA,NA,NSCLC,2.7,30444,30360,2,FALSE,NA,FALSE,NA,30750,0,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,1,50,No,Lymph Node,FALSE,NA,NA,PD1 alone,17-Mar,NA,NA,NA,587326,NA,LUAD,NA,NA,40,YES,lymph node,30421,2,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,1181,Metastasis,Male,Former smoker,Matched,"Note: Low tumor content (approximately 10% or less). Negative mutation, MSIsensor, copy number and structural variant results should be interpreted with caution.",Included,FALSE,NA,0,10,SOC,No,"2017, Wk. 13",NA,1935
P-0019098_3687415_347998,,P-0019098,1,discovery,HobS17-119045592994,3687415,601319 (bronchial washing from same procedure),1,1,1,2,56,1,0,1,3.9,4.1,0,,1,Adenocarcinoma,2,1,1,Atezolizumab,1,0,0,0,12,1,3,1,1,3,1,2,2,lymph node,G1473E,0,0,0,0,0,D176Tfs*111 (driver),0,0,0,0,0,0,0,G1473E,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,D176Tfs*111 (driver),0,0,0,0,0,#REF!,P-0019098-T01-IM6,56,56,3.9,FALSE,G1473E,NO,FALSE,NA,SD,FALSE,NA,Lung Adenocarcinoma,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,95.6,26.3,96.9,SSL,4/13/17,Durable clinical benefit,NA,NSCLC,4.1,21088,20740,1,FALSE,NA,FALSE,NA,21181,0.0457,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Atezolizumab,2,0,No,Lymph Node,FALSE,NA,NA,PD1 alone,17-Apr,MICROSATELLITE STABLE (MSS). This result is for investigational use only. See MSI note below.,0,Stable,591939,30,LUAD,NA,NA,14.4,YES,lymph node,21105,12,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,705,Metastasis,Female,Former smoker,Matched,NA,Included,TRUE,D176Tfs*111 (driver),26.3,20,SOC,No,"2017, Wk. 15",NA,1961
P-0019262_4289868_347985,,P-0019262,1,discovery,HobS17-974422641471,4289868,712042,1,1,1,2,53,2,15,1,4.2,4.6,1,5.8,1,Large cell,2,1,1,Atezolizumab,1,0,0,0,4.1,1,4,1,,3,1,2,1,brain,0,0,0,0,0,0,P281Rfs*6 (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,P281Rfs*6 (driver),0,0,0,0,0,#REF!,P-0019262-T02-IM6,53,55,4.2,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Large Cell Neuroendocrine Carcinoma,0,NA,CT chest/abdomen/pelvis,96.7,33.4,98,NA,2010/7/17,NA,19881,NSCLC,4.6,19813,19704,1,FALSE,NA,FALSE,NA,19881,0.564,IMPACT468,NA,Large cell neuroendocrine,Yes,MSKCC,Atezolizumab,2,0,No,Brain,FALSE,NA,NA,PD1 alone,17-Oct,MICROSATELLITE INSTABILITY-INDETERMINATE. See MSI note below.,5.23,Indeterminate,725805,38,LUNE,5.8,NA,15,YES,brain,19828,4.1,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,456,Metastasis,Female,Current smoker (within 6 months of diagnosis),Matched,NA,Included,TRUE,P281Rfs*6 (driver),33.4,60,SOC,Yes,"2017, Wk. 40",NA,1963
P-0019390_3369552_190732,Empty,P-0019390,0,discovery,HobS17-897427091981,3369552,598474,1,1,1,1,69,1,42,0,4.1,1.5,1,14.8,1,Adenocarcinoma,1,1,1,Pembrolizumab,1,0,0,0,1.9,1,4,1,,3,1,2,,adrenal,A207Qfs*42,0,0,0,0,0,0,Q1098* (driver),0,0,0,0,0,0,A207Qfs*42,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Q1098* (driver),0,#REF!,P-0019390-T01-IM6,69,69,4.1,FALSE,A207Qfs*42,YES,TRUE,Q1098* (driver),POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,30,NA,CT chest/abdomen/pelvis,98.2,49.2,99.5,NA,4/25/17,NA,25761,NSCLC,1.5,25480,25312,0,FALSE,NA,FALSE,NA,25761,0.343,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,1,30,No,Adrenal,FALSE,NA,NA,PD1 alone,17-Apr,MICROSATELLITE STABLE (MSS). This result is for investigational use only. See MSI note below.,1.43,Stable,598973,56,LUAD,14.8,NA,42,YES,adrenal,25371,1.9,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,986,Metastasis,Male,Former smoker,Matched,NA,Included,FALSE,NA,49.2,60,SOC,Yes,"2017, Wk. 17",NA,1948
P-0019599_597881_347990,,P-0019599,1,discovery,HobS17-273606450067,597881,597884,1,1,1,1,73,1,14,2,2.5,1.6,1,0.5,1,Adenocarcinoma,2,1,1,Pembrolizumab,1,0,0,0,0.5,1,8,1,,3,1,2,1,duodenum,0,G660D (driver),0,0,0,0,0,0,0,0,L858R (driver),0,0,0,0,0,0,0,G660D (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0019599-T01-IM6,73,74,2.5,FALSE,NA,NO,FALSE,NA,POD/death,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,80,NA,CT chest/abdomen/pelvis,97.7,42.1,99.1,NA,2005/4/17,NA,26981,NSCLC,1.6,26965,26965,2,TRUE,L858R (driver),TRUE,G660D (driver),26981,0.2677,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,2,80,No,Duodenum,FALSE,NA,NA,PD1 alone,17-May,MICROSATELLITE INSTABILITY-HIGH (MSI-H). This result is for investigational use only. See MSI note below.,27.99,Instable,603039,48,LUAD,0.5,NA,14,YES,duodenum,26981,0.5,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,873,Metastasis,Male,Former smoker,Matched,NA,Included,FALSE,NA,42.1,50,SOC,Yes,"2017, Wk. 18",NA,1943
P-0019804_4584939_190630,,P-0019804,1,discovery,HobS17-789528953380,4584939,,1,1,1,2,69,1,14,1,4.3,0.8,0,,1,Adenocarcinoma,2,2,1,Durvalumab,1,0,0,0,12.9,1,3,1,1,3,2,2,2,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0019804-T02-IM6,69,73,4.3,FALSE,NA,NO,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,15,NA,CT chest/abdomen/pelvis,76.6,7,60.3,NA,2007/6/17,Durable clinical benefit,NA,NSCLC,0.8,25595,25259,1,FALSE,NA,FALSE,NA,26938,0.0364,IMPACT468,90,Adenocarcinoma,No,MSKCC,Durvalumab,2,20,No,NA,FALSE,NA,NA,PD1 alone,17-Jul,MICROSATELLITE STABLE (MSS). This result is for investigational use only. See MSI note below.,0.18,Stable,641527,8,LUAD,NA,NA,14,YES,lung,25651,12.9,1:PROGRESS,Lung,12-179,FALSE,NA,FALSE,NA,Tumor,1,806,Primary,Female,Former smoker,Matched,NA,Included,FALSE,NA,7,30,Clinical trial,No,"2017, Wk. 27",NA,1945
P-0019914_3756115_347926,Empty,P-0019914,0,discovery,HobS17-568632814864,3756115,597237,1,1,1,2,68,1,10,1,3.9,2,0,,1,Adenocarcinoma,2,1,1,Pembrolizumab,1,0,0,0,3,1,4,1,,3,1,2,,adrenal,0,0,0,0,0,0,0,Q611* (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Q611* (driver),0,#REF!,P-0019914-T02-IM6,68,68,3.9,FALSE,NA,NO,TRUE,Q611* (driver),POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,79.1,7.9,63.8,NA,2006/6/17,NA,NA,NSCLC,2,25025,24959,1,FALSE,NA,FALSE,NA,25350,0.1886,IMPACT468,60,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,2,0,No,Adrenal Gland,FALSE,NA,NA,PD1 alone,17-Jun,MICROSATELLITE STABLE (MSS). This result is for investigational use only. See MSI note below.,0.12,Stable,600774,9,LUAD,NA,NA,10,YES,adrenal,25050,3,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,1025,Metastasis,Female,Former smoker,Matched,NA,Included,FALSE,NA,7.9,60,SOC,No,"2017, Wk. 23",NA,1950
P-0020140_3369277_190910,,P-0020140,1,discovery,HobS17-381329097759,3369277,,1,1,1,1,72,1,165,1,3.7,1.4,1,5.5,1,Adenocarcinoma,1,1,1,Pembrolizumab,1,0,0,0,2.3,1,4,1,,3,2,2,2,lymph node,0,0,0,0,0,0,E138Rfs*20 (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,E138Rfs*20 (driver),0,0,0,0,0,#REF!,P-0020140-T02-IM6,72,74,3.7,FALSE,NA,YES,FALSE,NA,POD,FALSE,NA,Lung Adenocarcinoma,Lung Adenocarcinoma,50,NA,CT chest/abdomen/pelvis,85.8,9.7,75.5,NA,8/17/17,NA,26751,NSCLC,1.4,26630,26584,1,FALSE,NA,FALSE,NA,26751,0.0045,IMPACT468,NA,Adenocarcinoma,No,MSKCC,Pembrolizumab,1,NA,NA,Soft Tissue,FALSE,NA,NA,PD1 alone,17-Aug,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,670341,11,LUAD,5.5,NA,165,YES,lymph node,26655,2.3,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,425,Metastasis,Male,Former smoker,Matched,This sample has been nominated for further analysis using the Archer targeted RNAseq assay. Assay will be performed if additional material is available and results will be reported under a separate accession number.,Excluded,TRUE,E138Rfs*20 (driver),9.7,70,SOC,Yes,"2017, Wk. 33",NA,1944
P-0020347_3369672_190670,,P-0020347,1,discovery,HobS16-292474709884,3369672,493123,1,1,1,2,53,1,10,1,3.5,1.9,1,3.9,1,Adenocarcinoma,2,1,1,Atezolizumab,1,0,0,0,1.5,1,4,1,,3,2,2,1,bone,0,0,0,0,0,0,X199_splice (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,X199_splice (driver),0,0,0,0,0,#REF!,P-0020347-T01-IM6,53,55,3.5,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,44.1,3.5,30.4,NA,5/31/17,NA,19732,NSCLC,1.9,19634,19612,1,FALSE,NA,FALSE,NA,19732,0.0892,IMPACT468,50,Adenocarcinoma,No,MSKCC,Atezolizumab,2,0,No,Lymph Node,FALSE,NA,NA,PD1 alone,17-May,MICROSATELLITE STABLE (MSS). This result is for investigational use only. See MSI note below.,0.07,Stable,621905,4,LUAD,3.9,NA,10,YES,bone,19658,1.5,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,494,Metastasis,Female,Former smoker,Matched,NA,Included,TRUE,X199_splice (driver),3.5,60,SOC,Yes,"2017, Wk. 22",NA,1963
P-0020422_3756262_347983,,P-0020422,1,discovery,HobS17-651185392155,3756262,574535,1,1,1,2,67,1,0,1,3.8,2.1,1,2.9,1,Adenocarcinoma,3,1,1,Atezolizumab,1,0,0,0,1.4,1,4,1,,1,1,2,1,lung,0,0,0,0,0,0,E138* (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,E138* (driver),0,0,0,0,0,#REF!,P-0020422-T01-IM6,67,68,3.8,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Lung Adenocarcinoma,Lung Adenocarcinoma,0,NA,CT chest,95.7,27.2,97,NA,2006/6/17,NA,24628,NSCLC,2.1,24560,24539,1,FALSE,NA,FALSE,NA,24628,0.0443,IMPACT468,70,Adenocarcinoma,Yes,MSKCC,Atezolizumab,3,1,Yes,NA,FALSE,NA,NA,PD1 alone,17-Jun,MICROSATELLITE STABLE (MSS). This result is for investigational use only. See MSI note below.,0.14,Stable,553675,31,LUAD,2.9,NA,12.25,YES,lung,24581,1.4,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,855,Unknown,Female,Former smoker,Matched,NA,Included,TRUE,E138* (driver),27.2,20,SOC,Yes,"2017, Wk. 23",NA,1950
P-0020643_679972_190960,,P-0020643,1,discovery,HobS17-001252371187,679972,641460,1,1,1,2,65,2,40,1,3.9,3.9,0,,1,Squamous,2,1,1,Pembrolizumab,1,0,0,0,9,1,2,0,,3,1,2,1,adrenal,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0020643-T01-IM6,65,66,3.9,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Poorly Differentiated Non-Small Cell Lung Cancer,10,NA,CT chest/abdomen/pelvis,92.8,16.7,90.4,NA,6/15/17,NA,NA,NSCLC,3.9,24315,23735,1,FALSE,NA,FALSE,NA,24502,0.0323,IMPACT468,95,Squamous,Yes,MSKCC,Pembrolizumab,2,10,No,Adrenal Gland,FALSE,NA,NA,PD1 alone,17-Jun,MICROSATELLITE STABLE (MSS). This result is for investigational use only. See MSI note below.,0.18,Stable,634203,18,NSCLCPD,NA,NA,40,YES,adrenal,24008,9,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,674,Metastasis,Female,Current smoker (within 6 months of diagnosis),Matched,NA,Included,FALSE,NA,16.7,60,SOC,No,"2017, Wk. 24",NA,1952
P-0021034_679437_347876,,P-0021034,1,discovery,HobS17-954566589108,679437,,1,1,1,2,73,2,48,1,3.5,6.9,0,,1,Adenocarcinoma,1,1,1,Pembrolizumab,1,0,0,0,10.6,1,2,0,,1,1,2,3,pleura,0,R929Q,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R929Q,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0021034-T01-IM6,73,75,3.5,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,90,NA,CT chest,79.1,7.9,63.8,NA,6/28/17,NA,NA,NSCLC,6.9,27101,26922,1,FALSE,NA,FALSE,R929Q,27767,0.0392,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,1,95,No,NA,FALSE,NA,NA,PD1 alone,17-Jun,MICROSATELLITE STABLE (MSS). This result is for investigational use only. See MSI note below.,0.32,Stable,624007,9,LUAD,NA,NA,48,YES,pleura,27245,10.6,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,716,Metastasis,Female,Current smoker (within 6 months of diagnosis),Matched,NA,Included,FALSE,NA,7.9,20,SOC,No,"2017, Wk. 26",NA,1943
P-0021094_4289907_348009,,P-0021094,1,discovery,HobS17-170097407155,4289907,,1,1,1,2,69,1,45,1,3.6,6,1,1.8,1,Adenocarcinoma,2,1,1,Atezolizumab,1,0,0,0,1.2,1,5,1,,3,1,2,2,lymph node,0,0,0,0,0,0,L282Sfs*5 (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,L282Sfs*5 (driver),0,0,0,0,0,#REF!,P-0021094-T01-IM6,69,70,3.6,FALSE,NA,NO,FALSE,NA,POD/brain,FALSE,NA,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,0,NA,CT chest/abdomen/pelvis,63.5,5.3,46.4,Cytolyt,6/29/17,NA,25439,NSCLC,6,25420,25384,1,FALSE,NA,FALSE,NA,25439,0.004,IMPACT468,NA,Adenocarcinoma,Yes,MSKCC,Atezolizumab,2,0,No,Lymph Node,FALSE,NA,NA,PD1 alone,17-Jun,MICROSATELLITE STABLE (MSS). This result is for investigational use only. See MSI note below.,0,Stable,646162,6,NSCLC,1.8,NA,45,YES,lymph node,25420,1.2,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,783,Metastasis,Female,Former smoker,Matched,"Note: Low tumor content (approximately 20% or less).  Negative copy number and structural variant results, as well as low (stable) MSIsensor scores, should be interpreted with caution.",Included,TRUE,L282Sfs*5 (driver),5.3,20,SOC,Yes,"2017, Wk. 26",NA,1948
P-0021231_645588_348006,,P-0021231,1,discovery,HobS17-507040166458,645588,645586,1,1,1,1,55,1,75,1,3.6,2.5,1,3.7,1,Squamous,2,1,1,Pembrolizumab,1,0,0,0,2.1,1,5,1,,3,1,2,1,soft tissue (abdomen),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0021231-T01-IM6,55,55,3.6,FALSE,NA,NO,FALSE,NA,POD/brain,FALSE,NA,Non-Small Cell Lung Cancer,Lung Squamous Cell Carcinoma,5,NA,CT chest/abdomen/pelvis,76.6,7,60.3,NA,2007/4/17,NA,20172,NSCLC,2.5,20122,20059,1,FALSE,NA,FALSE,NA,20172,0.4055,IMPACT468,95,Squamous,Yes,MSKCC,Pembrolizumab,2,5,No,Abdomen,FALSE,NA,NA,PD1 alone,17-Jul,MICROSATELLITE STABLE (MSS). This result is for investigational use only. See MSI note below.,0.61,Stable,653182,8,LUSC,3.7,NA,75,YES,soft tissue (abdomen),20122,2.1,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,700,Metastasis,Male,Former smoker,Matched,NA,Included,FALSE,NA,7,60,SOC,Yes,"2017, Wk. 27",NA,1963
P-0021266_4289891_347877,Empty,P-0021266,0,discovery,HobS16-647090699390,4289891,,1,1,1,2,54,1,0,1,4.3,10,1,18.7,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,9.3,1,1,0,,3,1,2,,brain,0,0,0,0,0,0,K84* (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,K84* (driver),0,0,0,0,0,#REF!,P-0021266-T01-IM6,54,55,4.3,FALSE,NA,YES,FALSE,NA,CR,FALSE,NA,Lung Adenocarcinoma,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,95,23.7,96.1,NA,2007/7/17,NA,20308,NSCLC,10,20140,19739,1,FALSE,NA,FALSE,NA,20308,0.3556,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,5,No,Brain,FALSE,NA,NA,PD1 alone,17-Jul,MICROSATELLITE STABLE (MSS). This result is for investigational use only. See MSI note below.,1.98,Stable,644978,27,LUAD,18.7,NA,7.5,YES,brain,20022,9.3,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,503,Metastasis,Female,Former smoker,Matched,NA,Included,TRUE,K84* (driver),23.7,40,SOC,Yes,"2017, Wk. 27",NA,1963
P-0021291_565806_347988,,P-0021291,1,discovery,HobS17-274102164889,565806,565808,1,1,1,2,56,1,45,1,3.8,1.6,0,,1,Adenocarcinoma,2,1,1,Pembrolizumab,0,0,1,0,22.8,0,2,0,,3,1,2,1,adrenal,0,0,0,0,0,0,0,E1032* (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,E1032* (driver),0,#REF!,P-0021291-T01-IM6,56,57,3.8,FALSE,NA,NO,TRUE,E1032* (driver),PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,5,NA,CT chest/abdomen/pelvis,94.1,19.3,93.3,NA,2007/11/17,NA,NA,NSCLC,1.6,21409,20732,1,FALSE,NA,FALSE,NA,21425,0.161,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,2,10,No,Adrenal,FALSE,NA,NA,PD1 alone,17-Jul,MICROSATELLITE STABLE (MSS). This result is for investigational use only. See MSI note below.,0.36,Stable,566290,22,LUAD,NA,NA,45,YES,adrenal,21425,22.8,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,761,Metastasis,Female,Former smoker,Matched,NA,Included,FALSE,NA,19.3,30,SOC,No,"2017, Wk. 28",NA,1961
P-0021375_3756290_348007,,P-0021375,1,discovery,HobS17-025318041019,3756290,654911,1,1,1,1,68,1,0,1,3.4,2.3,1,1,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,1,1,8,1,,3,1,2,2,bone,0,0,0,P181S,0,0,STK11-intragenic,S711* (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,P181S,0,0,0,0,0,0,0,0,0,0,0,0,STK11-intragenic,0,0,S711* (driver),0,#REF!,P-0021375-T01-IM6,68,70,3.4,FALSE,NA,YES,TRUE,S711* (driver),POD/death,FALSE,NA,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,0,NA,CT chest/abdomen/pelvis,73.7,6.1,56.8,NA,2007/11/17,NA,25191,NSCLC,2.3,25175,25161,1,FALSE,NA,FALSE,NA,25191,0.0931,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,0,No,Bone,FALSE,NA,NA,PD1 alone,17-Jul,MICROSATELLITE STABLE (MSS). This result is for investigational use only. See MSI note below.,0.41,Stable,653290,7,NSCLC,1,NA,0.5,YES,bone,25191,1,1:PROGRESS,Lung,NA,FALSE,P181S,FALSE,NA,Tumor,1,721,Metastasis,Male,Former smoker,Matched,This sample has been nominated for further analysis using the Archer targeted RNAseq assay as an apparent driver-negative cancer. Assay will be performed if additional material is available and results will be reported under a separate accession number.,Included,FALSE,STK11-intragenic,6.1,30,SOC,Yes,"2017, Wk. 28",NA,1948
P-0021442_3756144_190988,,P-0021442,1,discovery,HobS17-099446926433,3756144,3756154,1,1,1,2,66,1,58,1,3.4,1.6,1,2.5,1,Adenocarcinoma,2,1,1,Atezolizumab,1,0,0,0,1.8,1,5,1,,1,1,2,1,lymph node,0,0,0,0,0,0,X200_splice (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,X200_splice (driver),0,0,0,0,0,#REF!,P-0021442-T01-IM6,66,67,3.4,FALSE,NA,YES,FALSE,NA,POD/brain,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest,87.1,10.5,77,Cytolyt,2007/11/17,NA,24264,NSCLC,1.6,24241,24187,1,FALSE,NA,FALSE,NA,24264,0.5208,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Atezolizumab,2,0,No,Lymph node,FALSE,NA,NA,PD1 alone,17-Jul,MICROSATELLITE STABLE (MSS). This result is for investigational use only. See MSI note below.,0.83,Stable,651077,12,LUAD,2.5,NA,58,YES,lymph node,24243,1.8,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,977,Metastasis,Female,Former smoker,Matched,NA,Included,TRUE,X200_splice (driver),10.5,40,SOC,Yes,"2017, Wk. 28",NA,1951
P-0021470_627662_347910,,P-0021470,1,discovery,HobS17-289511837184,627662,627682,1,1,1,1,47,2,28,0,3.8,2.5,1,15.2,1,Adenocarcinoma,1,1,1,Pembrolizumab,1,0,0,0,2.5,1,4,1,,1,2,2,1,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0021470-T01-IM6,47,49,3.8,FALSE,NA,YES,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,70,NA,CT chest,87.1,10.5,77,NA,7/14/17,NA,17866,NSCLC,2.5,17463,17402,0,FALSE,NA,FALSE,NA,17866,0.0805,IMPACT468,95,Adenocarcinoma,No,MSKCC,Pembrolizumab,1,70,No,Brain,FALSE,NA,NA,PD1 alone,17-Jul,MICROSATELLITE STABLE (MSS). This result is for investigational use only. See MSI note below.,0.2,Stable,582735,11,LUAD,15.2,NA,28,YES,lung,17479,2.5,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,611,Metastasis,Male,Current smoker (within 6 months of diagnosis),Matched,"Note: Low tumor content (approximately 20% or less). Negative mutation, copy number and structural variant results should be interpreted with caution.",Included,FALSE,NA,10.5,20,SOC,Yes,"2017, Wk. 28",NA,1969
P-0021696_3369844_190817,Empty,P-0021696,0,discovery,HobS17-235230770019,3369844,571313,1,1,1,2,69,2,0,2,3.2,1.8,1,2.7,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,1.6,1,4,1,,3,1,2,,lymph node,0,0,0,0,0,0,X97_splice (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,X97_splice (driver),0,0,0,0,0,#REF!,P-0021696-T01-IM6,69,71,3.2,FALSE,NA,YES,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,0,NA,CT chest/abdomen/pelvis,82.2,8.8,68.4,NA,7/27/17,NA,25532,NSCLC,1.8,25491,25449,2,FALSE,NA,FALSE,NA,25532,0.1051,IMPACT468,80,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,0,No,Lymph Node,FALSE,NA,NA,PD1 alone,17-Jul,MICROSATELLITE STABLE (MSS). This result is for investigational use only. See MSI note below.,0,Stable,665484,10,NSCLC,2.7,NA,unk,YES,lymph node,25498,1.6,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,602,Metastasis,Female,Current smoker (within 6 months of diagnosis),Matched,NA,Included,TRUE,X97_splice (driver),8.8,70,SOC,Yes,"2017, Wk. 30",NA,1947
P-0021797_679930_190439,,P-0021797,1,discovery,HobS17-251166392991,679930,655390,1,1,1,1,38,1,0,1,4.2,1.2,0,,1,Adenocarcinoma,1,1,1,Pembrolizumab,1,0,0,0,18.3,1,1,0,,1,1,2,1,lung,0,Y772_A775dup (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Y772_A775dup (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0021797-T01-IM6,38,40,4.2,FALSE,NA,NO,FALSE,NA,CR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,60,NA,CT chest,44.1,3.5,30.4,NA,7/29/17,NA,NA,NSCLC,1.2,14310,14142,1,FALSE,NA,TRUE,Y772_A775dup (driver),14954,0.0384,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,1,60,No,NA,FALSE,NA,NA,PD1 alone,17-Jul,MICROSATELLITE STABLE (MSS). This result is for investigational use only. See MSI note below.,0,Stable,658648,4,LUAD,NA,NA,13.5,YES,lung,14700,18.3,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,649,Primary,Male,Former smoker,Matched,NA,Included,FALSE,NA,3.5,20,SOC,No,"2017, Wk. 30",NA,1978
P-0021833_3687900_347967,Empty,P-0021833,0,discovery,HobS17-000583633457,3687900,3687576,1,1,1,2,65,0,0,1,4.3,1.9,0,,1,Adenocarcinoma,1,1,1,Atezolizumab,1,0,0,0,10.1,1,2,0,,2,1,2,,liver,0,0,S66C,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,S66C,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0021833-T01-IM6,65,67,4.3,FALSE,NA,YES,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen,91.4,14,86.9,NA,2008/1/17,NA,NA,NSCLC,1.9,24476,23992,1,FALSE,NA,FALSE,NA,24749,0.5585,IMPACT468,60,Adenocarcinoma,Yes,MSKCC,Atezolizumab,1,0,No,Liver,FALSE,NA,NA,PD1 alone,17-Aug,MICROSATELLITE STABLE (MSS). This result is for investigational use only. See MSI note below.,1.29,Stable,665530,16,LUAD,NA,NA,0,YES,liver,24299,10.1,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,S66C,Tumor,1,720,Metastasis,Female,Never smoker,Matched,NA,Included,FALSE,NA,14,10,SOC,No,"2017, Wk. 31",NA,1951
P-0022001_3369480_190916,,P-0022001,1,discovery,HobS17-459082131048,3369480,,1,1,1,2,67,0,0,1,3.4,7.5,1,6.6,1,Adenocarcinoma,2,1,1,Atezolizumab,1,0,0,0,1.2,1,4,1,,3,1,2,2,pleura,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0022001-T01-IM6,67,68,3.4,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Lung Adenocarcinoma,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,38.1,2.6,25.9,NA,8/17/17,NA,24896,NSCLC,7.5,24715,24694,1,FALSE,NA,FALSE,NA,24896,0.0777,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Atezolizumab,2,0,No,Pleura,FALSE,NA,NA,PD1 alone,17-Aug,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,674367,3,LUAD,6.6,NA,0,YES,pleura,24732,1.2,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,880,Metastasis,Female,Never smoker,Matched,NA,Included,FALSE,NA,2.6,20,SOC,Yes,"2017, Wk. 33",NA,1950
P-0022033_3687897_348016,,P-0022033,1,discovery,HobS17-151582904179,3687897,3687570,1,1,1,2,71,1,55,1,3.4,1.5,1,8,1,Squamous,2,1,1,Atezolizumab,1,0,0,0,0.7,1,4,1,,3,1,2,3,soft tissue (iliac),0,0,0,W324R,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,W324R,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0022033-T01-IM6,71,72,3.4,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Squamous Cell Carcinoma,0,NA,CT chest/abdomen/pelvis,73.7,6.1,56.8,NA,8/17/17,NA,26371,NSCLC,1.5,26149,26127,1,FALSE,NA,FALSE,NA,26371,0.3485,IMPACT468,95,Squamous,Yes,MSKCC,Atezolizumab,2,0,No,Lymph Node,FALSE,NA,NA,PD1 alone,17-Aug,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,670324,7,LUSC,8,NA,55,YES,soft tissue (iliac),26149,0.7,1:PROGRESS,Lung,NA,FALSE,W324R,FALSE,NA,Tumor,1,858,Metastasis,Female,Former smoker,Matched,NA,Included,FALSE,NA,6.1,30,SOC,Yes,"2017, Wk. 33",NA,1946
P-0022103_675423_347869,Empty,P-0022103,0,discovery,HobS17-228749785910,675423,666606,1,1,1,2,72,2,15,0,3.7,1.2,0,,1,Adenocarcinoma,2,1,1,Pembrolizumab,1,0,0,0,2.5,1,4,1,,1,1,2,,lung,0,0,0,0,0,0,0,Q372Afs*28 (driver),AMP (driver),AMP (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Q372Afs*28 (driver),0,#REF!,P-0022103-T01-IM6,72,72,3.7,FALSE,NA,NO,TRUE,Q372Afs*28 (driver),POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,70,NA,CT chest,54.1,4.4,38.5,NA,8/17/17,NA,NA,NSCLC,1.2,26405,26301,0,TRUE,AMP (driver),FALSE,NA,26557,0.2535,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,2,80,No,NA,FALSE,NA,NA,PD1 alone,17-Aug,MICROSATELLITE STABLE (MSS). See MSI note below.,0.19,Stable,675548,5,LUAD,NA,NA,15,YES,lung,26378,2.5,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,853,Primary,Female,Current smoker (within 6 months of diagnosis),Matched,NA,Included,FALSE,NA,4.4,20,SOC,No,"2017, Wk. 33",NA,1946
P-0022291_2359747_347986,,P-0022291,1,discovery,HobS18-712205993970,2359747,993133,1,1,1,2,68,2,147,1,3.9,1.5,1,8.1,1,Large Cell,1,1,1,Atezolizumab,1,0,0,0,2,1,4,1,,3,1,2,2,lung,0,0,0,0,G469A (driver),0,X200_splice (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,G469A (driver),0,0,0,0,0,0,0,X200_splice (driver),0,0,0,0,0,#REF!,P-0022291-T02-IM6,68,69,3.9,FALSE,NA,NO,FALSE,NA,POD,TRUE,G469A (driver),Non-Small Cell Lung Cancer,Large Cell Neuroendocrine Carcinoma,1,NA,CT chest/abdomen/pelvis,79.1,7.9,63.8,NA,3/28/18,NA,25387,NSCLC,1.5,25182,25140,1,FALSE,NA,FALSE,NA,25387,0.1481,IMPACT468,95,Large Cell,Yes,MSKCC,Atezolizumab,1,5,No,NA,FALSE,NA,NA,PD1 alone,18-Mar,MICROSATELLITE STABLE (MSS). See MSI note below.,0.14,Stable,986123,9,LUNE,8.1,NA,147,YES,lung,25201,2,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,913,Primary,Female,Current smoker (within 6 months of diagnosis),Matched,NA,Included,TRUE,X200_splice (driver),7.9,20,SOC,Yes,"2018, Wk. 13",NA,1949
P-0022301_682887_191113,,P-0022301,1,discovery,HobS17-879434708494,682887,682898,1,1,1,1,76,1,30,1,3,2,1,3.9,1,Squamous,2,1,1,Pembrolizumab,1,0,0,0,2.5,1,6,1,,3,1,2,1,lung,0,0,0,0,V487L,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,V487L,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0022301-T01-IM6,76,77,3,FALSE,NA,NO,FALSE,NA,POD/bone,FALSE,V487L,Non-Small Cell Lung Cancer,Poorly Differentiated Non-Small Cell Lung Cancer,1,NA,CT chest/abdomen/pelvis,93.7,18.4,92.4,NA,8/18/17,NA,28093,NSCLC,2,28038,27975,1,FALSE,NA,FALSE,NA,28093,0.1102,IMPACT468,95,Squamous,Yes,MSKCC,Pembrolizumab,2,1,No,NA,FALSE,NA,NA,PD1 alone,17-Aug,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,684104,21,NSCLCPD,3.9,NA,30,YES,lung,28052,2.5,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,604,Primary,Male,Former smoker,Matched,"Note: Low tumor content (approximately 20% or less).  Negative mutation, copy number and structural variant results, as well as low (stable) MSIsensor scores, should be interpreted with caution.",Included,FALSE,NA,18.4,10,SOC,Yes,"2017, Wk. 33",NA,1941
P-0022304_3687393_348015,Empty,P-0022304,0,discovery,HobS17-042908516312,3687393,3687466,1,1,1,1,71,1,75,1,4.1,1.5,1,16.7,1,Adenocarcinoma,2,1,1,Atezolizumab,1,0,0,0,4,1,4,1,,3,1,2,,lymph node,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0022304-T01-IM6,71,72,4.1,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,13.1,0.9,7.8,Cytolyt,8/17/17,NA,26722,NSCLC,1.5,26334,26215,1,FALSE,NA,FALSE,NA,26722,0.0036,IMPACT468,NA,Adenocarcinoma,Yes,MSKCC,Atezolizumab,2,0,NA,Lymph Node,FALSE,NA,NA,PD1 alone,17-Aug,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,671597,1,LUAD,16.7,NA,75,YES,lymph node,26337,4,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,854,Metastasis,Male,Former smoker,Matched,"Note: Low tumor content (approximately 20% or less).  Negative mutation, copy number and structural variant results, as well as low (stable) MSIsensor scores, should be interpreted with caution.",Excluded,FALSE,NA,0.9,20,SOC,Yes,"2017, Wk. 33",NA,1946
P-0022377_3369583_190420,,P-0022377,1,discovery,HobS17-873198918388,3369583,683215,1,1,1,1,63,2,0,1,3.6,1.9,1,5,1,Adenocarcinoma,2,1,1,Atezolizumab,1,0,0,0,1.9,1,4,1,,1,1,2,3,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0022377-T01-IM6,63,65,3.6,FALSE,NA,YES,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,0,NA,CT chest,25.2,1.8,16.1,NA,8/17/17,NA,23486,NSCLC,1.9,23375,23333,1,FALSE,NA,FALSE,NA,23486,0.2469,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Atezolizumab,2,50,No,NA,FALSE,NA,NA,PD1 alone,17-Aug,MICROSATELLITE STABLE (MSS). See MSI note below.,1.51,Stable,686680,2,NSCLC,5,NA,38.7,YES,lung,23392,1.9,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,787,Primary,Male,Current smoker (within 6 months of diagnosis),Matched,NA,Included,FALSE,NA,1.8,20,SOC,Yes,"2017, Wk. 33",NA,1953
P-0022808_685813_348017,,P-0022808,1,discovery,HobS17-124554110580,685813,685911,1,1,1,2,75,0,0,1,3.9,4.7,1,3.6,1,Adenocarcinoma,2,1,1,Pembrolizumab,1,0,0,0,2.8,1,4,1,,3,1,2,1,bone,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0022808-T01-IM6,75,76,3.9,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,1,NA,CT chest/abdomen/pelvis,63.5,5.3,46.4,NA,2009/6/17,NA,27782,NSCLC,4.7,27738,27673,1,FALSE,NA,FALSE,NA,27782,0.3906,IMPACT468,80,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,2,1,Yes,Bone,FALSE,NA,NA,PD1 alone,17-Sep,MICROSATELLITE STABLE (MSS). See MSI note below.,0.45,Stable,687852,6,LUAD,3.6,NA,0,YES,bone,27758,2.8,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,653,Metastasis,Female,Never smoker,Matched,NA,Included,FALSE,NA,5.3,20,SOC,Yes,"2017, Wk. 36",NA,1942
P-0022949_718022_190435,,P-0022949,1,discovery,HobS17-563290934215,718022,618675,1,1,1,1,61,2,46,1,3.7,2.3,0,,1,Adenocarcinoma,1,1,1,Pembrolizumab,1,0,0,0,2.7,1,5,1,,2,2,2,2,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0022949-T01-IM6,61,62,3.7,FALSE,NA,NO,FALSE,NA,POD/brain,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,80,NA,CT chest/abdomen,82.2,8.8,68.4,NA,9/15/17,NA,NA,NSCLC,2.3,22305,22284,1,FALSE,NA,FALSE,NA,22433,0.0022,IMPACT468,95,Adenocarcinoma,No,MSKCC,Pembrolizumab,1,80,No,NA,FALSE,NA,NA,PD1 alone,17-Sep,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,620874,10,LUAD,NA,NA,46,YES,lung,22367,2.7,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,423,Primary,Male,Current smoker (within 6 months of diagnosis),Matched,"Note: Low tumor content (approximately 20% or less).  Negative copy number and structural variant results, as well as low (stable) MSIsensor scores, should be interpreted with caution.",Included,FALSE,NA,8.8,10,SOC,No,"2017, Wk. 37",NA,1956
P-0023014_4289834_348018,,P-0023014,1,discovery,HobS17-509244200148,4289834,3687472,1,1,1,1,69,1,15,1,3.5,4.8,1,1.3,1,Adenocarcinoma,2,1,1,Atezolizumab,1,0,0,0,1.3,1,8,1,,3,1,2,1,lymph node,0,0,0,0,0,0,R103_R104del,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R103_R104del,0,0,0,0,0,#REF!,P-0023014-T01-IM6,69,70,3.5,FALSE,NA,NO,FALSE,NA,POD/death,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,54.1,4.4,38.5,Cytolyt,9/22/17,NA,25328,NSCLC,4.8,25289,25289,1,FALSE,NA,FALSE,NA,25328,0.3095,IMPACT468,NA,Adenocarcinoma,Yes,MSKCC,Atezolizumab,2,0,No,Lymph Node,FALSE,NA,NA,PD1 alone,17-Sep,MICROSATELLITE STABLE (MSS). See MSI note below.,0.56,Stable,691829,5,LUAD,1.3,NA,15,YES,lymph node,25328,1.3,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,830,Metastasis,Male,Former smoker,Matched,NA,Included,FALSE,R103_R104del,4.4,40,SOC,Yes,"2017, Wk. 38",NA,1948
P-0023023_3369314_190846,,P-0023023,1,discovery,HobS16-952196077499,3369314,,1,1,1,1,63,1,12,1,4.1,2.9,0,,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,8.4,1,3,1,1,3,1,2,2,lymph node,0,0,0,0,0,"AMP (driver), D1010Y (driver)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,AMP (driver),AMP (driver),D1010Y (driver),0,0,0,0,0,0,0,0,0,#REF!,P-0023023-T01-IM6,63,64,4.1,FALSE,NA,NO,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,1,NA,CT chest/abdomen/pelvis,79.1,7.9,63.8,Cytolyt,9/19/17,Durable clinical benefit,NA,NSCLC,2.9,23311,23059,1,FALSE,NA,FALSE,NA,23824,0.0205,IMPACT468,NA,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,0,No,Lymph Node,TRUE,"AMP (driver), D1010Y (driver)",NA,PD1 alone,17-Sep,MICROSATELLITE STABLE (MSS). See MSI note below.,0.06,Stable,421633,9,LUAD,NA,NA,12,YES,lymph node,23315,8.4,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,689,Metastasis,Male,Former smoker,Matched,NA,Included,FALSE,NA,7.9,30,SOC,No,"2017, Wk. 38",NA,1954
P-0023408_4289948_348005,,P-0023408,1,discovery,HobS17-491904637192,4289948,3687565,1,1,1,2,64,2,0,2,3.5,3.7,1,1,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,1,1,8,1,,3,1,2,2,lymph node,0,0,X833_splice,0,0,0,R28Pfs*135 (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,X833_splice,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R28Pfs*135 (driver),0,0,0,0,0,#REF!,P-0023408-T01-IM6,64,65,3.5,FALSE,NA,NO,FALSE,NA,POD/death,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,85.9,9.7,74.8,NA,2010/4/17,NA,23572,NSCLC,3.7,23543,23543,2,FALSE,NA,FALSE,NA,23572,0.4437,IMPACT468,NA,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,0,No,Lymph Node,FALSE,NA,NA,PD1 alone,17-Oct,MICROSATELLITE STABLE (MSS). See MSI note below.,1.38,Stable,722792,11,LUAD,1,NA,17.6,YES,lymph node,23572,1,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,X833_splice,Tumor,1,402,Metastasis,Female,Current smoker (within 6 months of diagnosis),Matched,Note: Copy number profile is suggestive of broad copy number loss on Chromosome arm 3p21.,Included,TRUE,R28Pfs*135 (driver),9.7,50,SOC,Yes,"2017, Wk. 40",NA,1953
P-0023464_3369827_191203,,P-0023464,1,discovery,HobS17-271419330718,3369827,3731730,1,1,1,2,79,1,33,2,3.1,3.5,1,8.4,1,Adenocarcinoma,2,1,1,Atezolizumab,1,0,0,0,5.3,1,3,1,2,3,1,2,2,pleura,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0023464-T01-IM6,79,80,3.1,FALSE,NA,NO,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,85.9,9.7,74.8,NA,2010/6/17,No durable clinical benefit,29306,NSCLC,3.5,29189,29049,2,FALSE,NA,FALSE,NA,29306,0.1313,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Atezolizumab,2,0,No,NA,FALSE,NA,NA,PD1 alone,17-Oct,MICROSATELLITE STABLE (MSS). See MSI note below.,0.64,Stable,560849,11,LUAD,8.4,NA,33,YES,pleura,29211,5.3,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,891,Primary,Female,Former smoker,Matched,NA,Included,FALSE,NA,9.7,30,SOC,Yes,"2017, Wk. 40",NA,1938
P-0023598_4289933_348024,,P-0023598,1,discovery,HobS17-406560106683,4289933,727646,1,1,1,2,67,2,20,1,3.5,0.5,0,,1,Adenocarcinoma,2,1,1,Pembrolizumab,1,0,0,0,3.6,1,2,0,,3,1,2,3,lymph node,G2R,0,L1665Ffs*7,0,0,0,0,0,0,0,0,0,0,0,G2R,0,0,0,0,0,0,0,L1665Ffs*7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0023598-T01-IM6,67,68,3.5,FALSE,G2R,YES,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,30,NA,CT chest/abdomen/pelvis,92.3,14.9,89.1,Cytolyt,10/31/17,NA,NA,NSCLC,0.5,24676,24676,1,FALSE,NA,FALSE,NA,25366,0.1282,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,2,50,No,Lymph Node,FALSE,NA,NA,PD1 alone,17-Oct,MICROSATELLITE STABLE (MSS). See MSI note below.,0.26,Stable,726229,17,LUAD,NA,NA,20,YES,lymph node,24786,3.6,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,L1665Ffs*7,Tumor,1,744,Metastasis,Female,Current smoker (within 6 months of diagnosis),Matched,NA,Included,FALSE,NA,14.9,30,SOC,No,"2017, Wk. 44",NA,1950
P-0023779_3687755_347868,,P-0023779,1,discovery,HobS17-873050609275,3687755,3687561,1,1,1,1,74,1,0,1,3.2,0.9,1,1.6,1,NOS,2,1,1,Atezolizumab,1,0,0,0,1.6,1,3,1,2,3,1,2,2,lung,0,0,0,0,0,0,K44* (driver),0,0,0,A120G,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,K44* (driver),0,0,0,0,0,#REF!,P-0023779-T01-IM6,74,75,3.2,FALSE,NA,NO,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,0,NA,CT chest/abdomen/pelvis,82.2,8.8,68.4,NA,10/18/17,No durable clinical benefit,27316,NSCLC,0.9,27287,27266,1,FALSE,A120G,FALSE,NA,27316,0.1124,IMPACT468,95,NOS,Yes,MSKCC,Atezolizumab,2,0,No,NA,FALSE,NA,NA,PD1 alone,17-Oct,MICROSATELLITE STABLE (MSS). See MSI note below.,0.63,Stable,718414,10,NSCLC,1.6,NA,17.25,YES,lung,27316,1.6,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,488,Primary,Male,Former smoker,Matched,NA,Included,TRUE,K44* (driver),8.8,40,SOC,Yes,"2017, Wk. 42",NA,1943
P-0023902_3369540_190647,,P-0023902,1,discovery,HobS17-084667988803,3369540,609996,1,1,1,2,52,0,0,1,3.6,0.6,1,7,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,1.8,1,4,1,,3,2,2,1,bone,0,0,0,0,0,0,0,0,0,0,L747P (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0023902-T01-IM6,52,54,3.6,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,37.9,2.6,25.7,NA,10/22/17,NA,19464,NSCLC,0.6,19292,19250,1,TRUE,L747P (driver),FALSE,NA,19464,0.4111,IMPACT468,NA,Adenocarcinoma,No,MSKCC,Nivolumab,2,0,No,NA,FALSE,NA,NA,PD1 alone,17-Oct,MICROSATELLITE STABLE (MSS). See MSI note below.,1.41,Stable,738586,3,LUAD,7,NA,0,YES,bone,19305,1.8,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,501,Primary,Female,Never smoker,Matched,NA,Included,FALSE,NA,2.6,50,SOC,Yes,"2017, Wk. 42",NA,1964
P-0023926_3756140_348025,,P-0023926,1,discovery,HobS17-318375072786,3756140,736392,1,1,1,2,69,2,0,1,2.8,2.6,1,0.8,1,NOS,2,1,1,Pembrolizumab,1,0,0,0,0.8,1,8,1,,3,1,2,1,liver,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0023926-T01-IM6,69,69,2.8,FALSE,NA,YES,FALSE,NA,POD/death,FALSE,NA,Lung Adenocarcinoma,Lung Adenocarcinoma,10,NA,CT chest/abdomen/pelvis,61.9,5.3,45.8,NA,10/25/17,NA,25253,NSCLC,2.6,25229,25229,1,FALSE,NA,FALSE,NA,25253,0.4219,IMPACT468,95,NOS,Yes,MSKCC,Pembrolizumab,2,10,No,Liver,FALSE,NA,NA,PD1 alone,17-Oct,MICROSATELLITE STABLE (MSS). See MSI note below.,0.64,Stable,751121,6,LUAD,0.8,NA,unk,YES,liver,25253,0.8,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,733,Metastasis,Female,Current smoker (within 6 months of diagnosis),Matched,"Note: This sample is being considered for further analysis using the Archer targeted RNAseq assay for detection of gene fusion transcript, as an apparent driver-negative cancer case. Assay will be performed if additional material is available and results ",Included,FALSE,NA,5.3,30,SOC,Yes,"2017, Wk. 43",NA,1949
P-0024467_3756362_348014,,P-0024467,1,discovery,HobS17-297677787795,3756362,757009,1,1,1,1,76,1,56,1,3.8,1.3,0,,1,Adenocarcinoma,2,1,1,Atezolizumab,0,1,0,0,7.6,0,2,0,,1,1,2,2,lymph node,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0024467-T01-IM6,76,77,3.8,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,80,NA,CT chest,63.5,5.3,46.4,SSL,11/14/17,NA,NA,NSCLC,1.3,28268,27827,1,FALSE,NA,FALSE,NA,28538,0.1465,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Atezolizumab,2,80,No,Lymph Node,FALSE,NA,NA,PD1 alone,17-Nov,MICROSATELLITE STABLE (MSS). See MSI note below.,0.2,Stable,754620,6,LUAD,NA,NA,56,YES,lymph node,28059,7.6,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,828,Metastasis,Male,Former smoker,Matched,NA,Included,FALSE,NA,5.3,40,SOC,No,"2017, Wk. 46",NA,1941
P-0024561_3756282_348032,,P-0024561,1,discovery,HobS17-087299190561,3756282,767327,1,1,1,2,68,0,0,1,4.1,2.4,1,6.8,1,Adenocarcinoma,4,1,1,Atezolizumab,1,0,0,0,3.3,1,4,1,,3,1,2,2,lung,0,0,0,0,0,0,Y253Gfs*15 (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Y253Gfs*15 (driver),0,0,0,0,0,#REF!,P-0024561-T01-IM6,68,69,4.1,FALSE,NA,YES,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,25.2,1.8,16.1,NA,11/17/17,NA,25198,NSCLC,2.4,25082,24991,1,FALSE,NA,FALSE,NA,25198,0.2434,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Atezolizumab,4,0,No,NA,FALSE,NA,NA,PD1 alone,17-Nov,MICROSATELLITE STABLE (MSS). See MSI note below.,0.78,Stable,758515,2,LUAD,6.8,NA,0,YES,lung,25092,3.3,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,790,Primary,Female,Never smoker,Matched,NA,Included,TRUE,Y253Gfs*15 (driver),1.8,40,SOC,Yes,"2017, Wk. 46",NA,1949
P-0024764_4289925_348034,,P-0024764,1,discovery,HobS17-067836908873,4289925,3687476,1,1,1,2,74,2,50,1,3.8,1.8,0,,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,5.1,1,3,1,2,3,1,2,1,lymph node,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0024764-T01-IM6,74,74,3.8,FALSE,NA,NO,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,89.7,12.3,82.3,Cytolyt,11/23/17,No durable clinical benefit,NA,NSCLC,1.8,27095,27011,1,FALSE,NA,FALSE,NA,27459,0.1055,IMPACT468,NA,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,0,No,Lymph node,FALSE,NA,NA,PD1 alone,17-Nov,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,745092,14,LUAD,NA,NA,50,YES,lymph node,27167,5.1,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,692,Metastasis,Female,Current smoker (within 6 months of diagnosis),Matched,NA,Included,FALSE,NA,12.3,20,SOC,No,"2017, Wk. 47",NA,1944
P-0024980_982742_348033,,P-0024980,1,discovery,HobS18-408791297596,982742,930204,1,1,1,2,64,2,20,1,4.4,7.9,1,2.5,1,Adenocarcinoma,2,1,1,Pembrolizumab,1,0,0,0,2,1,4,1,,3,2,2,2,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0024980-T03-IM6,64,65,4.4,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,100,NA,CT chest/abdomen/pelvis,NA,NA,NA,NA,2004/4/18,NA,23742,NSCLC,7.9,23712,23665,1,FALSE,NA,FALSE,NA,23742,0,IMPACT468,70,Adenocarcinoma,No,MSKCC,Pembrolizumab,2,95,Yes,NA,FALSE,NA,NA,PD1 alone,18-Apr,NA,0,Do not report,999292,NA,LUAD,2.5,NA,20,YES,lung,23726,2,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,428,Primary,Female,Current smoker (within 6 months of diagnosis),Matched,Note: Absence of any somatic mutations (including silent mutations) and any copy number changes suggests very low tumor content. Negative results should be interpreted with caution. Repeat testing on a separate sample may be indicated.,Included,FALSE,NA,0,10,SOC,Yes,"2018, Wk. 14",NA,1953
P-0025018_3756036_348011,,P-0025018,1,discovery,HobS17-390978637153,3756036,878614,1,1,1,1,78,1,35,1,3.1,3.7,1,1.5,1,Squamous,2,1,1,Atezolizumab,1,0,0,0,1.5,1,8,1,,3,1,2,4,lymph node,0,0,0,G798D,0,0,0,0,AMP (driver),AMP (driver),0,EGFR-LANCL2 fusion,0,0,0,0,0,0,0,0,0,0,0,0,0,0,G798D,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0025018-T01-IM6,78,79,3.1,FALSE,NA,NO,FALSE,NA,POD/death,FALSE,NA,Non-Small Cell Lung Cancer,Lung Squamous Cell Carcinoma,0,NA,CT chest/abdomen/pelvis,62.5,5.3,45.6,Cytolyt,2012/1/17,NA,28694,NSCLC,3.7,28668,28647,1,TRUE,"AMP (driver), EGFR-LANCL2 fusion",FALSE,NA,28694,0.001,IMPACT468,80,Squamous,Yes,MSKCC,Atezolizumab,2,0,No,Lymph Node,FALSE,NA,NA,PD1 alone,17-Dec,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,769138,5,LUSC,1.5,NA,35,YES,lymph node,28694,1.5,1:PROGRESS,Lung,NA,FALSE,G798D,FALSE,NA,Tumor,1,970,Metastasis,Male,Former smoker,Matched,NA,Included,FALSE,NA,5.3,10,SOC,Yes,"2017, Wk. 48",NA,1939
P-0025245_877691_347976,,P-0025245,1,discovery,HobS17-161148218025,877691,877743,1,1,1,1,43,1,18,0,4.3,2.8,1,6.2,1,Adenocarcinoma,3,1,1,Pembrolizumab,1,0,0,0,3.5,1,4,1,,3,1,2,3,lung,0,Y772_A775dup (driver),S340F,0,0,0,0,Q766Sfs*67 (driver),0,0,0,0,0,0,0,0,0,0,Y772_A775dup (driver),0,0,0,S340F,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Q766Sfs*67 (driver),0,#REF!,P-0025245-T01-IM6,43,43,4.3,FALSE,NA,NO,TRUE,Q766Sfs*67 (driver),POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,75,NA,CT chest/abdomen/pelvis,98.4,51.8,99.6,NA,2012/7/17,NA,16105,NSCLC,2.8,16008,15917,0,FALSE,NA,TRUE,Y772_A775dup (driver),16105,0.0954,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,3,80,No,NA,FALSE,NA,NA,PD1 alone,17-Dec,MICROSATELLITE INSTABILITY-INDETERMINATE. See MSI note below.,8.96,Indeterminate,889768,59,LUAD,6.2,NA,18,YES,lung,16025,3.5,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,S340F,Tumor,1,572,Primary,Male,Former smoker,Matched,NA,Included,FALSE,NA,51.8,20,SOC,Yes,"2017, Wk. 49",NA,1975
P-0025354_3687759_348026,,P-0025354,1,discovery,HobS17-882967413773,3687759,3687558,1,1,1,2,60,1,92,2,4.2,1.4,0,,1,Adenocarcinoma,1,1,1,Nivolumab,0,1,0,0,11.1,0,3,1,1,1,1,2,1,lung,0,0,0,0,0,0,"P281Rfs*6 (driver), Y166* (driver)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"P281Rfs*6 (driver), Y166* (driver)",0,0,0,0,0,#REF!,P-0025354-T01-IM6,60,60,4.2,FALSE,NA,NO,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest,87.1,10.5,77,NA,2012/9/17,Durable clinical benefit,NA,NSCLC,1.4,22076,21961,2,FALSE,NA,FALSE,NA,22366,0.1563,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Nivolumab,1,0,No,NA,FALSE,NA,NA,PD1 alone,17-Dec,MICROSATELLITE STABLE (MSS). See MSI note below.,0.07,Stable,888320,12,LUAD,NA,NA,92,YES,lung,22300,11.1,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,672,Primary,Female,Former smoker,Matched,Note: Copy number profile is suggestive of broad copy number gain on Chromosome arm 8q.,Included,TRUE,"P281Rfs*6 (driver), Y166* (driver)",10.5,40,SOC,No,"2017, Wk. 49",NA,1958
P-0025465_1080598_348038,,P-0025465,1,discovery,HobS17-157012766445,1080598,926578,1,1,1,1,67,2,20,1,4,5.4,0,,1,Squamous,1,1,1,Pembrolizumab,1,0,0,0,12.7,1,2,0,,3,1,2,1,lymph node,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0025465-T01-IM6,67,68,4,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,70,NA,CT chest/abdomen/pelvis,25.2,1.8,16.1,NA,12/22/17,NA,NA,NSCLC,5.4,25134,24763,1,FALSE,NA,FALSE,NA,25386,0.0025,IMPACT468,60,Squamous,Yes,MSKCC,Pembrolizumab,1,80,Yes,Lymph Node,FALSE,NA,NA,PD1 alone,17-Dec,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,892695,2,LUAD,NA,NA,20,YES,lymph node,25150,12.7,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,762,Metastasis,Male,Current smoker (within 6 months of diagnosis),Matched,"Note: Low tumor content (approximately 20% or less). Negative MSIsensor, copy number and structural variant results should be interpreted with caution.  Additional mutations may not be detected due to low tumor content. Note: This sample has been nominate",Included,FALSE,NA,1.8,10,SOC,No,"2017, Wk. 51",NA,1950
P-0025598_4289870_348036,,P-0025598,1,discovery,HobS17-921050510424,4289870,902376,1,1,1,2,58,1,15,0,4,2.3,1,5.8,1,Adenocarcinoma,1,1,1,Pembrolizumab,1,0,0,0,2.5,1,4,1,,1,1,2,2,lung,0,0,0,0,0,0,D237H,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,D237H,0,0,0,0,0,#REF!,P-0025598-T01-IM6,58,59,4,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,60,NA,CT chest,91,13.2,85.8,NA,12/21/17,NA,21498,NSCLC,2.3,21454,21321,0,FALSE,NA,FALSE,NA,21498,0.1604,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,1,60,No,NA,FALSE,NA,NA,PD1 alone,17-Dec,MICROSATELLITE STABLE (MSS). See MSI note below.,0.41,Stable,897420,15,LUAD,5.8,NA,15,YES,lung,21396,2.5,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,874,Primary,Female,Former smoker,Matched,NA,Included,FALSE,D237H,13.2,40,SOC,Yes,"2017, Wk. 51",NA,1959
P-0025657_732453_348022,Empty,P-0025657,0,discovery,HobS17-115477439659,732453,729613,1,1,1,2,68,0,0,1,3.1,3.3,0,,1,NOS,2,1,1,Pembrolizumab,1,0,0,0,2.1,1,3,1,2,3,2,2,,lymph node,0,0,0,0,0,"AMP (driver), X963_splice (driver), MET-intragenic - Archer",0,0,AMP (driver),AMP (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,AMP (driver),AMP (driver),X963_splice (driver),MET-intragenic - Archer,0,0,0,0,0,0,0,0,#REF!,P-0025657-T02-IM6,68,69,3.1,FALSE,NA,YES,FALSE,NA,SD,FALSE,NA,Lung Squamous Cell Carcinoma,Lung Squamous Cell Carcinoma,90,NA,CT chest/abdomen/pelvis,78.5,7.9,64.1,NA,9/27/18,No durable clinical benefit,NA,NSCLC,3.3,25142,25093,1,TRUE,AMP (driver),FALSE,NA,25446,0.1319,IMPACT468,95,NOS,No,MSKCC,Pembrolizumab,2,90,No,Muscle,TRUE,"AMP (driver), X963_splice (driver), MET-intragenic - Archer",NA,PD1 alone,18-Sep,MICROSATELLITE STABLE (MSS). See MSI note below.,0.06,Stable,NA,8,LUSC,NA,NA,0,NO,lymph node,25156,2.1,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,532,Metastasis,Female,Never smoker,Matched,NA,Included,FALSE,NA,7.9,30,SOC,No,"2018, Wk. 39",NA,1950
P-0025777_3687409_348037,Empty,P-0025777,0,discovery,HobS18-081725613360,3687409,3687428,1,1,1,2,49,1,0,1,4.3,2.4,1,2,1,Adenocarcinoma,2,1,1,Pembrolizumab,1,0,0,0,1.6,1,4,1,,3,1,2,,bone,0,0,0,0,0,0,P221Lfs*66 (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,P221Lfs*66 (driver),0,0,0,0,0,#REF!,P-0025777-T01-IM6,49,49,4.3,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,37.9,2.6,25.7,NA,12/30/17,NA,18198,NSCLC,2.4,18136,18136,1,FALSE,NA,FALSE,NA,18198,0.2484,IMPACT468,70,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,2,0,No,Brain,FALSE,NA,NA,PD1 alone,17-Dec,MICROSATELLITE STABLE (MSS). See MSI note below.,0.47,Stable,903204,3,LUAD,2,NA,unk,YES,bone,18186,1.6,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,648,Metastasis,Female,Former smoker,Matched,NA,Included,TRUE,P221Lfs*66 (driver),2.6,70,SOC,Yes,"2017, Wk. 52",NA,1969
P-0025917_4289872_190757,,P-0025917,1,discovery,HobS17-197852051385,4289872,,1,1,1,2,62,1,37,2,3.3,13.8,1,4.4,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,1.7,1,4,1,,3,1,2,2,lung,0,0,P826L,0,0,C584Wfs*10,STK11-intragenic,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,P826L,0,0,0,0,0,0,0,0,0,0,0,C584Wfs*10,0,0,0,0,STK11-intragenic,0,0,0,0,#REF!,P-0025917-T02-IM6,62,63,3.3,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Lung Adenocarcinoma,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,96.2,30.7,97.8,NA,1/24/18,NA,22908,NSCLC,13.8,22816,22773,2,FALSE,NA,FALSE,NA,22908,0.1477,IMPACT468,NA,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,0,No,NA,FALSE,C584Wfs*10,NA,PD1 alone,18-Jan,MICROSATELLITE INSTABILITY-INDETERMINATE. See MSI note below.,5.06,Indeterminate,916722,35,LUAD,4.4,NA,37,YES,lung,22825,1.7,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,P826L,Tumor,1,262,Primary,Female,Former smoker,Matched,NA,Included,FALSE,STK11-intragenic,30.7,40,SOC,Yes,"2018, Wk. 04",NA,1955
P-0026121_3369596_190361,,P-0026121,1,discovery,HobS17-087308912274,3369596,947228,1,1,1,1,70,2,50,1,2.7,4.9,1,8.3,1,Adenocarcinoma,1,1,1,Pembrolizumab,1,0,0,0,5.5,1,2,0,,3,1,2,4,pleura,0,0,0,0,0,AMP (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,AMP (driver),AMP (driver),0,0,0,0,0,0,0,0,0,0,#REF!,P-0026121-T01-IM6,70,71,2.7,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Pleomorphic Carcinoma of the Lung,100,NA,CT chest/abdomen/pelvis,44.1,3.5,30.4,NA,7/14/18,NA,26155,NSCLC,4.9,26050,25903,1,FALSE,NA,FALSE,NA,26155,0.1062,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,1,95,No,Pleura,TRUE,AMP (driver),NA,PD1 alone,18-Jul,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,908764,4,LUPC,8.3,NA,50,YES,pleura,26071,5.5,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,439,Metastasis,Male,Current smoker (within 6 months of diagnosis),Matched,NA,Included,FALSE,NA,3.5,30,SOC,Yes,"2018, Wk. 28",NA,1947
P-0026289_935685_190549,,P-0026289,1,discovery,HobS17-774060438975,935685,1007038,1,1,1,2,58,1,0,1,4.1,1.7,0,,1,Adenocarcinoma,1,1,1,Pembrolizumab,1,0,0,0,16.6,1,2,0,,3,1,2,2,lung,0,R970L,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R970L,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0026289-T01-IM6,58,58,4.1,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,80,NA,CT chest/abdomen/pelvis,87.1,10.5,77,NA,1/23/18,NA,NA,NSCLC,1.7,21512,21173,1,FALSE,NA,FALSE,R970L,21804,0.0088,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,1,50,No,NA,FALSE,NA,NA,PD1 alone,18-Jan,MICROSATELLITE STABLE (MSS). See MSI note below.,0.08,Stable,914999,12,LUAD,NA,NA,unk,YES,lung,21677,16.6,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,537,Primary,Female,Former smoker,Matched,Note: Multiple deletion events in GNAS involving exons 1-13 in the tumor sample may suggest the presence of somatically acquired processed pseudogenes.,Included,FALSE,NA,10.5,20,SOC,No,"2018, Wk. 04",NA,1960
P-0026552_4289913_190866,,P-0026552,1,discovery,HobS17-738472762807,4289913,743440,1,1,1,2,66,1,33,1,3.4,2.3,0,,1,Large cell,2,1,1,Nivolumab,1,0,0,0,8.4,1,2,0,,3,2,2,4,lymph node,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0026552-T02-IM6,66,69,3.4,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Large Cell Neuroendocrine Carcinoma,0,NA,CT chest/abdomen/pelvis,63.5,5.3,46.4,NA,7/17/18,NA,NA,NSCLC,2.3,24654,24416,1,FALSE,NA,FALSE,NA,25152,0.0661,IMPACT468,95,Large cell neuroendocrine,No,MSKCC,Nivolumab,2,5,No,Axilla,FALSE,NA,NA,PD1 alone,18-Jul,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,1102389,6,LUNE,NA,NA,33,YES,lymph node,24671,8.4,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,735,Metastasis,Female,Former smoker,Matched,NA,Included,FALSE,NA,5.3,30,SOC,No,"2018, Wk. 29",NA,1950
P-0026574_3687340_190659,,P-0026574,1,discovery,HobS17-605645168065,3687340,976690,1,1,1,1,76,1,50,1,3.2,2.7,0,,1,Squamous,2,1,1,Pembrolizumab,0,0,0,1,9.3,0,2,0,,3,1,2,1,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0026574-T02-IM6,76,77,3.2,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Squamous Cell Carcinoma,30,NA,CT chest/abdomen/pelvis,92.3,14.9,89.1,NA,3/20/18,NA,NA,NSCLC,2.7,28037,27789,1,FALSE,NA,FALSE,NA,28072,0.0933,IMPACT468,95,Squamous,Yes,MSKCC,Pembrolizumab,2,30,No,NA,FALSE,NA,NA,PD1 alone,18-Mar,MICROSATELLITE STABLE (MSS). See MSI note below.,0.35,Stable,974581,17,LUSC,NA,NA,50,YES,lung,28071,9.3,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,435,Primary,Male,Former smoker,Matched,NA,Included,FALSE,NA,14.9,30,SOC,No,"2018, Wk. 12",NA,1941
P-0026958_959478_348049,,P-0026958,1,discovery,HobS18-855091713286,959478,949851,1,1,1,2,73,1,0,3,3.2,1.9,0,,1,Adenocarcinoma,1,1,1,Pembrolizumab,1,0,0,0,0.6,1,7,1,,3,1,2,1,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0026958-T01-IM6,73,74,3.2,FALSE,NA,NO,FALSE,NA,POD/clinical,FALSE,NA,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,80,NA,CT chest/abdomen/pelvis,85.9,9.7,74.8,NA,2002/9/18,NA,NA,NSCLC,1.9,26921,26921,3,FALSE,NA,FALSE,NA,26940,0.0565,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,1,80,No,NA,FALSE,NA,NA,PD1 alone,18-Feb,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,944455,11,NSCLC,NA,NA,33.75,YES,lung,26940,0.6,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,725,Primary,Female,Former smoker,Matched,"Note: Low tumor content (approximately 20% or less). Negative mutation, MSIsensor, copy number and structural variant results should be interpreted with caution.",Included,FALSE,NA,9.7,20,SOC,No,"2018, Wk. 06",NA,1944
P-0027088_991962_348046,Empty,P-0027088,0,discovery,HobS18-717793012977,991962,944129,1,1,1,1,45,1,0,2,3.2,4.9,1,1,1,Adenocarcinoma,1,1,1,Pembrolizumab,1,0,0,0,1,1,8,1,,3,1,2,,pleura,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0027088-T01-IM6,45,46,3.2,FALSE,NA,YES,FALSE,NA,POD/death,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,95,NA,CT chest/abdomen/pelvis,25.2,1.8,16.1,NA,2/17/18,NA,16719,NSCLC,4.9,16711,16690,2,FALSE,NA,FALSE,NA,16719,0.4015,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,1,95,No,NA,FALSE,NA,NA,PD1 alone,18-Feb,MICROSATELLITE STABLE (MSS). See MSI note below.,0.22,Stable,946691,2,LUAD,1,NA,8.5,YES,pleura,16719,1,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,717,Primary,Male,Former smoker,Matched,Note: This sample has been nominated for further analysis using the Archer targeted RNAseq assay as an apparent driver-negative cancer. Assay will be performed if additional material is available and results will be reported under a separate accession num,Included,FALSE,NA,1.8,30,SOC,Yes,"2018, Wk. 07",NA,1972
P-0027133_2215102_348042,,P-0027133,1,discovery,HobS18-602608203507,2215102,934925,1,1,1,2,58,1,0,1,4.1,2.3,1,1.9,1,Adenocarcinoma,1,1,1,Pembrolizumab,1,0,0,0,1.9,1,8,1,,1,1,2,1,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0027133-T01-IM6,58,59,4.1,FALSE,NA,NO,FALSE,NA,POD/death,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,60,NA,CT chest,89.7,12.3,82.3,NA,2/17/18,NA,21495,NSCLC,2.3,21468,21436,1,FALSE,NA,FALSE,NA,21495,0.1336,IMPACT468,70,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,1,60,Yes,NA,FALSE,NA,NA,PD1 alone,18-Feb,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,931191,14,LUAD,1.9,NA,76.5,YES,lung,21495,1.9,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,975,Primary,Female,Former smoker,Matched,NA,Included,FALSE,NA,12.3,20,SOC,Yes,"2018, Wk. 07",NA,1959
P-0027259_4289968_348051,,P-0027259,1,discovery,HobS18-513734668531,4289968,1061070,1,1,1,1,69,1,0,2,3,6,1,1.9,1,Squamous,2,1,1,Nivolumab,1,0,0,0,1.6,1,4,1,,3,1,2,3,soft tissue (gluteus),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0027259-T02-IM6,69,70,3,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Squamous Cell Carcinoma,5,NA,CT chest/abdomen/pelvis,92.3,14.9,89.1,NA,2006/8/18,NA,25457,NSCLC,6,25435,25400,2,FALSE,NA,FALSE,NA,25457,0.0628,IMPACT468,95,Squamous,Yes,MSKCC,Nivolumab,2,1,No,Soft Tissue,FALSE,NA,NA,PD1 alone,18-Jun,MICROSATELLITE STABLE (MSS). See MSI note below.,0.24,Stable,1061488,17,LUSC,1.9,NA,79.5,YES,soft tissue (gluteus),25450,1.6,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,649,Metastasis,Male,Former smoker,Matched,Note: This tumor sample is clonally related to the sample tested in M18-3034.. Note: Copy number profile is suggestive of broad copy number gain on Chromosome 20q11-13.,Included,FALSE,NA,14.9,30,SOC,Yes,"2018, Wk. 23",NA,1949
P-0027343_3687770_348040,,P-0027343,1,discovery,HobS17-024417576131,3687770,3687546,1,1,1,1,93,1,0,2,3.3,2.1,1,0.1,1,Adenocarcinoma,1,1,1,Pembrolizumab,1,0,0,0,0.1,1,8,1,,3,1,2,1,soft tissue (humerus),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0027343-T01-IM6,93,>90,3.3,FALSE,NA,NO,FALSE,NA,POD/death,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,80,NA,CT chest/abdomen/pelvis,87.1,10.5,77,NA,2/25/18,NA,34153,NSCLC,2.1,34149,34149,2,FALSE,NA,FALSE,NA,34153,0.1779,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,1,80,No,Bone,FALSE,NA,NA,PD1 alone,18-Feb,MICROSATELLITE STABLE (MSS). See MSI note below.,0.3,Stable,909664,10,LUAD,0.1,NA,unk,YES,soft tissue (humerus),34153,0.1,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,793,Metastasis,Male,Former smoker,Matched,NA,Included,FALSE,NA,10.5,30,SOC,Yes,"2018, Wk. 08",NA,1924
P-0027455_988311_191052,,P-0027455,1,discovery,HobS17-890662305758,988311,956457,1,1,1,1,72,2,60,1,3.3,3.8,0,,1,Squamous,1,1,1,Pembrolizumab,1,0,0,0,15.1,1,3,1,1,1,1,2,1,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0027455-T01-IM6,72,73,3.3,FALSE,NA,NO,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,50,NA,CT chest,NA,NA,NA,NA,2003/2/18,Durable clinical benefit,NA,NSCLC,3.8,27055,26612,1,FALSE,NA,FALSE,NA,27200,0.0029,IMPACT468,NA,Squamous,Yes,MSKCC,Pembrolizumab,1,NA,NA,NA,FALSE,NA,NA,PD1 alone,18-Mar,NA,0,Do not report,963315,NA,NSCLC,NA,NA,60,YES,lung,27073,15.1,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,622,Primary,Male,Current smoker (within 6 months of diagnosis),Matched,Note: Absence of any somatic mutations (including silent mutations) and any copy number changes suggests very low tumor content. Negative results should be interpreted with caution. Repeat testing on a separate sample may be indicated.,Excluded,FALSE,NA,0,10,SOC,No,"2018, Wk. 09",NA,1945
P-0027576_4289962_348044,Empty,P-0027576,0,discovery,HobS17-435198519982,4289962,1026410,1,1,1,1,65,1,35,2,3.7,3.9,1,3,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,0.8,1,4,1,,3,1,2,,chest wall,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0027576-T01-IM6,65,65,3.7,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,54.1,4.4,38.5,NA,2003/9/18,NA,23889,NSCLC,3.9,23799,23799,2,FALSE,NA,FALSE,NA,23889,0.0105,IMPACT468,NA,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,0,No,Chest Wall,FALSE,NA,NA,PD1 alone,18-Mar,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,940732,5,LUAD,3,NA,35,YES,chest wall,23822,0.8,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,516,Metastasis,Male,Former smoker,Matched,"Note: Low tumor content (approximately 20% or less).  Negative mutation, copy number and structural variant results, as well as low (stable) MSIsensor scores, should be interpreted with caution.",Included,FALSE,NA,4.4,10,SOC,Yes,"2018, Wk. 10",NA,1953
P-0027664_3687693_348045,Empty,P-0027664,0,discovery,HobS18-814713139263,3687693,3687419,1,1,1,1,68,1,50,1,3.6,2,0,,1,Adenocarcinoma,2,1,1,Atezolizumab,1,0,0,0,1.2,1,4,1,,1,1,2,,lung,0,0,0,0,0,0,0,0,AMP (driver),AMP (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0027664-T01-IM6,68,69,3.6,FALSE,NA,YES,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest,54.1,4.4,38.5,NA,2003/7/18,NA,NA,NSCLC,2,25298,25135,1,TRUE,AMP (driver),FALSE,NA,25361,0.2163,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Atezolizumab,2,0,No,NA,FALSE,NA,NA,PD1 alone,18-Mar,MICROSATELLITE STABLE (MSS). See MSI note below.,0.14,Stable,948171,5,LUAD,NA,NA,50,YES,lung,25172,1.2,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,870,Primary,Male,Former smoker,Matched,NA,Included,FALSE,NA,4.4,30,SOC,No,"2018, Wk. 10",NA,1949
P-0027673_3756305_348039,,P-0027673,1,discovery,HobS17-598759123991,3756305,926496,1,1,1,2,71,1,72,2,3.2,2.9,0,,1,Adenocarcinoma,1,1,1,Atezolizumab,0,0,1,0,13.5,0,2,0,,3,1,2,1,lymph node,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0027673-T01-IM6,71,71,3.2,FALSE,NA,YES,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,91.4,14,86.9,NA,2003/8/18,NA,NA,NSCLC,2.9,26527,26029,2,FALSE,NA,FALSE,NA,26542,0.7096,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Atezolizumab,1,0,No,Lymph node,FALSE,NA,NA,PD1 alone,18-Mar,MICROSATELLITE STABLE (MSS). See MSI note below.,0.77,Stable,922319,16,LUAD,NA,NA,72,YES,lymph node,26439,13.5,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,809,Metastasis,Female,Former smoker,Matched,NA,Included,FALSE,NA,14,50,SOC,No,"2018, Wk. 10",NA,1947
P-0027713_3756068_348008,,P-0027713,1,discovery,HobS18-015272367294,3756068,972496,1,1,1,1,73,1,30,1,3.4,2.5,0,,1,Squamous,3,1,1,Nivolumab,1,0,0,0,1.1,1,4,1,,3,1,2,2,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0027713-T01-IM6,73,73,3.4,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Squamous Cell Carcinoma,0,NA,CT chest/abdomen/pelvis,37.9,2.6,25.7,NA,2003/9/18,NA,NA,NSCLC,2.5,26829,26801,1,FALSE,NA,FALSE,NA,27294,0.0697,IMPACT468,95,Squamous,Yes,MSKCC,Nivolumab,3,0,No,NA,FALSE,NA,NA,PD1 alone,18-Mar,MICROSATELLITE STABLE (MSS). See MSI note below.,0.39,Stable,968721,3,LUSC,NA,NA,30,YES,lung,26836,1.1,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,1084,Primary,Male,Former smoker,Matched,Note: Copy number profile is suggestive of broad copy number gain on Chromosome arm 20q.,Included,FALSE,NA,2.6,30,SOC,No,"2018, Wk. 10",NA,1945
P-0027726_4346318_347977,,P-0027726,1,discovery,HobS16-374717129880,4346318,529914,1,1,1,2,66,2,43,1,3.7,2.4,0,,1,Adenocarcinoma,2,1,1,Pembrolizumab,1,0,0,0,9.7,1,3,1,1,3,1,2,2,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0027726-T01-IM6,66,67,3.7,FALSE,NA,NO,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,30,NA,CT chest/abdomen/pelvis,94.3,20.2,93.7,NA,3/23/18,Durable clinical benefit,NA,NSCLC,2.4,24539,24266,1,FALSE,NA,FALSE,NA,24749,0.0297,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,2,30,No,NA,FALSE,NA,NA,PD1 alone,18-Mar,MICROSATELLITE STABLE (MSS). See MSI note below.,0.1,Stable,988516,23,LUAD,NA,NA,43,YES,lung,24560,9.7,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,724,Primary,Female,Current smoker (within 6 months of diagnosis),Matched,NA,Included,FALSE,NA,20.2,30,SOC,No,"2018, Wk. 12",NA,1951
P-0027733_3369798_191026,,P-0027733,1,discovery,HobS16-029626334107,3369798,3547945,1,1,1,1,86,1,60,1,3.5,2.3,1,15.6,1,Adenocarcinoma,1,1,1,Pembrolizumab,1,0,0,0,15.6,1,1,0,,3,1,2,2,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0027733-T01-IM6,86,88,3.5,FALSE,NA,NO,FALSE,NA,CR,FALSE,NA,Lung Adenocarcinoma,Lung Adenocarcinoma,80,NA,CT chest/abdomen/pelvis,0,0,0,NA,2003/11/18,NA,32066,NSCLC,2.3,31778,31590,1,FALSE,NA,FALSE,NA,32066,0.0003,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,1,80,No,NA,FALSE,NA,NA,PD1 alone,18-Mar,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,533441,NA,LUAD,15.6,NA,60,YES,lung,32066,15.6,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,492,Primary,Male,Former smoker,Matched,Note: Absence of any somatic mutations (including silent mutations) and any copy number changes suggests very low tumor content. Negative results should be interpreted with caution. Repeat testing on a separate sample may be indicated.,Included,FALSE,NA,0,10,SOC,Yes,"2018, Wk. 10",NA,1930
P-0027742_3687775_348050,,P-0027742,1,discovery,HobS18-920925890959,3687775,3687524,1,1,1,2,62,1,0,1,3.6,1.5,1,10.1,1,Adenocarcinoma,2,1,1,Atezolizumab,1,0,0,0,1.5,1,4,1,,1,1,2,2,soft tissue (spine),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0027742-T01-IM6,62,62,3.6,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest,25.2,1.8,16.1,NA,2003/9/18,NA,23001,NSCLC,1.5,22735,22693,1,FALSE,NA,FALSE,NA,23001,0.0479,IMPACT468,NA,Adenocarcinoma,Yes,MSKCC,Atezolizumab,2,NA,NA,Spine,FALSE,NA,NA,PD1 alone,18-Mar,MICROSATELLITE STABLE (MSS). See MSI note below.,0.3,Stable,972839,2,LUAD,10.1,NA,unk,YES,soft tissue (spine),22739,1.5,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,625,Metastasis,Female,Former smoker,Matched,"Note: Low tumor content (approximately 20% or less).  Negative mutation, copy number and structural variant results, as well as low (stable) MSIsensor scores, should be interpreted with caution.",Excluded,FALSE,NA,1.8,10,SOC,Yes,"2018, Wk. 10",NA,1956
P-0027855_3755985_348052,,P-0027855,1,discovery,HobS18-960063949330,3755985,968251,1,1,1,1,81,1,0,1,4.1,3.5,1,2.9,1,Adenocarcinoma,2,1,1,Pembrolizumab,1,0,0,0,2.9,1,8,1,,3,1,2,1,lung,0,AMP (driver),0,0,0,0,P281Rfs*6 (driver),0,0,0,0,0,0,0,0,0,AMP (driver),AMP (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,P281Rfs*6 (driver),0,0,0,0,0,#REF!,P-0027855-T01-IM6,81,81,4.1,FALSE,NA,NO,FALSE,NA,POD/death,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,2,NA,CT chest/abdomen/pelvis,76.6,7,60.3,NA,3/13/18,NA,29734,NSCLC,3.5,29710,29647,1,FALSE,NA,TRUE,AMP (driver),29734,0.3165,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,2,5,No,NA,FALSE,NA,NA,PD1 alone,18-Mar,MICROSATELLITE STABLE (MSS). See MSI note below.,0.13,Stable,964559,8,LUAD,2.9,NA,4.5,YES,lung,29734,2.9,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,773,Primary,Male,Former smoker,Matched,"Note: Copy number profile is suggestive of broad copy number gains on Chromosome arms 5p (including TERT), and 6p21.2-25.",Included,TRUE,P281Rfs*6 (driver),7,30,SOC,Yes,"2018, Wk. 11",NA,1937
P-0028173_3756072_348047,,P-0028173,1,discovery,HobS18-598399137594,3756072,962781,1,1,1,2,71,1,40,1,3.9,2.4,1,3.4,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,1.9,1,4,1,,3,1,2,1,soft tissue (T9),0,0,0,0,0,0,Q220Pfs*45 (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Q220Pfs*45 (driver),0,0,0,0,0,#REF!,P-0028173-T01-IM6,71,71,3.9,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,54.1,4.4,38.5,NA,3/22/18,NA,26086,NSCLC,2.4,26017,25981,1,FALSE,NA,FALSE,NA,26086,0.2116,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,0,No,Soft Tissue,FALSE,NA,NA,PD1 alone,18-Mar,MICROSATELLITE STABLE (MSS). See MSI note below.,0.28,Stable,984337,5,LUAD,3.4,NA,40,YES,soft tissue (T9),26040,1.9,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,438,Metastasis,Female,Former smoker,Matched,"Note: Copy number profile is suggestive of broad copy number gain on Chromosome arm 1q. Note: Copy number profile is suggestive of broad copy number loss on Chromosome 1p, 3p, 9, 18q and 19p (including STK11 and KEAP1).",Included,TRUE,Q220Pfs*45 (driver),4.4,50,SOC,Yes,"2018, Wk. 12",NA,1947
P-0028239_3687799_347932,Empty,P-0028239,0,discovery,HobS18-210324430915,3687799,3687508,1,1,1,1,80,1,75,0,3.8,5.2,1,6.5,1,Adenocarcinoma,2,1,1,Atezolizumab,1,0,0,0,6.5,1,3,1,1,3,1,2,,soft tissue (C2),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0028239-T01-IM6,80,80,3.8,FALSE,NA,YES,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,25.2,1.8,16.1,NA,3/23/18,Durable clinical benefit,29475,NSCLC,5.2,29376,29277,0,FALSE,NA,FALSE,NA,29475,0.1721,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Atezolizumab,2,0,No,Soft Tissue,FALSE,NA,NA,PD1 alone,18-Mar,MICROSATELLITE STABLE (MSS). See MSI note below.,0.1,Stable,983501,2,LUAD,6.5,NA,75,YES,soft tissue (C2),29475,6.5,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,487,Metastasis,Male,Former smoker,Matched,Note: Copy number profile from IMPACT assay and allele specific copy number analysis by FACETS suggest loss of heterozygosity of BAP1. The results by FACETS are for investigational use. Confirmation of copy number changes by alternate methods is suggested,Included,FALSE,NA,1.8,60,SOC,Yes,"2018, Wk. 12",NA,1938
P-0028320_996223_348057,Empty,P-0028320,0,discovery,HobS18-171659199802,996223,996168,1,1,1,2,60,1,30,1,3.5,1.9,1,1.3,1,Adenocarcinoma,2,1,1,Pembrolizumab,1,0,0,0,1.2,1,4,1,,2,1,2,,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0028320-T01-IM6,60,70,3.5,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,20,NA,CT chest/abdomen,92.8,16.7,90.4,NA,3/30/18,NA,25698,NSCLC,1.9,25657,25657,1,FALSE,NA,FALSE,NA,25698,0.3516,IMPACT468,60,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,2,1,Yes,NA,FALSE,NA,NA,PD1 alone,18-Mar,MICROSATELLITE STABLE (MSS). See MSI note below.,1.34,Stable,988637,18,LUAD,1.3,NA,30,YES,lung,25693,1.2,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,848,Primary,Female,Former smoker,Matched,Note: Copy number profile is suggestive of a fragmented genome.,Included,FALSE,NA,16.7,50,SOC,Yes,"2018, Wk. 13",NA,1948
P-0028712_4290932_347898,Empty,P-0028712,0,discovery,HobS15-681218400797,4290932,1006844,1,1,1,2,67,1,80,1,3.7,1.5,1,14.8,1,Adenocarcinoma,2,1,1,Atezolizumab,1,0,0,0,5.2,1,5,1,,3,1,2,,brain,0,0,0,0,0,0,0,K1862* (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,K1862* (driver),0,#REF!,P-0028712-T01-IM6,67,68,3.7,FALSE,NA,YES,TRUE,K1862* (driver),POD/brain,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,94.3,20.2,93.7,NA,2004/6/18,NA,25128,NSCLC,1.5,24726,24679,1,FALSE,NA,FALSE,NA,25128,0.532,IMPACT468,80,Adenocarcinoma,Yes,MSKCC,Atezolizumab,2,10,Yes,Brain,FALSE,NA,NA,PD1 alone,18-Apr,MICROSATELLITE STABLE (MSS). See MSI note below.,1.58,Stable,1000381,23,LUAD,14.8,NA,80,YES,brain,24836,5.2,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,338,Metastasis,Female,Former smoker,Matched,NA,Included,FALSE,NA,20.2,60,SOC,Yes,"2018, Wk. 14",NA,1950
P-0028723_3369223_190762,,P-0028723,1,discovery,HobS18-124915503066,3369223,1007970,1,1,1,1,65,1,0,1,3.4,2.4,0,,1,Adenocarcinoma,1,1,1,Pembrolizumab,0,0,1,0,14.9,0,2,0,,1,1,2,2,pleural fluid,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0028723-T01-IM6,65,65,3.4,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Lung Adenocarcinoma,Lung Adenocarcinoma,100,NA,CT chest,89,11.4,81.7,Formalin,2004/6/18,NA,NA,NSCLC,2.4,24267,23742,1,FALSE,NA,FALSE,NA,24267,0.1098,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,1,95,No,Pleural Fluid,FALSE,NA,NA,PD1 alone,18-Apr,MICROSATELLITE STABLE (MSS). See MSI note below.,0.12,Stable,1002095,13,LUAD,NA,NA,40.5,YES,pleural fluid,24197,14.9,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,570,Metastasis,Male,Former smoker,Matched,NA,Included,FALSE,NA,11.4,50,SOC,No,"2018, Wk. 14",NA,1953
P-0029465_1049320_347972,,P-0029465,1,discovery,HobS18-859767622839,1049320,1044476,1,1,1,2,56,2,20,1,3.9,0.8,0,,1,Squamous,1,1,1,Nivolumab,0,0,1,0,15.2,0,2,0,,1,2,2,2,lung,0,0,0,0,P328S,0,0,K1124M,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,P328S,0,0,0,0,0,0,0,0,0,0,0,K1124M,0,#REF!,P-0029465-T01-IM6,56,57,3.9,FALSE,NA,NO,FALSE,K1124M,PR,FALSE,P328S,Non-Small Cell Lung Cancer,Lung Squamous Cell Carcinoma,1,NA,CT chest,87.1,10.5,77,NA,2005/7/18,NA,NA,NSCLC,0.8,21094,20630,1,FALSE,NA,FALSE,NA,21108,0.4164,IMPACT468,NA,Squamous,No,MSKCC,Nivolumab,1,NA,NA,Lymph Node,FALSE,NA,NA,PD1 alone,18-May,MICROSATELLITE STABLE (MSS). See MSI note below.,1.18,Stable,1024805,12,LUSC,NA,NA,20,YES,lung,21093,15.2,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,810,Metastasis,Female,Current smoker (within 6 months of diagnosis),Matched,NA,Excluded,FALSE,NA,10.5,50,SOC,No,"2018, Wk. 19",NA,1961
P-0029593_3687377_348063,,P-0029593,1,discovery,HobS18-123476156864,3687377,1034789,1,1,1,1,75,2,60,1,3.5,0.9,0,,1,Adenocarcinoma,1,1,1,Pembrolizumab,1,0,0,0,8.7,1,4,1,,3,1,2,1,pleural fluid,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0029593-T01-IM6,75,76,3.5,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,75,NA,CT chest/abdomen/pelvis,87.1,10.5,77,SSL,2005/6/18,NA,NA,NSCLC,0.9,28079,27589,1,FALSE,NA,FALSE,NA,28105,0.4443,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,1,80,No,Pleural Fliud,FALSE,NA,NA,PD1 alone,18-May,MICROSATELLITE STABLE (MSS). See MSI note below.,0.4,Stable,1032740,12,LUAD,NA,NA,60,YES,pleural fluid,27855,8.7,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,655,Metastasis,Male,Current smoker (within 6 months of diagnosis),Matched,NA,Included,FALSE,NA,10.5,50,SOC,No,"2018, Wk. 18",NA,1942
P-0029975_4289971_348060,,P-0029975,1,discovery,HobS18-865224748252,4289971,1032756,1,1,1,1,65,2,52,0,4.2,1,0,,1,Squamous,1,1,1,Pembrolizumab,1,0,0,0,11.4,1,2,0,,3,1,2,3,liver,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0029975-T01-IM6,65,67,4.2,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Lung Squamous Cell Carcinoma,Lung Squamous Cell Carcinoma,80,NA,CT chest/abdomen/pelvis,61.9,5.3,45.8,NA,5/19/18,NA,NA,NSCLC,1,24390,23928,0,FALSE,NA,FALSE,NA,24432,0.3543,IMPACT468,95,Squamous,Yes,MSKCC,Pembrolizumab,1,80,No,Liver,FALSE,NA,NA,PD1 alone,18-May,MICROSATELLITE STABLE (MSS). See MSI note below.,1.52,Stable,1044108,5,LUSC,NA,NA,52,YES,liver,24275,11.4,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,767,Metastasis,Male,Current smoker (within 6 months of diagnosis),Matched,Note: Copy number profile is suggestive of multiple chromosome level losses and gains.,Included,FALSE,NA,5.3,70,SOC,No,"2018, Wk. 20",NA,1952
P-0030125_3756001_348064,,P-0030125,1,discovery,HobS18-704357102979,3756001,1070496,1,1,1,2,66,2,0,1,3.8,1.7,1,10.7,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,6.4,1,3,1,1,3,1,2,1,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0030125-T01-IM6,66,67,3.8,FALSE,NA,NO,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,13.1,0.9,7.8,NA,5/26/18,Durable clinical benefit,24433,NSCLC,1.7,24289,24107,1,FALSE,NA,FALSE,NA,24433,0.0003,IMPACT468,90,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,0,No,NA,FALSE,NA,NA,PD1 alone,18-May,MICROSATELLITE STABLE (MSS). See MSI note below.,0.12,Stable,1044051,1,LUAD,10.7,NA,24.5,YES,lung,24302,6.4,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,322,Primary,Female,Current smoker (within 6 months of diagnosis),Matched,"Note: Low tumor content (approximately 20% or less).  Negative mutation, copy number and structural variant results, as well as low (stable) MSIsensor scores, should be interpreted with caution.",Included,FALSE,NA,0.9,10,SOC,Yes,"2018, Wk. 21",NA,1952
P-0030323_3756121_348010,Empty,P-0030323,0,discovery,HobS18-208727912893,3756121,1014825,1,1,1,1,61,1,40,0,4.3,3,0,,1,Pleomorphic,1,1,1,Pembrolizumab,1,0,0,0,9.5,1,2,0,,1,1,2,,adrenal,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0030323-T01-IM6,61,63,4.3,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Pleomorphic Carcinoma of the Lung,0,NA,CT chest,92.3,14.9,89.1,NA,2006/2/18,NA,NA,NSCLC,3,22882,22427,0,FALSE,NA,FALSE,NA,22973,0.0268,IMPACT468,95,Pleomorphic,Yes,MSKCC,Pembrolizumab,1,10,No,Adrenal,FALSE,NA,NA,PD1 alone,18-Jun,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,1002031,17,LUPC,NA,NA,40,YES,adrenal,22716,9.5,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,770,Metastasis,Male,Former smoker,Matched,NA,Included,FALSE,NA,14.9,40,SOC,No,"2018, Wk. 22",NA,1956
P-0030654_1065326_348066,,P-0030654,1,discovery,HobS18-493961569132,1065326,1067278,1,1,1,2,75,1,60,1,3.6,2.2,1,5.1,1,Squamous,2,1,1,Pembrolizumab,1,0,0,0,1.2,1,4,1,,3,1,2,1,lung,0,0,P2183S,0,0,0,0,0,0,0,L369F,0,0,0,0,0,0,0,0,0,0,0,P2183S,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0030654-T01-IM6,75,76,3.6,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Squamous Cell Carcinoma,80,NA,CT chest/abdomen/pelvis,91,13.2,85.8,NA,6/18/18,NA,27615,NSCLC,2.2,27482,27461,1,FALSE,L369F,FALSE,NA,27615,0.2123,IMPACT468,95,Squamous,Yes,MSKCC,Pembrolizumab,2,80,No,NA,FALSE,NA,NA,PD1 alone,18-Jun,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,1063249,15,LUSC,5.1,NA,60,YES,lung,27496,1.2,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,P2183S,Tumor,1,775,Primary,Female,Former smoker,Matched,NA,Included,FALSE,NA,13.2,30,SOC,Yes,"2018, Wk. 25",NA,1943
P-0031112_679967_190876,,P-0031112,1,discovery,HobS17-186728287241,679967,641402,1,1,1,2,64,2,48,1,3.3,1.6,1,21.5,1,Squamous,1,1,1,Pembrolizumab,1,0,0,0,5.7,1,2,0,,2,2,2,2,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0031112-T02-IM6,64,66,3.3,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Squamous Cell Carcinoma,70,NA,CT chest/abdomen,76.6,7,60.3,NA,2008/8/18,NA,24085,NSCLC,1.6,23710,23430,1,FALSE,NA,FALSE,NA,24085,0.0006,IMPACT468,95,Squamous,No,MSKCC,Pembrolizumab,1,70,No,kidney,FALSE,NA,NA,PD1 alone,18-Aug,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,1134880,8,LUSC,21.5,NA,48,YES,lung,23603,5.7,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,506,Metastasis,Female,Current smoker (within 6 months of diagnosis),Matched,NA,Included,FALSE,NA,7,10,SOC,Yes,"2018, Wk. 32",NA,1953
P-0031665_3687783_348054,,P-0031665,1,discovery,HobS18-619322818319,3687783,3687518,1,1,1,1,71,1,0,1,3.2,2.9,1,6,1,Squamous,3,1,1,Nivolumab,1,0,0,0,3,1,3,1,2,3,1,2,1,chest wall,0,0,0,0,0,0,0,0,0,0,D416Y,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0031665-T01-IM6,71,72,3.2,FALSE,NA,NO,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Squamous Cell Carcinoma,0,NA,CT chest/abdomen/pelvis,79.1,7.9,63.8,NA,7/14/18,No durable clinical benefit,26134,NSCLC,2.9,25965,25951,1,FALSE,D416Y,FALSE,NA,26134,0.3237,IMPACT468,70,Squamous,Yes,MSKCC,Nivolumab,3,0,No,Chest Wall,FALSE,NA,NA,PD1 alone,18-Jul,MICROSATELLITE STABLE (MSS). See MSI note below.,0.19,Stable,1096950,9,LUSC,6,NA,67.5,YES,chest wall,26042,3,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,718,Metastasis,Male,Former smoker,Matched,Note: Copy number profile is suggestive of a fragmented genome.,Included,FALSE,NA,7.9,40,SOC,Yes,"2018, Wk. 28",NA,1947
P-0031727_987037_347893,,P-0031727,1,discovery,HobS17-923178924812,987037,924542,1,1,1,2,84,1,34,1,4.3,2,0,,1,Adenocarcinoma,1,1,1,Pembrolizumab,0,0,1,0,19.7,0,2,0,,3,1,2,3,lung,0,0,0,0,0,H1094Y (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,H1094Y (driver),0,0,0,0,0,0,0,0,0,#REF!,P-0031727-T01-IM6,84,85,4.3,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,100,NA,CT chest/abdomen/pelvis,44.1,3.5,30.4,NA,7/17/18,NA,NA,NSCLC,2,31258,30672,1,FALSE,NA,FALSE,NA,31279,0.0009,IMPACT468,80,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,1,95,Yes,NA,TRUE,H1094Y (driver),NA,PD1 alone,18-Jul,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,922342,4,LUAD,NA,NA,34,YES,lung,31273,19.7,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,568,Primary,Female,Former smoker,Matched,"Note: Low tumor content (approximately 20% or less).  Negative mutation, copy number and structural variant results, as well as low (stable) MSIsensor scores, should be interpreted with caution.",Included,FALSE,NA,3.5,10,SOC,No,"2018, Wk. 29",NA,1934
P-0032126_4290019_348002,,P-0032126,1,discovery,HobS17-740157691236,4290019,3687582,1,1,1,2,77,1,50,1,3.5,13.4,1,10.6,1,Adenocarcinoma,2,1,1,Pembrolizumab,1,0,0,0,8.6,1,2,0,,1,2,2,1,lung,0,0,0,0,0,0,F231Sfs*56 (driver),0,0,0,R98L,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,F231Sfs*56 (driver),0,0,0,0,0,#REF!,P-0032126-T01-IM6,77,80,3.5,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,50,NA,CT chest,76.6,7,60.3,NA,7/31/18,NA,28732,NSCLC,13.4,28585,28410,1,FALSE,R98L,FALSE,NA,28732,0.0072,IMPACT468,95,Adenocarcinoma,No,MSKCC,Pembrolizumab,2,50,No,NA,FALSE,NA,NA,PD1 alone,18-Jul,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,1118037,8,LUAD,10.6,NA,50,YES,lung,28671,8.6,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,771,Primary,Female,Former smoker,Matched,NA,Included,TRUE,F231Sfs*56 (driver),7,10,SOC,Yes,"2018, Wk. 31",NA,1939
P-0032182_3756135_348067,,P-0032182,1,discovery,HobS18-433128250177,3756135,1106754,1,1,1,2,62,2,50,1,4.1,6.3,0,,1,NOS,1,1,1,Pembrolizumab,1,0,0,0,5,1,3,1,2,1,1,2,4,lung,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0032182-T01-IM6,62,64,4.1,FALSE,NA,NO,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Poorly Differentiated Non-Small Cell Lung Cancer,90,NA,CT chest,44.1,3.5,30.4,NA,2008/1/18,No durable clinical benefit,NA,NSCLC,6.3,23082,22926,1,FALSE,NA,FALSE,NA,23385,0.0932,IMPACT468,95,NOS,Yes,MSKCC,Pembrolizumab,1,95,No,NA,FALSE,NA,NA,PD1 alone,18-Aug,MICROSATELLITE STABLE (MSS). See MSI note below.,0.8,Stable,1119410,4,NSCLCPD,NA,NA,50,YES,lung,23077,5,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,570,Primary,Female,Current smoker (within 6 months of diagnosis),Matched,NA,Included,FALSE,NA,3.5,60,SOC,No,"2018, Wk. 31",NA,1955
P-0032455_3687807_348062,,P-0032455,1,discovery,HobS18-042424481685,3687807,3687494,1,1,1,2,64,1,36,2,3.9,2,0,,1,Adenocarcinoma,1,1,1,Pembrolizumab,0,0,1,0,14.8,0,2,0,,3,1,2,3,lymph node,0,0,0,0,0,AMP (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,AMP (driver),AMP (driver),0,0,0,0,0,0,0,0,0,0,#REF!,P-0032455-T01-IM6,64,65,3.9,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,80,NA,CT chest/abdomen/pelvis,91,13.2,85.8,Formalin,2008/11/18,NA,NA,NSCLC,2,23964,23488,2,FALSE,NA,FALSE,NA,23989,0.4903,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,1,90,No,NA,TRUE,AMP (driver),NA,PD1 alone,18-Aug,MICROSATELLITE STABLE (MSS). See MSI note below.,2.05,Stable,1039320,15,LUAD,NA,NA,36,YES,lymph node,23940,14.8,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,648,Primary,Female,Former smoker,Matched,NA,Included,FALSE,NA,13.2,60,SOC,No,"2018, Wk. 32",NA,1954
P-0033892_3687366_348058,Empty,P-0033892,0,discovery,HobS18-350373791335,3687366,1006985,1,1,1,2,64,2,24,1,3.5,1.3,1,5.3,1,Adenocarcinoma,2,1,1,Nivolumab,1,0,0,0,1.4,1,4,1,,3,1,2,,pleural fluid,0,0,0,0,0,0,0,0,AMP (driver),AMP (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0033892-T01-IM6,64,66,3.5,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,87.1,10.5,77,SSL,2010/9/18,NA,23751,NSCLC,1.3,23686,23590,1,TRUE,AMP (driver),FALSE,NA,23751,0.3628,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,0,No,Pleural Fluid,FALSE,NA,NA,PD1 alone,18-Oct,MICROSATELLITE STABLE (MSS). See MSI note below.,0.66,Stable,NA,12,LUAD,5.3,NA,24,NO,pleural fluid,23634,1.4,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,635,Metastasis,Female,Current smoker (within 6 months of diagnosis),Matched,NA,Included,FALSE,NA,10.5,40,SOC,Yes,"2018, Wk. 41",NA,1953
P-0033978_955209_191087,,P-0033978,1,discovery,HobS17-494265535205,955209,955214,1,1,1,2,51,2,25,0,3.9,1.9,0,,1,Adenocarcinoma,2,1,1,Pembrolizumab,1,0,0,0,6.2,1,3,1,1,3,2,2,2,lung,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,P-0033978-T01-IM6,51,53,3.9,FALSE,NA,NO,FALSE,NA,SD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,80,NA,CT chest/abdomen/pelvis,37.9,2.6,25.7,NA,9/29/18,Durable clinical benefit,NA,NSCLC,1.9,18842,18799,0,FALSE,NA,FALSE,NA,19395,0.0097,IMPACT468,95,Adenocarcinoma,No,MSKCC,Pembrolizumab,2,90,No,NA,FALSE,NA,NA,PD1 alone,18-Sep,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,NA,3,LUAD,NA,NA,25,NO,lung,18987,6.2,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,456,Primary,Female,Current smoker (within 6 months of diagnosis),Matched,"Note: Low tumor content (approximately 20% or less).  Negative mutation, copy number and structural variant results, as well as low (stable) MSIsensor scores, should be interpreted with caution.",Included,FALSE,NA,2.6,10,SOC,No,"2018, Wk. 39",NA,1966
P-0033979_3756240_347897,,P-0033979,1,discovery,HobS18-816518528116,3756240,1173982,1,1,1,2,71,1,0,1,3,5.1,0,,1,Adenocarcinoma,2,1,1,Atezolizumab,1,0,0,0,4.6,1,2,0,,3,1,2,1,lung,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,P-0033979-T01-IM6,71,73,3,FALSE,NA,YES,FALSE,NA,PR,FALSE,NA,Lung Adenocarcinoma,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,14.3,0.9,8.9,NA,9/29/18,NA,NA,NSCLC,5.1,26227,26199,1,FALSE,NA,FALSE,NA,26552,0,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Atezolizumab,2,0,No,NA,FALSE,NA,NA,PD1 alone,18-Sep,MICROSATELLITE STABLE (MSS). See MSI note below.,0,Stable,NA,1,LUAD,NA,NA,62.5,NO,lung,26339,4.6,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,495,Primary,Female,Former smoker,Matched,NA,Included,FALSE,NA,0.9,20,SOC,No,"2018, Wk. 39",NA,1946
P-0034908_581421_347999,,P-0034908,1,discovery,HobS17-891883280858,581421,581401,1,1,1,1,76,2,36,2,3.8,1.8,0,,1,Squamous,1,1,1,Pembrolizumab,0,0,1,0,10.7,0,1,0,,1,2,2,3,lung,0,0,0,0,0,0,E199* (driver),Y803C,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,E199* (driver),0,0,0,Y803C,0,#REF!,P-0034908-T01-IM6,76,77,3.8,FALSE,NA,NO,FALSE,Y803C,CR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Squamous Cell Carcinoma,50,NA,CT chest,73.7,6.1,56.8,NA,2011/8/18,NA,NA,NSCLC,1.8,28089,27762,2,FALSE,NA,FALSE,NA,28101,0.6205,IMPACT468,80,Squamous,No,MSKCC,Pembrolizumab,1,60,No,Lymph Node,FALSE,NA,NA,PD1 alone,18-Nov,MICROSATELLITE STABLE (MSS). See MSI note below.,2.1,Stable,NA,7,LUSC,NA,NA,36,NO,lung,28087,10.7,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,707,Metastasis,Male,Current smoker (within 6 months of diagnosis),Matched,Note: Copy number profile is suggestive of multiple chromosome level losses and gains.,Included,TRUE,E199* (driver),6.1,30,SOC,No,"2018, Wk. 45",NA,1942
P-0035638_3687766_348028,,P-0035638,1,discovery,HobS17-256448265219,3687766,3687537,1,1,1,1,72,0,0,1,3.4,4.9,1,8,1,Squamous,1,1,1,Nivolumab,1,0,0,0,3.1,1,4,1,,3,1,2,1,lung,0,P627S,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,P627S,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0035638-T01-IM6,72,73,3.4,FALSE,NA,NO,FALSE,NA,POD,FALSE,NA,Non-Small Cell Lung Cancer,Lung Squamous Cell Carcinoma,0,NA,CT chest/abdomen/pelvis,91,13.2,85.8,NA,11/27/18,NA,26634,NSCLC,4.9,26476,26392,1,FALSE,NA,FALSE,P627S,26634,0.731,IMPACT468,95,Squamous,Yes,MSKCC,Nivolumab,1,0,No,NA,FALSE,NA,NA,PD1 alone,18-Nov,MICROSATELLITE STABLE (MSS). See MSI note below.,2.41,Stable,NA,15,LUSC,8,NA,0,NO,lung,26485,3.1,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,445,Primary,Male,Never smoker,Matched,Note: Copy number profile is suggestive of a fragmented genome.,Included,FALSE,NA,13.2,80,SOC,Yes,"2018, Wk. 48",NA,1946
P-0039832_3687381_348069,,P-0039832,1,discovery,HobS18-169847561081,3687381,1167717,1,1,1,2,75,1,0,1,3.4,1.6,0,,1,Adenocarcinoma,1,1,1,Pembrolizumab,0,0,1,0,11,0,2,0,,3,1,2,4,pleural fluid,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,P-0039832-T01-IM6,75,76,3.4,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Non-Small Cell Lung Cancer,Lung Adenocarcinoma,90,NA,CT chest/abdomen/pelvis,89.5,12.3,82.1,SSL,3/26/19,NA,NA,NSCLC,1.6,27762,27403,1,FALSE,NA,FALSE,NA,27787,0.1493,IMPACT468,50,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,1,95,Yes,NA,FALSE,NA,NA,PD1 alone,19-Mar,MICROSATELLITE STABLE (MSS). See MSI note below.,0.06,Stable,1167331,14,LUAD,NA,NA,22.5,YES,pleural fluid,27739,11,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,545,Primary,Female,Former smoker,Matched,NA,Included,FALSE,NA,12.3,30,SOC,No,"2019, Wk. 13",NA,1943
P-0040848_3687819_348029,Empty,P-0040848,0,discovery,HobS17-364135238135,3687819,757036,1,1,1,2,70,2,55,1,3.5,1.7,0,,1,Squamous,2,1,1,Pembrolizumab,1,0,0,0,11.8,1,3,1,1,3,1,2,,peritoneum,0,0,C2252F,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,C2252F,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,#REF!,P-0040848-T01-IM6,70,71,3.5,FALSE,NA,NO,FALSE,NA,SD,FALSE,NA,Lung Squamous Cell Carcinoma,Lung Squamous Cell Carcinoma,90,NA,CT chest/abdomen/pelvis,61.9,5.3,45.8,SSL,4/24/19,Durable clinical benefit,NA,NSCLC,1.7,26018,25675,1,FALSE,NA,FALSE,NA,26127,0.3339,IMPACT468,95,Squamous,Yes,Other Institute,Pembrolizumab,2,80,No,NA,FALSE,NA,NA,PD1 alone,19-Apr,MICROSATELLITE STABLE (MSS). See MSI note below.,0.52,Stable,1578306,6,LUSC,NA,NA,55,YES,peritoneum,26033,11.8,1:PROGRESS,Lung,NA,FALSE,NA,FALSE,C2252F,Tumor,1,486,Primary,Female,Current smoker (within 6 months of diagnosis),Matched,Note: Copy number profile is suggestive of multiple chromosome level losses and gains.,Included,FALSE,NA,5.3,50,SOC,No,"2019, Wk. 17",NA,1948
P-0044186_3687840_347924,Empty,P-0044186,0,discovery,HobS17-202014224501,3687840,3692567,1,1,1,1,65,2,38,1,4.1,2.4,0,,1,Adenocarcinoma,2,1,1,Pembrolizumab,0,1,0,0,19.4,0,2,0,,1,1,2,,lung,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,#N/A,P-0044186-T01-IM6,65,68,4.1,FALSE,NA,NO,FALSE,NA,PR,FALSE,NA,Lung Adenocarcinoma,Lung Adenocarcinoma,1,NA,CT chest,89.3,12.3,82.3,NA,7/20/19,NA,NA,NSCLC,2.4,24000,23958,1,FALSE,NA,FALSE,NA,24570,0.0866,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Pembrolizumab,2,5,No,NA,FALSE,NA,NA,PD1 alone,19-Jul,MICROSATELLITE STABLE (MSS). See MSI note below.,0.05,Stable,549270,14,LUAD,NA,NA,38,YES,lung,24549,19.4,0:CENSORED,Lung,NA,FALSE,NA,FALSE,NA,Tumor,1,792,Primary,Male,Current smoker (within 6 months of diagnosis),Matched,NA,Included,FALSE,NA,12.3,40,SOC,No,"2019, Wk. 29",NA,1952
P-0045298_3687318_348059,,P-0045298,1,discovery,HobS18-243518055648,3687318,3687426,1,1,1,1,74,1,0,1,3.6,1.9,0,,1,Adenocarcinoma,2,1,1,Nivolumab,0,0,1,0,12.7,0,2,0,,3,1,2,2,lung,0,0,0,R144L,L185P,0,0,D1850Gfs*4 (driver),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R144L,0,0,0,L185P,0,0,0,0,0,0,0,0,0,0,0,D1850Gfs*4 (driver),0,#REF!,P-0045298-T01-IM6,74,77,3.6,FALSE,NA,NO,TRUE,D1850Gfs*4 (driver),PR,FALSE,L185P,Lung Adenocarcinoma,Lung Adenocarcinoma,0,NA,CT chest/abdomen/pelvis,96.1,29.8,97.7,NA,8/22/19,NA,NA,NSCLC,1.9,27680,27233,1,FALSE,NA,FALSE,NA,27691,0.117,IMPACT468,95,Adenocarcinoma,Yes,MSKCC,Nivolumab,2,0,No,NA,FALSE,NA,NA,PD1 alone,19-Aug,MICROSATELLITE INSTABILITY-HIGH (MSI-H). See MSI note below.,13.28,Instable,1011552,34,LUAD,NA,NA,Cigars,YES,lung,27619,12.7,0:CENSORED,Lung,NA,FALSE,R144L,FALSE,NA,Tumor,1,648,Primary,Male,Former smoker,Matched,NA,Included,FALSE,NA,29.8,NA,SOC,No,"2019, Wk. 34",NA,1943
